data_2kib_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kib _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . 0.475 ' H1 ' ' C ' ' E' ' 7' ' ' SER . 99.1 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.394 -0.595 . . . . 1.0 109.394 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -107.63 125.68 51.64 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.525 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.36 134.58 7.57 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.249 -1.14 . . . . 1.0 110.249 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.06 137.84 31.34 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.014 0.435 . . . . 1.0 110.906 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.402 ' O ' ' CG2' ' A' ' 5' ' ' ILE . 11.1 tp -135.5 125.83 43.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 115.839 -0.618 . . . . 1.0 110.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 86.0 mt -124.6 128.15 48.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.849 -0.614 . . . . 1.0 110.433 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.035 -0.984 . . . . 1.0 110.515 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.371 -0.603 . . . . 1.0 109.371 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -132.88 130.05 39.19 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.276 -0.42 . . . . 1.0 110.22 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.08 137.06 9.35 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 110.592 -1.003 . . . . 1.0 110.592 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.75 29.22 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.914 0.387 . . . . 1.0 111.284 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -123.19 125.24 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.835 179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -115.04 133.01 56.41 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.374 -0.376 . . . . 1.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.92 -1.038 . . . . 1.0 110.342 179.077 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.342 -0.614 . . . . 1.0 109.342 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.29 126.05 52.39 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.2 -0.455 . . . . 1.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.3 134.7 7.54 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 110.309 -1.116 . . . . 1.0 110.309 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.87 135.14 27.4 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.869 0.366 . . . . 1.0 110.962 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.52 125.39 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.231 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.76 130.79 53.18 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.435 -0.348 . . . . 1.0 110.364 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 33.9 p . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.986 -1.007 . . . . 1.0 110.578 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.315 -0.624 . . . . 1.0 109.315 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 35.8 t80 -132.95 129.76 38.68 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.278 -0.419 . . . . 1.0 110.367 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.73 136.71 9.2 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.31 133.97 31.92 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.027 0.442 . . . . 1.0 111.179 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.8 mm -124.0 127.06 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.7 -0.682 . . . . 1.0 110.18 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 16.2 mt -117.38 131.52 56.76 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.218 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.036 -0.983 . . . . 1.0 110.574 179.958 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.37 -0.604 . . . . 1.0 109.37 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.49 125.59 51.46 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.268 -0.424 . . . . 1.0 110.446 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.07 135.87 8.36 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.257 -1.137 . . . . 1.0 110.257 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 135.56 26.77 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.986 0.422 . . . . 1.0 111.071 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . 0.406 HG22 HD12 ' E' ' 5' ' ' ILE . 96.1 mt -132.24 125.09 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.853 -0.612 . . . . 1.0 110.273 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 88.7 mt -124.31 130.74 53.04 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.332 -0.394 . . . . 1.0 110.519 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 7' ' ' SER . . . . . 0.475 ' C ' ' H1 ' ' A' ' 1' ' ' ASN . 14.9 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.566 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.372 -0.603 . . . . 1.0 109.372 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -133.14 130.09 38.75 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.092 -0.504 . . . . 1.0 110.418 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.2 137.19 9.42 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.427 -1.069 . . . . 1.0 110.427 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.48 131.93 26.9 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.826 0.346 . . . . 1.0 111.246 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.5 mm -122.86 125.75 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.968 -0.56 . . . . 1.0 109.965 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -114.5 129.07 56.63 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.124 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.018 -0.992 . . . . 1.0 110.586 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -107.26 126.03 51.9 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.473 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.65 134.74 7.63 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.252 -1.139 . . . . 1.0 110.252 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 138.94 31.7 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.98 0.419 . . . . 1.0 110.67 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 11.2 tp -136.09 125.9 40.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.793 -0.64 . . . . 1.0 110.253 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 85.5 mt -125.68 130.56 51.81 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 1.0 110.427 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.984 -1.007 . . . . 1.0 110.373 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.479 -0.563 . . . . 1.0 109.479 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -132.53 130.3 40.2 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.219 -0.446 . . . . 1.0 110.415 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.45 137.73 9.76 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.474 -1.051 . . . . 1.0 110.474 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.37 133.26 29.17 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.887 0.375 . . . . 1.0 111.184 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 95.7 mt -123.35 125.62 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 115.914 -0.584 . . . . 1.0 110.002 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -115.58 132.18 56.71 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.175 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.086 -0.959 . . . . 1.0 110.566 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.431 -0.581 . . . . 1.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' C' ' 6' ' ' LEU . 57.8 m-85 -130.67 149.61 52.25 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.308 -0.405 . . . . 1.0 110.357 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -146.49 148.36 19.98 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.622 -0.991 . . . . 1.0 110.622 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.75 142.05 26.25 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.984 0.421 . . . . 1.0 111.214 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.417 ' O ' ' O ' ' E' ' 3' ' ' GLY . 10.9 tp -135.0 127.61 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 115.71 -0.677 . . . . 1.0 109.876 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' C' ' 2' ' ' PHE . 42.4 mt -123.66 132.3 53.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.518 -0.31 . . . . 1.0 110.309 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.4 ' OXT' ' O ' ' E' ' 1' ' ' ASN . 66.3 m . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.768 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 28.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.415 -0.587 . . . . 1.0 109.415 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -132.76 130.57 40.11 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.35 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.55 140.62 11.97 Favored Glycine 0 N--CA 1.466 0.658 0 N-CA-C 110.452 -1.059 . . . . 1.0 110.452 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 139.08 34.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.94 0.4 . . . . 1.0 111.156 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -131.3 129.15 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.009 -0.541 . . . . 1.0 110.411 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 50.0 tp -120.75 129.65 53.71 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.113 -0.494 . . . . 1.0 110.566 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 47.5 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.953 -1.022 . . . . 1.0 110.585 179.764 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.344 -0.613 . . . . 1.0 109.344 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . 0.622 ' CD2' ' ND2' ' D' ' 1' ' ' ASN . 61.7 m-85 -130.67 149.53 52.28 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.289 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.54 149.27 21.39 Favored Glycine 0 N--CA 1.463 0.466 0 N-CA-C 110.491 -1.044 . . . . 1.0 110.491 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.46 140.05 22.54 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 1.0 111.098 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . 0.436 HG23 HD11 ' C' ' 5' ' ' ILE . 96.2 mt -133.28 129.07 56.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.001 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 2' ' ' PHE . 45.6 mt -123.56 132.58 53.93 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.317 -0.401 . . . . 1.0 110.471 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.545 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CD2' ' C' ' 2' ' ' PHE . 29.0 p30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -132.67 130.28 39.92 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.158 -0.474 . . . . 1.0 110.29 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.47 140.04 11.58 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.392 -1.083 . . . . 1.0 110.392 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.63 141.08 37.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.08 0.467 . . . . 1.0 110.996 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 11.0 tp -132.27 129.57 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.363 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 49.1 tp -122.31 127.18 49.51 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.439 -0.346 . . . . 1.0 110.183 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 13.5 m . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.981 -1.009 . . . . 1.0 110.632 179.924 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . 0.4 ' O ' ' OXT' ' A' ' 7' ' ' SER . 99.2 m-20 . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . 0.618 ' CD2' ' ND2' ' F' ' 1' ' ' ASN . 57.1 m-85 -130.27 149.25 52.05 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.314 -0.403 . . . . 1.0 110.262 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -146.54 147.75 18.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.65 140.7 25.03 Favored 'General case' 0 C--O 1.231 0.095 0 CA-C-O 121.052 0.454 . . . . 1.0 111.342 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -133.98 128.22 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 115.857 -0.61 . . . . 1.0 109.935 179.377 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . 0.439 ' O ' ' O ' ' G' ' 2' ' ' PHE . 44.7 mt -123.23 132.61 54.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.463 -0.335 . . . . 1.0 110.597 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.054 -0.974 . . . . 1.0 110.587 179.928 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . 0.618 ' ND2' ' CD2' ' E' ' 2' ' ' PHE . 29.1 p30 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.395 -0.594 . . . . 1.0 109.395 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -132.49 130.46 40.5 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.404 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.32 140.28 11.76 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.327 -1.109 . . . . 1.0 110.327 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.63 140.39 35.04 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.918 0.39 . . . . 1.0 110.973 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 11.2 tp -132.47 128.31 57.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.821 -0.627 . . . . 1.0 110.475 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 47.8 tp -120.01 126.96 52.11 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.298 -0.41 . . . . 1.0 110.334 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.897 -1.049 . . . . 1.0 110.565 179.893 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.279 -0.638 . . . . 1.0 109.279 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' E' ' 6' ' ' LEU . 59.9 m-85 -130.74 150.03 52.11 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.445 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.6 148.59 20.37 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.524 -1.03 . . . . 1.0 110.524 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.15 142.09 25.84 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.927 0.394 . . . . 1.0 110.857 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 10.6 tp -135.12 126.89 47.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 1.0 109.73 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' E' ' 2' ' ' PHE . 53.6 mt -122.54 132.78 54.47 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.907 0.384 . . . . 1.0 110.462 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.055 -0.974 . . . . 1.0 110.607 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 29.2 p30 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.348 -0.612 . . . . 1.0 109.348 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -132.28 130.61 41.1 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.275 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.7 140.74 12.05 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.73 138.41 32.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.865 0.364 . . . . 1.0 111.187 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . 0.402 HD12 HG22 ' H' ' 5' ' ' ILE . 96.1 mt -130.48 128.22 63.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.401 179.431 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 48.8 tp -119.04 127.96 53.91 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.356 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.433 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.295 -0.632 . . . . 1.0 109.295 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -106.81 123.18 47.77 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.182 -0.463 . . . . 1.0 110.404 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.54 132.84 7.24 Favored Glycine 0 N--CA 1.465 0.571 0 N-CA-C 110.285 -1.126 . . . . 1.0 110.285 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.22 137.84 34.62 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.061 0.458 . . . . 1.0 110.997 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 5' ' ' ILE . 10.8 tp -134.64 126.27 47.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.682 -0.69 . . . . 1.0 110.292 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 82.9 mt -123.95 130.86 53.27 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.991 -0.55 . . . . 1.0 110.503 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.448 179.883 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.246 -0.65 . . . . 1.0 109.246 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 65.6 t80 -128.74 130.36 46.97 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 121.056 0.455 . . . . 1.0 110.796 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.93 137.57 9.86 Favored Glycine 0 N--CA 1.466 0.698 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.83 133.9 29.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.849 0.357 . . . . 1.0 111.257 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 46.6 mm -125.08 129.23 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.917 -0.583 . . . . 1.0 110.355 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' D' ' 2' ' ' PHE . 45.7 tp -120.35 130.94 54.64 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.288 -0.415 . . . . 1.0 110.668 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' SER . . . . . 0.424 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 7.9 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.247 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.333 -0.617 . . . . 1.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -107.4 123.13 47.92 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.139 -0.482 . . . . 1.0 110.166 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.75 133.35 7.42 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.251 -1.14 . . . . 1.0 110.251 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.76 135.55 29.84 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 120.989 0.424 . . . . 1.0 111.02 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -131.97 126.43 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.913 -0.585 . . . . 1.0 110.128 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.2 mt -122.6 132.47 54.31 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.432 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.974 -1.013 . . . . 1.0 110.493 -179.988 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.304 -0.628 . . . . 1.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' B' ' 6' ' ' LEU . 67.7 t80 -128.71 130.39 47.07 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.741 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.11 137.4 9.72 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.304 -1.119 . . . . 1.0 110.304 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.6 135.33 31.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.994 0.426 . . . . 1.0 111.074 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -127.31 129.6 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.428 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 46.0 tp -120.05 128.81 53.85 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.328 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.968 -1.015 . . . . 1.0 110.549 179.965 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.3 -0.63 . . . . 1.0 109.3 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -106.54 123.33 47.93 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.329 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.92 133.26 7.36 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 110.28 -1.128 . . . . 1.0 110.28 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.49 133.81 29.77 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.883 0.373 . . . . 1.0 111.252 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -128.09 124.75 63.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.777 -0.647 . . . . 1.0 110.222 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 84.8 mt -123.64 131.6 53.65 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.867 0.365 . . . . 1.0 110.355 179.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.988 -1.005 . . . . 1.0 110.599 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' H' ' 6' ' ' LEU . 66.2 t80 -128.35 130.45 47.78 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.734 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.48 9.75 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.254 -1.138 . . . . 1.0 110.254 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -141.21 134.68 29.84 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.976 0.417 . . . . 1.0 111.102 -179.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -128.01 129.07 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.896 -0.593 . . . . 1.0 110.541 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' H' ' 2' ' ' PHE . 46.5 tp -118.85 128.28 54.3 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.72 -0.673 . . . . 1.0 110.266 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.049 -0.977 . . . . 1.0 110.545 179.987 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.448 -0.575 . . . . 1.0 109.448 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -106.37 124.19 49.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.167 -0.47 . . . . 1.0 110.342 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.62 132.6 6.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.93 138.67 35.78 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.025 0.44 . . . . 1.0 110.747 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 10.6 tp -134.88 125.28 45.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.846 -0.615 . . . . 1.0 110.079 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 83.6 mt -124.14 133.39 53.59 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.133 -0.485 . . . . 1.0 110.336 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.485 179.924 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.265 -0.642 . . . . 1.0 109.265 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . 0.426 ' O ' ' O ' ' F' ' 6' ' ' LEU . 67.2 t80 -128.45 130.47 47.62 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.201 -0.454 . . . . 1.0 110.681 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.92 10.03 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -141.33 134.52 29.39 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.892 0.377 . . . . 1.0 111.096 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.77 128.45 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.988 -0.551 . . . . 1.0 110.392 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' F' ' 2' ' ' PHE . 45.9 tp -118.35 127.3 53.56 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.103 -0.499 . . . . 1.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.076 -0.964 . . . . 1.0 110.372 179.893 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.443 -0.577 . . . . 1.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -107.78 124.37 49.95 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.105 -0.498 . . . . 1.0 110.307 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.13 133.65 7.49 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.272 -1.131 . . . . 1.0 110.272 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 136.74 32.13 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.031 0.443 . . . . 1.0 110.922 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.5 tp -133.67 126.07 50.73 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 115.753 -0.658 . . . . 1.0 110.258 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.8 mt -124.07 129.93 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.566 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.7 p . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.924 -1.036 . . . . 1.0 110.491 179.875 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.332 -0.618 . . . . 1.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . 0.404 ' O ' ' O ' ' D' ' 6' ' ' LEU . 71.5 t80 -129.03 130.32 46.45 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.691 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.52 137.58 9.93 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 110.404 -1.078 . . . . 1.0 110.404 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.54 134.02 29.99 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.965 0.412 . . . . 1.0 111.239 -179.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -124.46 128.22 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 CA-C-N 115.81 -0.632 . . . . 1.0 109.962 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . 0.401 ' O ' ' O ' ' D' ' 2' ' ' PHE . 47.2 tp -118.66 131.18 56.16 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.965 0.412 . . . . 1.0 110.655 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' SER . . . . . 0.542 ' OG ' ' CE2' ' E' ' 2' ' ' PHE . 1.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.02 -0.99 . . . . 1.0 110.309 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.38 -0.6 . . . . 1.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.21 124.35 50.14 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.18 -0.463 . . . . 1.0 110.165 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.47 133.96 7.59 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.369 -1.092 . . . . 1.0 110.369 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.65 134.48 26.93 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.984 0.421 . . . . 1.0 110.925 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.01 126.37 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 115.973 -0.558 . . . . 1.0 110.081 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.9 mt -122.99 132.04 53.97 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.319 -0.4 . . . . 1.0 110.374 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.587 179.983 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.275 -0.639 . . . . 1.0 109.275 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' B' ' 6' ' ' LEU . 73.0 t80 -129.05 130.35 46.45 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.712 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.36 9.8 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.253 -1.139 . . . . 1.0 110.253 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.32 133.87 30.13 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.941 0.4 . . . . 1.0 111.251 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.7 mm -124.22 128.79 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.744 -0.662 . . . . 1.0 110.241 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . 0.404 ' O ' ' O ' ' B' ' 2' ' ' PHE . 48.4 tp -119.14 127.72 53.6 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.397 . . . . 1.0 110.235 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.978 -1.01 . . . . 1.0 110.535 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.399 -0.593 . . . . 1.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . 0.542 ' CE2' ' OG ' ' B' ' 7' ' ' SER . 7.0 m-85 -107.85 124.34 49.94 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.254 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.28 134.42 7.82 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.71 133.15 26.72 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.895 0.378 . . . . 1.0 111.251 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.2 mm -127.93 125.08 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.787 -0.642 . . . . 1.0 110.235 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -123.78 130.46 52.66 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.882 0.373 . . . . 1.0 110.478 179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.577 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' H' ' 6' ' ' LEU . 71.8 t80 -128.79 130.19 46.67 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.91 0.386 . . . . 1.0 110.764 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.67 10.0 Favored Glycine 0 N--CA 1.467 0.727 0 N-CA-C 110.245 -1.142 . . . . 1.0 110.245 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.0 133.41 28.35 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.956 0.408 . . . . 1.0 111.236 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.42 128.59 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.128 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . 0.422 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.2 tp -118.75 128.12 54.18 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.172 -0.467 . . . . 1.0 110.256 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.908 -1.044 . . . . 1.0 110.468 179.899 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.3 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.57 124.93 50.66 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.211 -0.45 . . . . 1.0 110.284 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.82 133.48 7.32 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.217 -1.153 . . . . 1.0 110.217 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.9 137.75 33.39 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.956 0.408 . . . . 1.0 110.745 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 9.7 tp -134.09 125.77 48.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.894 -0.594 . . . . 1.0 110.178 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.9 mt -124.24 131.01 53.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.336 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.1 p . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.501 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.255 -0.646 . . . . 1.0 109.255 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . 0.422 ' O ' ' O ' ' F' ' 6' ' ' LEU . 72.9 t80 -128.49 130.26 47.25 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.285 -0.416 . . . . 1.0 110.74 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.54 138.03 10.22 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.276 -1.129 . . . . 1.0 110.276 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.56 134.38 30.48 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.992 0.425 . . . . 1.0 111.107 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . 0.419 HD11 HG21 ' H' ' 5' ' ' ILE . 96.3 mt -124.74 127.81 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.967 -0.56 . . . . 1.0 110.146 179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' F' ' 2' ' ' PHE . 48.8 tp -118.67 128.94 55.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.418 -0.356 . . . . 1.0 110.293 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.999 -1.001 . . . . 1.0 110.419 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.48 -0.563 . . . . 1.0 109.48 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -106.13 122.61 46.54 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.221 -0.445 . . . . 1.0 110.46 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.16 134.36 7.58 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.202 -1.159 . . . . 1.0 110.202 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 139.13 32.91 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.1 0.476 . . . . 1.0 111.186 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.414 ' O ' ' CG2' ' A' ' 5' ' ' ILE . 11.1 tp -134.04 124.96 47.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 115.599 -0.728 . . . . 1.0 110.124 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -126.52 131.89 51.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.079 -0.51 . . . . 1.0 110.54 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.071 -0.966 . . . . 1.0 110.485 179.903 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.489 1.482 0 N-CA-C 109.396 -0.594 . . . . 1.0 109.396 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 36.2 t80 -131.98 130.74 41.85 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.291 -0.413 . . . . 1.0 110.413 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.89 138.0 10.31 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.52 132.18 27.24 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.843 0.354 . . . . 1.0 111.283 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.35 125.57 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.016 -0.538 . . . . 1.0 110.077 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -114.57 129.49 56.67 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.506 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' F' ' 1' ' ' ASN . 21.0 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.322 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 1.0 109.337 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -106.39 122.75 46.89 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.224 -0.443 . . . . 1.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.86 134.8 7.74 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.144 -1.183 . . . . 1.0 110.144 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.68 136.94 29.52 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.921 0.391 . . . . 1.0 111.177 -179.597 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . 0.421 HD11 HG23 ' C' ' 5' ' ' ILE . 96.1 mt -130.72 124.34 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.09 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 86.5 mt -125.37 132.13 52.85 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.456 -0.338 . . . . 1.0 110.472 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 90.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 1.0 110.559 179.88 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 109.214 -0.661 . . . . 1.0 109.214 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -132.09 130.54 41.37 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.457 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.53 10.07 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.3 -1.12 . . . . 1.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.28 134.71 31.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.01 0.433 . . . . 1.0 111.036 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -126.99 127.38 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.382 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 15.9 mt -116.11 131.57 56.9 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.351 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 118.006 -0.997 . . . . 1.0 110.517 179.864 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.442 -0.577 . . . . 1.0 109.442 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -106.19 122.65 46.65 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.336 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.31 134.89 7.83 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.208 -1.157 . . . . 1.0 110.208 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 137.01 30.37 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.951 0.405 . . . . 1.0 111.426 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . 0.409 HG23 HD12 ' E' ' 5' ' ' ILE . 96.2 mt -131.18 124.32 55.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.836 -0.62 . . . . 1.0 110.12 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 87.2 mt -125.87 131.37 52.39 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.186 -0.461 . . . . 1.0 110.442 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 83.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.063 -0.97 . . . . 1.0 110.579 179.821 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . 0.513 ' N ' ' OG ' ' B' ' 7' ' ' SER . 98.9 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' H' ' 6' ' ' LEU . 36.3 t80 -132.05 130.95 41.97 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.347 -0.388 . . . . 1.0 110.519 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.08 138.39 10.51 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 131.67 25.37 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.921 0.391 . . . . 1.0 111.309 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.8 mm -122.88 126.33 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.017 -0.538 . . . . 1.0 110.127 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . 0.412 ' O ' ' O ' ' H' ' 2' ' ' PHE . 15.5 mt -114.99 127.59 55.76 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.137 -0.483 . . . . 1.0 109.974 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.614 179.863 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -106.38 123.25 47.77 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.304 -0.407 . . . . 1.0 110.36 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.92 134.36 7.5 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.113 -1.195 . . . . 1.0 110.113 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.8 140.04 32.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.048 0.452 . . . . 1.0 110.926 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . 0.413 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 11.1 tp -134.52 124.85 45.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.698 -0.683 . . . . 1.0 110.007 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -126.87 133.34 50.73 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.456 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.98 -1.009 . . . . 1.0 110.403 -179.992 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . 0.412 ' O ' ' O ' ' F' ' 6' ' ' LEU . 38.3 t80 -132.01 131.13 42.23 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.375 -0.375 . . . . 1.0 110.48 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.27 138.79 10.74 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.391 -1.084 . . . . 1.0 110.391 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.79 132.48 27.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.91 0.386 . . . . 1.0 111.267 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.7 mm -122.89 126.39 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.083 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . 0.414 ' O ' ' O ' ' F' ' 2' ' ' PHE . 15.9 mt -116.4 129.24 56.13 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.387 -0.369 . . . . 1.0 110.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 35.1 p . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.024 -0.988 . . . . 1.0 110.38 179.827 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . 0.622 ' CZ ' ' ND2' ' B' ' 1' ' ' ASN . 6.9 m-85 -106.01 122.12 45.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.435 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.62 134.22 7.46 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 110.337 -1.105 . . . . 1.0 110.337 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 138.06 30.31 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.114 0.483 . . . . 1.0 110.967 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.7 tp -135.09 125.23 44.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 115.721 -0.672 . . . . 1.0 110.239 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.5 mt -125.1 129.62 50.57 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.996 -0.547 . . . . 1.0 110.513 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.2 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.469 179.874 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CZ ' ' A' ' 2' ' ' PHE . 59.4 t-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . 0.517 ' N ' ' OD1' ' B' ' 1' ' ' ASN . 72.6 t80 -129.46 129.85 45.15 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.675 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.79 136.01 8.81 Favored Glycine 0 N--CA 1.467 0.72 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.2 134.16 27.27 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.033 0.444 . . . . 1.0 111.497 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -124.85 128.43 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.721 -0.672 . . . . 1.0 109.995 179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . 0.424 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 45.7 tp -121.17 132.99 55.17 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.833 0.349 . . . . 1.0 110.903 -179.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' SER . . . . . 0.525 ' OG ' ' CZ ' ' E' ' 2' ' ' PHE . 17.5 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.01 . . . . 1.0 110.562 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.286 -0.635 . . . . 1.0 109.286 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -106.62 122.42 46.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.235 -0.439 . . . . 1.0 110.241 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.41 134.87 7.72 Favored Glycine 0 N--CA 1.465 0.605 0 N-CA-C 110.384 -1.086 . . . . 1.0 110.384 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.84 135.45 26.11 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.95 0.405 . . . . 1.0 111.098 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -131.25 124.81 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.157 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 88.0 mt -124.26 132.0 53.56 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.43 -0.35 . . . . 1.0 110.284 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 32.5 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.019 -0.991 . . . . 1.0 110.55 179.847 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' D' ' 2' ' ' PHE . 60.0 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.335 -0.617 . . . . 1.0 109.335 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . 0.513 ' N ' ' OD1' ' D' ' 1' ' ' ASN . 74.7 t80 -129.08 129.77 45.67 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.777 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.6 135.8 8.74 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.198 -1.161 . . . . 1.0 110.198 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 133.81 26.64 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.0 0.429 . . . . 1.0 111.335 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.53 128.41 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.757 -0.656 . . . . 1.0 110.022 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' B' ' 2' ' ' PHE . 45.6 tp -120.02 128.8 53.87 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.369 -0.378 . . . . 1.0 110.298 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 7' ' ' SER . . . . . 0.487 ' HG ' HD22 ' B' ' 1' ' ' ASN . 3.7 m . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.002 -0.999 . . . . 1.0 110.575 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.31 -0.626 . . . . 1.0 109.31 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . 0.525 ' CZ ' ' OG ' ' B' ' 7' ' ' SER . 7.0 m-85 -106.14 122.15 45.61 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.232 -0.44 . . . . 1.0 110.275 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.97 134.81 7.73 Favored Glycine 0 N--CA 1.465 0.6 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.28 136.07 27.62 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.969 0.414 . . . . 1.0 111.172 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.18 124.41 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.201 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.49 130.89 53.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.207 -0.451 . . . . 1.0 110.428 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.551 179.908 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' F' ' 2' ' ' PHE . 59.6 t-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.367 -0.605 . . . . 1.0 109.367 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . 0.524 ' N ' ' OD1' ' F' ' 1' ' ' ASN . 73.0 t80 -130.22 129.52 43.47 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.041 -0.527 . . . . 1.0 110.593 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.63 136.03 8.86 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.151 -1.179 . . . . 1.0 110.151 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.57 133.38 25.51 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 121.059 0.457 . . . . 1.0 111.417 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -124.94 128.33 73.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-N 115.699 -0.682 . . . . 1.0 110.063 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' H' ' 2' ' ' PHE . 45.8 tp -119.56 127.92 53.44 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.015 -0.538 . . . . 1.0 110.28 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 7' ' ' SER . . . . . 0.601 ' HG ' HD22 ' H' ' 1' ' ' ASN . 7.0 m . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.005 -0.998 . . . . 1.0 110.485 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.289 -0.634 . . . . 1.0 109.289 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' H' ' 1' ' ' ASN . 7.1 m-85 -105.89 122.98 47.23 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.289 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.55 134.02 7.26 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 110.291 -1.124 . . . . 1.0 110.291 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.49 139.14 31.41 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.041 0.448 . . . . 1.0 110.759 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 10.8 tp -135.76 124.91 39.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 1.0 110.22 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.26 130.74 52.66 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.37 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 37.7 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.536 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . 0.601 HD22 ' HG ' ' F' ' 7' ' ' SER . 59.5 t-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.404 -0.591 . . . . 1.0 109.404 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . 0.519 ' N ' ' OD1' ' H' ' 1' ' ' ASN . 74.3 t80 -129.49 129.82 45.06 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.199 -0.455 . . . . 1.0 110.694 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 136.34 8.97 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.385 -1.086 . . . . 1.0 110.385 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.29 134.61 27.76 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.038 0.447 . . . . 1.0 111.288 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . 0.418 HD11 HG22 ' H' ' 5' ' ' ILE . 96.3 mt -125.59 127.65 71.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.931 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' F' ' 2' ' ' PHE . 47.0 tp -119.59 129.96 54.89 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.341 -0.39 . . . . 1.0 110.409 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 59.5 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.997 -1.001 . . . . 1.0 110.501 179.878 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -105.12 123.59 48.09 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.153 -0.476 . . . . 1.0 110.28 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -128.78 137.57 9.72 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.589 -1.004 . . . . 1.0 110.589 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -144.44 141.12 29.39 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-O 120.94 0.4 . . . . 1.0 111.046 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' E' ' 3' ' ' GLY . 10.9 tp -141.35 125.79 17.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.71 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 60.2 mt -120.74 132.67 55.18 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.968 -0.56 . . . . 1.0 110.32 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.534 179.869 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.268 -0.641 . . . . 1.0 109.268 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' D' ' 6' ' ' LEU . 56.2 t80 -128.22 130.53 48.11 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.248 -0.433 . . . . 1.0 110.725 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.86 137.48 9.65 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.332 -1.107 . . . . 1.0 110.332 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.38 135.62 32.29 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.913 0.387 . . . . 1.0 111.23 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -127.03 130.05 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.888 -0.596 . . . . 1.0 110.278 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 47.0 tp -120.42 130.78 54.49 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.016 0.436 . . . . 1.0 110.604 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' F' ' 1' ' ' ASN . 52.0 p . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 117.793 -1.099 . . . . 1.0 110.208 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.353 -0.61 . . . . 1.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -105.49 123.45 47.92 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.224 -0.444 . . . . 1.0 110.212 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.03 138.2 10.1 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.699 -0.96 . . . . 1.0 110.699 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.16 140.36 26.59 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.959 0.409 . . . . 1.0 110.75 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 19.8 tt -140.39 126.62 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 116.059 -0.518 . . . . 1.0 110.061 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 69.4 mt -120.04 133.76 55.44 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.245 -0.434 . . . . 1.0 110.27 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 34.4 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.511 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.272 -0.64 . . . . 1.0 109.272 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -128.38 130.44 47.69 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.225 -0.443 . . . . 1.0 110.632 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.9 137.3 9.53 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.278 -1.129 . . . . 1.0 110.278 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.72 136.33 32.48 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.06 0.457 . . . . 1.0 110.947 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . 0.42 HD12 HG22 ' D' ' 5' ' ' ILE . 96.6 mt -128.75 130.58 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.907 -0.588 . . . . 1.0 110.519 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . 0.402 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.3 tp -120.51 129.52 53.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.232 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 95.5 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.496 -179.998 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -105.25 123.77 48.41 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.195 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -129.33 138.0 9.95 Favored Glycine 0 N--CA 1.468 0.776 0 N-CA-C 110.695 -0.962 . . . . 1.0 110.695 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.03 140.2 27.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.793 0.33 . . . . 1.0 111.079 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . 0.425 ' O ' ' O ' ' A' ' 3' ' ' GLY . 20.2 tt -140.44 125.42 19.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.465 179.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 62.2 mt -119.66 132.54 55.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.282 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.543 179.943 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . 0.525 ' N ' ' OG ' ' B' ' 7' ' ' SER . 98.9 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -128.21 130.58 48.22 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.264 -0.426 . . . . 1.0 110.666 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 137.23 9.48 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.204 -1.159 . . . . 1.0 110.204 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -140.88 136.1 31.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.059 0.457 . . . . 1.0 111.032 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -129.44 130.24 67.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 115.915 -0.584 . . . . 1.0 110.523 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.9 tp -119.84 129.02 54.21 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.575 -0.739 . . . . 1.0 110.207 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.945 -1.026 . . . . 1.0 110.556 179.864 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -105.16 124.32 49.33 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.218 -0.446 . . . . 1.0 110.3 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.62 137.72 9.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.651 -0.98 . . . . 1.0 110.651 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.38 141.13 28.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.904 0.383 . . . . 1.0 110.629 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . 0.405 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 11.1 tp -141.59 126.34 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.989 -0.551 . . . . 1.0 110.312 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . 0.478 ' C ' ' HG ' ' G' ' 7' ' ' SER . 65.2 mt -120.33 131.78 55.01 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.225 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 7' ' ' SER . . . . . 0.478 ' HG ' ' C ' ' G' ' 6' ' ' LEU . 2.2 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.474 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.376 -0.602 . . . . 1.0 109.376 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' F' ' 6' ' ' LEU . 58.1 t80 -127.79 130.47 48.75 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.941 0.401 . . . . 1.0 110.713 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.19 137.58 9.68 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.361 -1.096 . . . . 1.0 110.361 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -140.67 135.79 31.99 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.855 0.36 . . . . 1.0 111.166 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -127.17 129.88 71.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 116.013 -0.54 . . . . 1.0 110.367 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 49.2 tp -120.42 128.34 53.1 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.195 -0.457 . . . . 1.0 110.216 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 52.1 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.942 -1.028 . . . . 1.0 110.439 179.754 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -124.28 135.39 53.35 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.354 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -133.51 134.16 7.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.08 132.17 20.38 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.149 0.5 . . . . 1.0 110.946 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.447 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 10.1 tp -137.99 122.43 22.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.472 -0.786 . . . . 1.0 110.217 -179.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 mt -119.51 135.4 54.79 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.932 0.396 . . . . 1.0 110.888 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.3 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.116 -0.945 . . . . 1.0 110.384 179.646 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -131.57 132.35 44.04 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.18 -0.464 . . . . 1.0 110.665 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.12 136.76 9.01 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.431 -1.068 . . . . 1.0 110.431 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.61 133.37 30.61 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.801 0.334 . . . . 1.0 110.883 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -125.47 128.16 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.543 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -119.11 127.52 53.44 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.007 -0.542 . . . . 1.0 110.051 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.878 -1.058 . . . . 1.0 110.632 179.719 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.418 -0.586 . . . . 1.0 109.418 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . 0.402 ' N ' ' CD1' ' C' ' 2' ' ' PHE . 33.1 m-85 -123.99 135.42 53.62 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.222 -0.444 . . . . 1.0 110.21 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.42 134.77 7.57 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.496 -1.041 . . . . 1.0 110.496 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.13 128.67 15.04 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-O 121.023 0.439 . . . . 1.0 111.048 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.74 124.19 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.818 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 61.7 mt -118.35 132.48 56.27 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.809 0.337 . . . . 1.0 110.451 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 5.9 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.048 -0.977 . . . . 1.0 110.503 179.975 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . 0.431 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.4 -0.593 . . . . 1.0 109.4 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -132.07 131.83 42.77 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.695 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.74 136.21 8.72 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.402 -1.079 . . . . 1.0 110.402 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.14 133.11 31.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.916 0.389 . . . . 1.0 110.843 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.3 mm -124.66 128.28 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.377 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 50.7 tp -118.64 126.5 52.07 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.046 -0.524 . . . . 1.0 109.99 179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.025 -0.988 . . . . 1.0 110.578 179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -123.7 134.88 53.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.251 -0.431 . . . . 1.0 110.164 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -133.19 135.1 7.87 Favored Glycine 0 N--CA 1.466 0.666 0 N-CA-C 110.442 -1.063 . . . . 1.0 110.442 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.11 128.31 13.78 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.969 0.414 . . . . 1.0 111.465 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.1 mt -134.25 124.17 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.838 -0.619 . . . . 1.0 110.205 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 54.2 mt -118.38 133.25 56.04 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.306 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.932 -1.032 . . . . 1.0 110.468 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.389 -0.597 . . . . 1.0 109.389 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -131.52 132.17 43.99 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.188 -0.46 . . . . 1.0 110.747 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.02 136.55 8.89 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.421 -1.071 . . . . 1.0 110.421 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.07 132.32 28.21 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.826 0.346 . . . . 1.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 45.9 mm -125.07 127.75 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.408 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 tp -117.41 126.36 52.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.731 -0.668 . . . . 1.0 110.13 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.946 -1.026 . . . . 1.0 110.566 179.984 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.484 -0.561 . . . . 1.0 109.484 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 37.3 m-85 -124.15 136.08 53.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.229 -0.441 . . . . 1.0 110.259 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.66 135.11 7.74 Favored Glycine 0 N--CA 1.466 0.652 0 N-CA-C 110.355 -1.098 . . . . 1.0 110.355 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.49 127.77 12.13 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.025 0.44 . . . . 1.0 111.271 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.99 125.29 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.73 -0.668 . . . . 1.0 110.115 179.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 57.8 mt -117.82 132.77 56.4 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 1.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.496 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 55.6 p30 . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.447 -0.575 . . . . 1.0 109.447 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -131.25 132.09 44.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.283 -0.417 . . . . 1.0 110.694 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.4 136.42 8.79 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.506 -1.037 . . . . 1.0 110.506 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.32 134.09 32.08 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.806 0.336 . . . . 1.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . 0.423 HD13 HG21 ' H' ' 5' ' ' ILE . 96.0 mt -125.55 127.82 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.149 -0.478 . . . . 1.0 110.484 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -118.05 127.56 53.92 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.056 -0.52 . . . . 1.0 110.109 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.008 -0.996 . . . . 1.0 110.595 179.942 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . 0.497 ' H3 ' ' C ' ' E' ' 7' ' ' SER . 49.9 p-10 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.457 -0.572 . . . . 1.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -105.49 124.67 49.93 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.141 -0.481 . . . . 1.0 110.403 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -127.51 135.26 8.65 Favored Glycine 0 N--CA 1.466 0.641 0 N-CA-C 110.503 -1.039 . . . . 1.0 110.503 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.74 136.9 33.0 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.022 0.439 . . . . 1.0 110.734 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . 0.444 ' O ' ' O ' ' E' ' 3' ' ' GLY . 19.8 tt -137.49 122.69 24.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.604 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 48.4 mt -119.21 133.81 55.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.496 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.481 179.991 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -131.4 130.8 43.04 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.21 -0.45 . . . . 1.0 110.442 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.88 137.57 10.04 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.387 -1.085 . . . . 1.0 110.387 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.28 132.62 30.03 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.864 0.364 . . . . 1.0 111.092 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.57 125.86 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 1.0 110.199 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.7 mt -114.37 131.87 56.41 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.258 -0.428 . . . . 1.0 110.48 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 71.2 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.362 179.707 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' C' ' 1' ' ' ASN . 49.8 p-10 . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -105.42 124.37 49.44 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.11 -0.495 . . . . 1.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.67 135.26 8.62 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.573 -1.011 . . . . 1.0 110.573 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 132.74 25.53 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.813 0.34 . . . . 1.0 110.86 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.35 123.34 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.121 -0.49 . . . . 1.0 109.971 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 58.9 mt -117.92 132.23 56.43 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.861 0.363 . . . . 1.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 7' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' C' ' 7' ' ' SER . 14.6 t . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.001 -1.0 . . . . 1.0 110.439 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.352 -0.61 . . . . 1.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -131.59 130.68 42.52 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.428 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.37 9.96 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.365 -1.094 . . . . 1.0 110.365 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.17 134.55 32.94 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.919 0.39 . . . . 1.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.85 127.16 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.013 -0.539 . . . . 1.0 110.47 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 15.9 mt -115.27 131.43 56.93 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.084 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.955 -1.021 . . . . 1.0 110.546 179.896 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' E' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.482 -0.562 . . . . 1.0 109.482 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -105.84 124.76 50.09 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.126 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -127.52 137.01 9.57 Favored Glycine 0 N--CA 1.467 0.73 0 N-CA-C 110.46 -1.056 . . . . 1.0 110.46 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 132.81 24.49 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.894 0.378 . . . . 1.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . 0.432 HG23 HD11 ' E' ' 5' ' ' ILE . 96.3 mt -131.86 121.53 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.971 -0.559 . . . . 1.0 110.386 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 50.8 mt -117.84 133.31 56.06 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.107 -0.497 . . . . 1.0 110.242 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 7' ' ' SER . . . . . 0.497 ' C ' ' H3 ' ' A' ' 1' ' ' ASN . 10.3 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.099 -0.953 . . . . 1.0 110.491 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.364 -0.606 . . . . 1.0 109.364 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -131.52 130.91 42.95 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.171 -0.468 . . . . 1.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.07 137.54 9.98 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.79 133.86 30.99 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.854 0.359 . . . . 1.0 110.882 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.5 126.43 67.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 CA-C-N 116.136 -0.484 . . . . 1.0 110.512 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -113.32 129.8 56.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.46 -0.791 . . . . 1.0 110.07 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.59 179.913 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' G' ' 1' ' ' ASN . 49.5 p-10 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.46 -0.57 . . . . 1.0 109.46 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -105.83 125.34 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.156 -0.474 . . . . 1.0 110.429 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.46 136.51 9.14 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.416 -1.073 . . . . 1.0 110.416 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 131.76 24.14 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.923 0.392 . . . . 1.0 111.016 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.4 mm -128.57 121.77 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.79 -0.641 . . . . 1.0 110.495 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 55.7 mt -119.0 132.15 56.05 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.072 -0.344 . . . . 1.0 110.072 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.474 -179.879 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.411 -0.589 . . . . 1.0 109.411 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -130.85 131.03 44.34 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.935 0.398 . . . . 1.0 110.395 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 138.24 10.41 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.494 -1.042 . . . . 1.0 110.494 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.82 29.33 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.883 0.373 . . . . 1.0 111.046 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.5 mm -123.41 126.72 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 115.998 -0.546 . . . . 1.0 110.138 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 16.1 mt -115.98 133.94 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.192 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.077 -0.963 . . . . 1.0 110.337 179.851 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ASN . . . . . 0.411 ' H2 ' ' C ' ' E' ' 7' ' ' SER . 99.1 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.313 -0.625 . . . . 1.0 109.313 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -104.89 122.97 46.9 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.243 -0.435 . . . . 1.0 110.437 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -130.28 133.64 7.47 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.82 136.0 31.98 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-O 121.026 0.441 . . . . 1.0 110.925 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 19.9 tt -134.63 124.74 45.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.681 -0.69 . . . . 1.0 110.421 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 62.1 mt -121.62 133.44 54.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.825 -0.625 . . . . 1.0 110.53 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.531 179.891 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 1' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 2' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' D' ' 6' ' ' LEU . 67.4 t80 -130.26 131.06 45.32 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.2 -0.454 . . . . 1.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 139.45 11.2 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.445 -1.062 . . . . 1.0 110.445 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.43 134.44 27.26 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.027 0.441 . . . . 1.0 111.365 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.39 128.72 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.899 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' LEU . . . . . 0.418 ' O ' ' O ' ' D' ' 2' ' ' PHE . 50.3 tp -120.99 134.12 55.29 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.903 0.382 . . . . 1.0 111.082 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' SER . . . . . 0.448 ' OG ' ' OD1' ' F' ' 1' ' ' ASN . 11.6 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.795 -1.097 . . . . 1.0 110.057 179.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.366 -0.605 . . . . 1.0 109.366 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -105.07 123.14 47.3 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.203 -0.453 . . . . 1.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.91 133.6 7.36 Favored Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.325 -1.11 . . . . 1.0 110.325 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.01 132.71 25.56 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.885 0.374 . . . . 1.0 110.884 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.67 124.95 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 116.081 -0.509 . . . . 1.0 109.994 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 68.9 mt -120.06 132.85 55.59 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.217 -0.447 . . . . 1.0 110.34 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 21.3 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.545 179.947 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 1' ' ' ASN . . . . . 0.423 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.2 p30 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.35 -0.611 . . . . 1.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 2' ' ' PHE . . . . . 0.418 ' O ' ' O ' ' B' ' 6' ' ' LEU . 68.7 t80 -130.13 130.93 45.41 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.251 -0.432 . . . . 1.0 110.686 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.94 139.11 11.0 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.366 -1.094 . . . . 1.0 110.366 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 134.21 27.24 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.987 0.423 . . . . 1.0 111.168 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.39 128.7 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.011 179.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 6' ' ' LEU . . . . . 0.407 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.6 tp -120.3 128.91 53.74 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.178 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.568 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.307 -0.627 . . . . 1.0 109.307 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.11 123.28 47.55 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.163 -0.472 . . . . 1.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.5 136.38 8.84 Favored Glycine 0 N--CA 1.466 0.644 0 N-CA-C 110.136 -1.186 . . . . 1.0 110.136 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 130.51 20.58 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.812 0.339 . . . . 1.0 111.231 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 5' ' ' ILE . . . . . 0.407 ' O ' ' O ' ' A' ' 3' ' ' GLY . 47.9 mm -126.13 123.5 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.276 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 68.2 mt -120.61 132.49 55.16 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.434 -0.348 . . . . 1.0 110.275 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 7' ' ' SER . . . . . 0.411 ' C ' ' H2 ' ' A' ' 1' ' ' ASN . 27.5 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.931 -1.033 . . . . 1.0 110.566 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 1' ' ' ASN . . . . . 0.448 ' OD1' ' OG ' ' B' ' 7' ' ' SER . 57.2 p30 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.514 -0.55 . . . . 1.0 109.514 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 2' ' ' PHE . . . . . 0.434 ' O ' ' O ' ' H' ' 6' ' ' LEU . 68.5 t80 -130.38 130.73 44.74 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.209 -0.451 . . . . 1.0 110.797 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.01 139.1 10.98 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.47 133.86 26.37 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.019 0.437 . . . . 1.0 111.2 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 46.5 mm -124.73 128.26 73.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.789 -0.642 . . . . 1.0 109.91 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 6' ' ' LEU . . . . . 0.409 ' O ' ' O ' ' H' ' 2' ' ' PHE . 50.9 tp -119.3 128.58 54.27 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.165 -0.471 . . . . 1.0 110.291 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.634 -179.951 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.09 123.84 48.51 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.236 -0.438 . . . . 1.0 110.546 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.54 135.75 8.39 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.187 -1.165 . . . . 1.0 110.187 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.76 131.66 22.89 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.979 0.419 . . . . 1.0 111.099 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.8 mm -126.48 123.61 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.447 179.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 67.2 mt -120.97 131.54 54.39 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.155 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.9 p . . . . . 0 C--O 1.221 -0.404 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.556 -179.942 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 1' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 56.7 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.441 -0.577 . . . . 1.0 109.441 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 2' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' F' ' 6' ' ' LEU . 69.5 t80 -130.03 130.86 45.48 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.216 -0.447 . . . . 1.0 110.706 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.35 139.3 11.07 Favored Glycine 0 N--CA 1.465 0.603 0 N-CA-C 110.474 -1.05 . . . . 1.0 110.474 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.03 135.19 28.99 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.972 0.415 . . . . 1.0 111.252 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.09 128.03 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.907 -0.588 . . . . 1.0 109.934 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 6' ' ' LEU . . . . . 0.434 ' O ' ' O ' ' F' ' 2' ' ' PHE . 50.5 tp -119.84 131.54 55.31 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.383 -0.371 . . . . 1.0 110.393 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 51.7 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.061 -0.971 . . . . 1.0 110.287 179.846 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.475 ' H1 ' ' C ' ' E' ' 7' ' ' SER . 99.1 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.394 -0.595 . . . . 1.0 109.394 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -107.63 125.68 51.64 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.525 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.36 134.58 7.57 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.249 -1.14 . . . . 1.0 110.249 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.06 137.84 31.34 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.014 0.435 . . . . 1.0 110.906 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.402 ' O ' ' CG2' ' A' ' 5' ' ' ILE . 11.1 tp -135.5 125.83 43.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 115.839 -0.618 . . . . 1.0 110.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 86.0 mt -124.6 128.15 48.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.849 -0.614 . . . . 1.0 110.433 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.035 -0.984 . . . . 1.0 110.515 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.371 -0.603 . . . . 1.0 109.371 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -132.88 130.05 39.19 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.276 -0.42 . . . . 1.0 110.22 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.08 137.06 9.35 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 110.592 -1.003 . . . . 1.0 110.592 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.75 29.22 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.914 0.387 . . . . 1.0 111.284 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -123.19 125.24 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.835 179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -115.04 133.01 56.41 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.374 -0.376 . . . . 1.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.92 -1.038 . . . . 1.0 110.342 179.077 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.342 -0.614 . . . . 1.0 109.342 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.29 126.05 52.39 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.2 -0.455 . . . . 1.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.3 134.7 7.54 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 110.309 -1.116 . . . . 1.0 110.309 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.87 135.14 27.4 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.869 0.366 . . . . 1.0 110.962 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.52 125.39 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.231 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.76 130.79 53.18 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.435 -0.348 . . . . 1.0 110.364 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 33.9 p . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.986 -1.007 . . . . 1.0 110.578 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.315 -0.624 . . . . 1.0 109.315 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 35.8 t80 -132.95 129.76 38.68 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.278 -0.419 . . . . 1.0 110.367 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.73 136.71 9.2 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.31 133.97 31.92 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.027 0.442 . . . . 1.0 111.179 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.8 mm -124.0 127.06 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.7 -0.682 . . . . 1.0 110.18 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 16.2 mt -117.38 131.52 56.76 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.218 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.036 -0.983 . . . . 1.0 110.574 179.958 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.37 -0.604 . . . . 1.0 109.37 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.49 125.59 51.46 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.268 -0.424 . . . . 1.0 110.446 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.07 135.87 8.36 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.257 -1.137 . . . . 1.0 110.257 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 135.56 26.77 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.986 0.422 . . . . 1.0 111.071 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . 0.406 HG22 HD12 ' E' ' 5' ' ' ILE . 96.1 mt -132.24 125.09 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.853 -0.612 . . . . 1.0 110.273 179.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 88.7 mt -124.31 130.74 53.04 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.332 -0.394 . . . . 1.0 110.519 179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 7' ' ' SER . . . . . 0.475 ' C ' ' H1 ' ' A' ' 1' ' ' ASN . 14.9 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.566 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.372 -0.603 . . . . 1.0 109.372 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -133.14 130.09 38.75 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.092 -0.504 . . . . 1.0 110.418 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.2 137.19 9.42 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.427 -1.069 . . . . 1.0 110.427 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.48 131.93 26.9 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.826 0.346 . . . . 1.0 111.246 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.5 mm -122.86 125.75 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.968 -0.56 . . . . 1.0 109.965 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -114.5 129.07 56.63 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.124 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.018 -0.992 . . . . 1.0 110.586 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -107.26 126.03 51.9 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.473 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.65 134.74 7.63 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.252 -1.139 . . . . 1.0 110.252 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 138.94 31.7 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.98 0.419 . . . . 1.0 110.67 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 11.2 tp -136.09 125.9 40.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.793 -0.64 . . . . 1.0 110.253 179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 85.5 mt -125.68 130.56 51.81 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 1.0 110.427 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.984 -1.007 . . . . 1.0 110.373 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.479 -0.563 . . . . 1.0 109.479 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -132.53 130.3 40.2 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.219 -0.446 . . . . 1.0 110.415 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.45 137.73 9.76 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.474 -1.051 . . . . 1.0 110.474 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.37 133.26 29.17 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.887 0.375 . . . . 1.0 111.184 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 95.7 mt -123.35 125.62 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 115.914 -0.584 . . . . 1.0 110.002 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -115.58 132.18 56.71 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.175 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.086 -0.959 . . . . 1.0 110.566 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.431 -0.581 . . . . 1.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' C' ' 6' ' ' LEU . 57.8 m-85 -130.67 149.61 52.25 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.308 -0.405 . . . . 1.0 110.357 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -146.49 148.36 19.98 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.622 -0.991 . . . . 1.0 110.622 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.75 142.05 26.25 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.984 0.421 . . . . 1.0 111.214 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.417 ' O ' ' O ' ' E' ' 3' ' ' GLY . 10.9 tp -135.0 127.61 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 115.71 -0.677 . . . . 1.0 109.876 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' C' ' 2' ' ' PHE . 42.4 mt -123.66 132.3 53.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.518 -0.31 . . . . 1.0 110.309 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.4 ' OXT' ' O ' ' E' ' 1' ' ' ASN . 66.3 m . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.768 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 28.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.415 -0.587 . . . . 1.0 109.415 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -132.76 130.57 40.11 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.35 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.55 140.62 11.97 Favored Glycine 0 N--CA 1.466 0.658 0 N-CA-C 110.452 -1.059 . . . . 1.0 110.452 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 139.08 34.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.94 0.4 . . . . 1.0 111.156 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -131.3 129.15 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.009 -0.541 . . . . 1.0 110.411 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 50.0 tp -120.75 129.65 53.71 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.113 -0.494 . . . . 1.0 110.566 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 47.5 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.953 -1.022 . . . . 1.0 110.585 179.764 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.344 -0.613 . . . . 1.0 109.344 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . 0.622 ' CD2' ' ND2' ' D' ' 1' ' ' ASN . 61.7 m-85 -130.67 149.53 52.28 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.289 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.54 149.27 21.39 Favored Glycine 0 N--CA 1.463 0.466 0 N-CA-C 110.491 -1.044 . . . . 1.0 110.491 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.46 140.05 22.54 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 1.0 111.098 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . 0.436 HG23 HD11 ' C' ' 5' ' ' ILE . 96.2 mt -133.28 129.07 56.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.001 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 2' ' ' PHE . 45.6 mt -123.56 132.58 53.93 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.317 -0.401 . . . . 1.0 110.471 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.545 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CD2' ' C' ' 2' ' ' PHE . 29.0 p30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -132.67 130.28 39.92 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.158 -0.474 . . . . 1.0 110.29 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.47 140.04 11.58 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.392 -1.083 . . . . 1.0 110.392 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.63 141.08 37.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.08 0.467 . . . . 1.0 110.996 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 11.0 tp -132.27 129.57 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.363 179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 49.1 tp -122.31 127.18 49.51 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.439 -0.346 . . . . 1.0 110.183 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 13.5 m . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.981 -1.009 . . . . 1.0 110.632 179.924 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . 0.4 ' O ' ' OXT' ' A' ' 7' ' ' SER . 99.2 m-20 . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . 0.618 ' CD2' ' ND2' ' F' ' 1' ' ' ASN . 57.1 m-85 -130.27 149.25 52.05 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.314 -0.403 . . . . 1.0 110.262 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -146.54 147.75 18.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.65 140.7 25.03 Favored 'General case' 0 C--O 1.231 0.095 0 CA-C-O 121.052 0.454 . . . . 1.0 111.342 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -133.98 128.22 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 115.857 -0.61 . . . . 1.0 109.935 179.377 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . 0.439 ' O ' ' O ' ' G' ' 2' ' ' PHE . 44.7 mt -123.23 132.61 54.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.463 -0.335 . . . . 1.0 110.597 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.054 -0.974 . . . . 1.0 110.587 179.928 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . 0.618 ' ND2' ' CD2' ' E' ' 2' ' ' PHE . 29.1 p30 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.395 -0.594 . . . . 1.0 109.395 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -132.49 130.46 40.5 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.404 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.32 140.28 11.76 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.327 -1.109 . . . . 1.0 110.327 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.63 140.39 35.04 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.918 0.39 . . . . 1.0 110.973 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 11.2 tp -132.47 128.31 57.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.821 -0.627 . . . . 1.0 110.475 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 47.8 tp -120.01 126.96 52.11 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.298 -0.41 . . . . 1.0 110.334 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.897 -1.049 . . . . 1.0 110.565 179.893 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.279 -0.638 . . . . 1.0 109.279 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' E' ' 6' ' ' LEU . 59.9 m-85 -130.74 150.03 52.11 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.445 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.6 148.59 20.37 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.524 -1.03 . . . . 1.0 110.524 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.15 142.09 25.84 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.927 0.394 . . . . 1.0 110.857 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 10.6 tp -135.12 126.89 47.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 1.0 109.73 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' E' ' 2' ' ' PHE . 53.6 mt -122.54 132.78 54.47 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.907 0.384 . . . . 1.0 110.462 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.055 -0.974 . . . . 1.0 110.607 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 29.2 p30 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.348 -0.612 . . . . 1.0 109.348 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -132.28 130.61 41.1 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.275 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.7 140.74 12.05 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.73 138.41 32.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.865 0.364 . . . . 1.0 111.187 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . 0.402 HD12 HG22 ' H' ' 5' ' ' ILE . 96.1 mt -130.48 128.22 63.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.401 179.431 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 48.8 tp -119.04 127.96 53.91 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.356 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.433 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.295 -0.632 . . . . 1.0 109.295 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -106.81 123.18 47.77 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.182 -0.463 . . . . 1.0 110.404 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.54 132.84 7.24 Favored Glycine 0 N--CA 1.465 0.571 0 N-CA-C 110.285 -1.126 . . . . 1.0 110.285 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.22 137.84 34.62 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.061 0.458 . . . . 1.0 110.997 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.415 ' O ' ' CG2' ' A' ' 5' ' ' ILE . 10.8 tp -134.64 126.27 47.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.682 -0.69 . . . . 1.0 110.292 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 82.9 mt -123.95 130.86 53.27 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.991 -0.55 . . . . 1.0 110.503 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.448 179.883 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.246 -0.65 . . . . 1.0 109.246 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 65.6 t80 -128.74 130.36 46.97 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 121.056 0.455 . . . . 1.0 110.796 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.93 137.57 9.86 Favored Glycine 0 N--CA 1.466 0.698 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.83 133.9 29.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.849 0.357 . . . . 1.0 111.257 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 46.6 mm -125.08 129.23 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.917 -0.583 . . . . 1.0 110.355 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' D' ' 2' ' ' PHE . 45.7 tp -120.35 130.94 54.64 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.288 -0.415 . . . . 1.0 110.668 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' SER . . . . . 0.424 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 7.9 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.247 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.333 -0.617 . . . . 1.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -107.4 123.13 47.92 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.139 -0.482 . . . . 1.0 110.166 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.75 133.35 7.42 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.251 -1.14 . . . . 1.0 110.251 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.76 135.55 29.84 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 120.989 0.424 . . . . 1.0 111.02 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -131.97 126.43 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.913 -0.585 . . . . 1.0 110.128 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.2 mt -122.6 132.47 54.31 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.432 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.974 -1.013 . . . . 1.0 110.493 -179.988 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.304 -0.628 . . . . 1.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' B' ' 6' ' ' LEU . 67.7 t80 -128.71 130.39 47.07 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.741 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.11 137.4 9.72 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.304 -1.119 . . . . 1.0 110.304 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.6 135.33 31.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.994 0.426 . . . . 1.0 111.074 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -127.31 129.6 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.428 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 46.0 tp -120.05 128.81 53.85 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.328 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.968 -1.015 . . . . 1.0 110.549 179.965 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.3 -0.63 . . . . 1.0 109.3 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -106.54 123.33 47.93 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.329 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.92 133.26 7.36 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 110.28 -1.128 . . . . 1.0 110.28 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.49 133.81 29.77 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.883 0.373 . . . . 1.0 111.252 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -128.09 124.75 63.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.777 -0.647 . . . . 1.0 110.222 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 84.8 mt -123.64 131.6 53.65 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.867 0.365 . . . . 1.0 110.355 179.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.988 -1.005 . . . . 1.0 110.599 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' H' ' 6' ' ' LEU . 66.2 t80 -128.35 130.45 47.78 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.734 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.48 9.75 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.254 -1.138 . . . . 1.0 110.254 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -141.21 134.68 29.84 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.976 0.417 . . . . 1.0 111.102 -179.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -128.01 129.07 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.896 -0.593 . . . . 1.0 110.541 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' H' ' 2' ' ' PHE . 46.5 tp -118.85 128.28 54.3 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.72 -0.673 . . . . 1.0 110.266 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.049 -0.977 . . . . 1.0 110.545 179.987 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.448 -0.575 . . . . 1.0 109.448 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -106.37 124.19 49.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.167 -0.47 . . . . 1.0 110.342 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.62 132.6 6.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.93 138.67 35.78 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.025 0.44 . . . . 1.0 110.747 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 10.6 tp -134.88 125.28 45.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.846 -0.615 . . . . 1.0 110.079 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 83.6 mt -124.14 133.39 53.59 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.133 -0.485 . . . . 1.0 110.336 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.485 179.924 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.265 -0.642 . . . . 1.0 109.265 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . 0.426 ' O ' ' O ' ' F' ' 6' ' ' LEU . 67.2 t80 -128.45 130.47 47.62 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.201 -0.454 . . . . 1.0 110.681 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.92 10.03 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -141.33 134.52 29.39 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.892 0.377 . . . . 1.0 111.096 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.77 128.45 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.988 -0.551 . . . . 1.0 110.392 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' F' ' 2' ' ' PHE . 45.9 tp -118.35 127.3 53.56 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.103 -0.499 . . . . 1.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.076 -0.964 . . . . 1.0 110.372 179.893 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.443 -0.577 . . . . 1.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 6.9 m-85 -107.78 124.37 49.95 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.105 -0.498 . . . . 1.0 110.307 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.13 133.65 7.49 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.272 -1.131 . . . . 1.0 110.272 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 136.74 32.13 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.031 0.443 . . . . 1.0 110.922 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.5 tp -133.67 126.07 50.73 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 115.753 -0.658 . . . . 1.0 110.258 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 84.8 mt -124.07 129.93 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.566 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.7 p . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.924 -1.036 . . . . 1.0 110.491 179.875 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.332 -0.618 . . . . 1.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.404 ' O ' ' O ' ' D' ' 6' ' ' LEU . 71.5 t80 -129.03 130.32 46.45 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.691 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.52 137.58 9.93 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 110.404 -1.078 . . . . 1.0 110.404 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.54 134.02 29.99 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.965 0.412 . . . . 1.0 111.239 -179.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -124.46 128.22 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 CA-C-N 115.81 -0.632 . . . . 1.0 109.962 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . 0.401 ' O ' ' O ' ' D' ' 2' ' ' PHE . 47.2 tp -118.66 131.18 56.16 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.965 0.412 . . . . 1.0 110.655 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' SER . . . . . 0.542 ' OG ' ' CE2' ' E' ' 2' ' ' PHE . 1.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.02 -0.99 . . . . 1.0 110.309 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.38 -0.6 . . . . 1.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.21 124.35 50.14 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.18 -0.463 . . . . 1.0 110.165 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.47 133.96 7.59 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.369 -1.092 . . . . 1.0 110.369 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.65 134.48 26.93 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.984 0.421 . . . . 1.0 110.925 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.01 126.37 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 115.973 -0.558 . . . . 1.0 110.081 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.9 mt -122.99 132.04 53.97 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.319 -0.4 . . . . 1.0 110.374 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.587 179.983 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.275 -0.639 . . . . 1.0 109.275 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' B' ' 6' ' ' LEU . 73.0 t80 -129.05 130.35 46.45 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.712 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.36 9.8 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.253 -1.139 . . . . 1.0 110.253 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.32 133.87 30.13 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.941 0.4 . . . . 1.0 111.251 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.7 mm -124.22 128.79 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.744 -0.662 . . . . 1.0 110.241 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . 0.404 ' O ' ' O ' ' B' ' 2' ' ' PHE . 48.4 tp -119.14 127.72 53.6 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.397 . . . . 1.0 110.235 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.978 -1.01 . . . . 1.0 110.535 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.399 -0.593 . . . . 1.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . 0.542 ' CE2' ' OG ' ' B' ' 7' ' ' SER . 7.0 m-85 -107.85 124.34 49.94 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.254 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.28 134.42 7.82 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.71 133.15 26.72 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.895 0.378 . . . . 1.0 111.251 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.2 mm -127.93 125.08 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.787 -0.642 . . . . 1.0 110.235 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -123.78 130.46 52.66 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.882 0.373 . . . . 1.0 110.478 179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.577 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' H' ' 6' ' ' LEU . 71.8 t80 -128.79 130.19 46.67 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.91 0.386 . . . . 1.0 110.764 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.67 10.0 Favored Glycine 0 N--CA 1.467 0.727 0 N-CA-C 110.245 -1.142 . . . . 1.0 110.245 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.0 133.41 28.35 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.956 0.408 . . . . 1.0 111.236 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.42 128.59 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.128 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . 0.422 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.2 tp -118.75 128.12 54.18 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.172 -0.467 . . . . 1.0 110.256 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.908 -1.044 . . . . 1.0 110.468 179.899 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.3 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.57 124.93 50.66 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.211 -0.45 . . . . 1.0 110.284 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.82 133.48 7.32 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.217 -1.153 . . . . 1.0 110.217 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.9 137.75 33.39 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.956 0.408 . . . . 1.0 110.745 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . 0.421 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 9.7 tp -134.09 125.77 48.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.894 -0.594 . . . . 1.0 110.178 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.9 mt -124.24 131.01 53.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.336 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.1 p . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.501 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.255 -0.646 . . . . 1.0 109.255 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . 0.422 ' O ' ' O ' ' F' ' 6' ' ' LEU . 72.9 t80 -128.49 130.26 47.25 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.285 -0.416 . . . . 1.0 110.74 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.54 138.03 10.22 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.276 -1.129 . . . . 1.0 110.276 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.56 134.38 30.48 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.992 0.425 . . . . 1.0 111.107 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . 0.419 HD11 HG21 ' H' ' 5' ' ' ILE . 96.3 mt -124.74 127.81 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.967 -0.56 . . . . 1.0 110.146 179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' F' ' 2' ' ' PHE . 48.8 tp -118.67 128.94 55.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.418 -0.356 . . . . 1.0 110.293 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.999 -1.001 . . . . 1.0 110.419 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.48 -0.563 . . . . 1.0 109.48 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 9.9 m-85 -106.13 122.61 46.54 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.221 -0.445 . . . . 1.0 110.46 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.16 134.36 7.58 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.202 -1.159 . . . . 1.0 110.202 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 139.13 32.91 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.1 0.476 . . . . 1.0 111.186 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.414 ' O ' ' CG2' ' A' ' 5' ' ' ILE . 11.1 tp -134.04 124.96 47.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 115.599 -0.728 . . . . 1.0 110.124 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -126.52 131.89 51.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.079 -0.51 . . . . 1.0 110.54 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.071 -0.966 . . . . 1.0 110.485 179.903 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.489 1.482 0 N-CA-C 109.396 -0.594 . . . . 1.0 109.396 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 36.2 t80 -131.98 130.74 41.85 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.291 -0.413 . . . . 1.0 110.413 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.89 138.0 10.31 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.52 132.18 27.24 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.843 0.354 . . . . 1.0 111.283 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.35 125.57 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.016 -0.538 . . . . 1.0 110.077 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -114.57 129.49 56.67 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.506 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' SER . . . . . 0.513 ' OG ' ' N ' ' F' ' 1' ' ' ASN . 21.0 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.322 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 1.0 109.337 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -106.39 122.75 46.89 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.224 -0.443 . . . . 1.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.86 134.8 7.74 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.144 -1.183 . . . . 1.0 110.144 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.68 136.94 29.52 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.921 0.391 . . . . 1.0 111.177 -179.597 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . 0.421 HD11 HG23 ' C' ' 5' ' ' ILE . 96.1 mt -130.72 124.34 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.09 179.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 86.5 mt -125.37 132.13 52.85 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.456 -0.338 . . . . 1.0 110.472 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 90.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 1.0 110.559 179.88 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 109.214 -0.661 . . . . 1.0 109.214 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -132.09 130.54 41.37 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.457 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.53 10.07 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.3 -1.12 . . . . 1.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.28 134.71 31.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.01 0.433 . . . . 1.0 111.036 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -126.99 127.38 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.382 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 15.9 mt -116.11 131.57 56.9 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.351 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 118.006 -0.997 . . . . 1.0 110.517 179.864 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.442 -0.577 . . . . 1.0 109.442 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 10.0 m-85 -106.19 122.65 46.65 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.336 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.31 134.89 7.83 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.208 -1.157 . . . . 1.0 110.208 179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 137.01 30.37 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.951 0.405 . . . . 1.0 111.426 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . 0.409 HG23 HD12 ' E' ' 5' ' ' ILE . 96.2 mt -131.18 124.32 55.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.836 -0.62 . . . . 1.0 110.12 179.356 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 87.2 mt -125.87 131.37 52.39 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.186 -0.461 . . . . 1.0 110.442 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 83.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.063 -0.97 . . . . 1.0 110.579 179.821 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . 0.513 ' N ' ' OG ' ' B' ' 7' ' ' SER . 98.9 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' H' ' 6' ' ' LEU . 36.3 t80 -132.05 130.95 41.97 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.347 -0.388 . . . . 1.0 110.519 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.08 138.39 10.51 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 131.67 25.37 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.921 0.391 . . . . 1.0 111.309 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.8 mm -122.88 126.33 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.017 -0.538 . . . . 1.0 110.127 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . 0.412 ' O ' ' O ' ' H' ' 2' ' ' PHE . 15.5 mt -114.99 127.59 55.76 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.137 -0.483 . . . . 1.0 109.974 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.614 179.863 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -106.38 123.25 47.77 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.304 -0.407 . . . . 1.0 110.36 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.92 134.36 7.5 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.113 -1.195 . . . . 1.0 110.113 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.8 140.04 32.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.048 0.452 . . . . 1.0 110.926 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . 0.413 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 11.1 tp -134.52 124.85 45.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.698 -0.683 . . . . 1.0 110.007 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -126.87 133.34 50.73 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.456 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.98 -1.009 . . . . 1.0 110.403 -179.992 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . 0.412 ' O ' ' O ' ' F' ' 6' ' ' LEU . 38.3 t80 -132.01 131.13 42.23 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.375 -0.375 . . . . 1.0 110.48 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.27 138.79 10.74 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.391 -1.084 . . . . 1.0 110.391 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.79 132.48 27.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.91 0.386 . . . . 1.0 111.267 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.7 mm -122.89 126.39 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.083 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . 0.414 ' O ' ' O ' ' F' ' 2' ' ' PHE . 15.9 mt -116.4 129.24 56.13 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.387 -0.369 . . . . 1.0 110.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 35.1 p . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.024 -0.988 . . . . 1.0 110.38 179.827 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.622 ' CZ ' ' ND2' ' B' ' 1' ' ' ASN . 6.9 m-85 -106.01 122.12 45.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.435 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.62 134.22 7.46 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 110.337 -1.105 . . . . 1.0 110.337 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 138.06 30.31 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.114 0.483 . . . . 1.0 110.967 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 10.7 tp -135.09 125.23 44.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 115.721 -0.672 . . . . 1.0 110.239 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 87.5 mt -125.1 129.62 50.57 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.996 -0.547 . . . . 1.0 110.513 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.2 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.469 179.874 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CZ ' ' A' ' 2' ' ' PHE . 59.4 t-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.517 ' N ' ' OD1' ' B' ' 1' ' ' ASN . 72.6 t80 -129.46 129.85 45.15 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.675 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.79 136.01 8.81 Favored Glycine 0 N--CA 1.467 0.72 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.2 134.16 27.27 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.033 0.444 . . . . 1.0 111.497 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -124.85 128.43 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.721 -0.672 . . . . 1.0 109.995 179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . 0.424 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 45.7 tp -121.17 132.99 55.17 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.833 0.349 . . . . 1.0 110.903 -179.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' SER . . . . . 0.525 ' OG ' ' CZ ' ' E' ' 2' ' ' PHE . 17.5 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.01 . . . . 1.0 110.562 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.286 -0.635 . . . . 1.0 109.286 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -106.62 122.42 46.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.235 -0.439 . . . . 1.0 110.241 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.41 134.87 7.72 Favored Glycine 0 N--CA 1.465 0.605 0 N-CA-C 110.384 -1.086 . . . . 1.0 110.384 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.84 135.45 26.11 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.95 0.405 . . . . 1.0 111.098 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -131.25 124.81 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.157 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 88.0 mt -124.26 132.0 53.56 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.43 -0.35 . . . . 1.0 110.284 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 32.5 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.019 -0.991 . . . . 1.0 110.55 179.847 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' D' ' 2' ' ' PHE . 60.0 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.335 -0.617 . . . . 1.0 109.335 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . 0.513 ' N ' ' OD1' ' D' ' 1' ' ' ASN . 74.7 t80 -129.08 129.77 45.67 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.777 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.6 135.8 8.74 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.198 -1.161 . . . . 1.0 110.198 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 133.81 26.64 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.0 0.429 . . . . 1.0 111.335 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.53 128.41 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.757 -0.656 . . . . 1.0 110.022 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' B' ' 2' ' ' PHE . 45.6 tp -120.02 128.8 53.87 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.369 -0.378 . . . . 1.0 110.298 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 7' ' ' SER . . . . . 0.487 ' HG ' HD22 ' B' ' 1' ' ' ASN . 3.7 m . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.002 -0.999 . . . . 1.0 110.575 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.31 -0.626 . . . . 1.0 109.31 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . 0.525 ' CZ ' ' OG ' ' B' ' 7' ' ' SER . 7.0 m-85 -106.14 122.15 45.61 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.232 -0.44 . . . . 1.0 110.275 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.97 134.81 7.73 Favored Glycine 0 N--CA 1.465 0.6 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.28 136.07 27.62 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.969 0.414 . . . . 1.0 111.172 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.18 124.41 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.201 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 88.2 mt -124.49 130.89 53.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.207 -0.451 . . . . 1.0 110.428 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.551 179.908 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' F' ' 2' ' ' PHE . 59.6 t-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.367 -0.605 . . . . 1.0 109.367 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . 0.524 ' N ' ' OD1' ' F' ' 1' ' ' ASN . 73.0 t80 -130.22 129.52 43.47 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.041 -0.527 . . . . 1.0 110.593 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.63 136.03 8.86 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.151 -1.179 . . . . 1.0 110.151 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.57 133.38 25.51 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 121.059 0.457 . . . . 1.0 111.417 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -124.94 128.33 73.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-N 115.699 -0.682 . . . . 1.0 110.063 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' H' ' 2' ' ' PHE . 45.8 tp -119.56 127.92 53.44 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.015 -0.538 . . . . 1.0 110.28 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 7' ' ' SER . . . . . 0.601 ' HG ' HD22 ' H' ' 1' ' ' ASN . 7.0 m . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.005 -0.998 . . . . 1.0 110.485 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.289 -0.634 . . . . 1.0 109.289 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' H' ' 1' ' ' ASN . 7.1 m-85 -105.89 122.98 47.23 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.289 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.55 134.02 7.26 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 110.291 -1.124 . . . . 1.0 110.291 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.49 139.14 31.41 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.041 0.448 . . . . 1.0 110.759 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 10.8 tp -135.76 124.91 39.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 1.0 110.22 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.26 130.74 52.66 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.37 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 37.7 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.536 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . 0.601 HD22 ' HG ' ' F' ' 7' ' ' SER . 59.5 t-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.404 -0.591 . . . . 1.0 109.404 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . 0.519 ' N ' ' OD1' ' H' ' 1' ' ' ASN . 74.3 t80 -129.49 129.82 45.06 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.199 -0.455 . . . . 1.0 110.694 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 136.34 8.97 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.385 -1.086 . . . . 1.0 110.385 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.29 134.61 27.76 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.038 0.447 . . . . 1.0 111.288 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . 0.418 HD11 HG22 ' H' ' 5' ' ' ILE . 96.3 mt -125.59 127.65 71.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.931 179.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' F' ' 2' ' ' PHE . 47.0 tp -119.59 129.96 54.89 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.341 -0.39 . . . . 1.0 110.409 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 59.5 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.997 -1.001 . . . . 1.0 110.501 179.878 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -105.12 123.59 48.09 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.153 -0.476 . . . . 1.0 110.28 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -128.78 137.57 9.72 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.589 -1.004 . . . . 1.0 110.589 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -144.44 141.12 29.39 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-O 120.94 0.4 . . . . 1.0 111.046 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' E' ' 3' ' ' GLY . 10.9 tp -141.35 125.79 17.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.71 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 60.2 mt -120.74 132.67 55.18 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.968 -0.56 . . . . 1.0 110.32 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.534 179.869 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.268 -0.641 . . . . 1.0 109.268 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' D' ' 6' ' ' LEU . 56.2 t80 -128.22 130.53 48.11 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.248 -0.433 . . . . 1.0 110.725 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.86 137.48 9.65 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.332 -1.107 . . . . 1.0 110.332 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.38 135.62 32.29 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.913 0.387 . . . . 1.0 111.23 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -127.03 130.05 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.888 -0.596 . . . . 1.0 110.278 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 47.0 tp -120.42 130.78 54.49 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.016 0.436 . . . . 1.0 110.604 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' F' ' 1' ' ' ASN . 52.0 p . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 117.793 -1.099 . . . . 1.0 110.208 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.353 -0.61 . . . . 1.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -105.49 123.45 47.92 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.224 -0.444 . . . . 1.0 110.212 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.03 138.2 10.1 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.699 -0.96 . . . . 1.0 110.699 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.16 140.36 26.59 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.959 0.409 . . . . 1.0 110.75 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 19.8 tt -140.39 126.62 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 116.059 -0.518 . . . . 1.0 110.061 179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 69.4 mt -120.04 133.76 55.44 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.245 -0.434 . . . . 1.0 110.27 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 34.4 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.511 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.272 -0.64 . . . . 1.0 109.272 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -128.38 130.44 47.69 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.225 -0.443 . . . . 1.0 110.632 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.9 137.3 9.53 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.278 -1.129 . . . . 1.0 110.278 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.72 136.33 32.48 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.06 0.457 . . . . 1.0 110.947 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . 0.42 HD12 HG22 ' D' ' 5' ' ' ILE . 96.6 mt -128.75 130.58 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.907 -0.588 . . . . 1.0 110.519 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . 0.402 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.3 tp -120.51 129.52 53.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.232 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 95.5 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.496 -179.998 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -105.25 123.77 48.41 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.195 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -129.33 138.0 9.95 Favored Glycine 0 N--CA 1.468 0.776 0 N-CA-C 110.695 -0.962 . . . . 1.0 110.695 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.03 140.2 27.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.793 0.33 . . . . 1.0 111.079 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . 0.425 ' O ' ' O ' ' A' ' 3' ' ' GLY . 20.2 tt -140.44 125.42 19.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.465 179.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 62.2 mt -119.66 132.54 55.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.282 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.543 179.943 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . 0.525 ' N ' ' OG ' ' B' ' 7' ' ' SER . 98.9 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -128.21 130.58 48.22 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.264 -0.426 . . . . 1.0 110.666 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 137.23 9.48 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.204 -1.159 . . . . 1.0 110.204 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -140.88 136.1 31.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.059 0.457 . . . . 1.0 111.032 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -129.44 130.24 67.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 115.915 -0.584 . . . . 1.0 110.523 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.9 tp -119.84 129.02 54.21 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.575 -0.739 . . . . 1.0 110.207 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.945 -1.026 . . . . 1.0 110.556 179.864 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -105.16 124.32 49.33 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.218 -0.446 . . . . 1.0 110.3 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.62 137.72 9.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.651 -0.98 . . . . 1.0 110.651 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.38 141.13 28.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.904 0.383 . . . . 1.0 110.629 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . 0.405 ' O ' ' CG2' ' G' ' 5' ' ' ILE . 11.1 tp -141.59 126.34 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.989 -0.551 . . . . 1.0 110.312 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . 0.478 ' C ' ' HG ' ' G' ' 7' ' ' SER . 65.2 mt -120.33 131.78 55.01 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.225 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 7' ' ' SER . . . . . 0.478 ' HG ' ' C ' ' G' ' 6' ' ' LEU . 2.2 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.474 -179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.376 -0.602 . . . . 1.0 109.376 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' F' ' 6' ' ' LEU . 58.1 t80 -127.79 130.47 48.75 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.941 0.401 . . . . 1.0 110.713 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.19 137.58 9.68 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.361 -1.096 . . . . 1.0 110.361 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -140.67 135.79 31.99 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.855 0.36 . . . . 1.0 111.166 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -127.17 129.88 71.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 116.013 -0.54 . . . . 1.0 110.367 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 49.2 tp -120.42 128.34 53.1 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.195 -0.457 . . . . 1.0 110.216 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 52.1 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.942 -1.028 . . . . 1.0 110.439 179.754 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -124.28 135.39 53.35 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.354 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -133.51 134.16 7.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.08 132.17 20.38 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.149 0.5 . . . . 1.0 110.946 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.447 ' CG2' ' O ' ' A' ' 5' ' ' ILE . 10.1 tp -137.99 122.43 22.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.472 -0.786 . . . . 1.0 110.217 -179.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 mt -119.51 135.4 54.79 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.932 0.396 . . . . 1.0 110.888 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.3 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.116 -0.945 . . . . 1.0 110.384 179.646 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -131.57 132.35 44.04 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.18 -0.464 . . . . 1.0 110.665 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.12 136.76 9.01 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.431 -1.068 . . . . 1.0 110.431 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.61 133.37 30.61 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.801 0.334 . . . . 1.0 110.883 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -125.47 128.16 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.543 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -119.11 127.52 53.44 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.007 -0.542 . . . . 1.0 110.051 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.878 -1.058 . . . . 1.0 110.632 179.719 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.418 -0.586 . . . . 1.0 109.418 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . 0.402 ' N ' ' CD1' ' C' ' 2' ' ' PHE . 33.1 m-85 -123.99 135.42 53.62 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.222 -0.444 . . . . 1.0 110.21 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.42 134.77 7.57 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.496 -1.041 . . . . 1.0 110.496 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.13 128.67 15.04 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-O 121.023 0.439 . . . . 1.0 111.048 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.74 124.19 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.818 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 61.7 mt -118.35 132.48 56.27 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.809 0.337 . . . . 1.0 110.451 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 5.9 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.048 -0.977 . . . . 1.0 110.503 179.975 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . 0.431 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.4 -0.593 . . . . 1.0 109.4 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -132.07 131.83 42.77 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.695 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.74 136.21 8.72 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.402 -1.079 . . . . 1.0 110.402 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.14 133.11 31.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.916 0.389 . . . . 1.0 110.843 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.3 mm -124.66 128.28 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.377 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 50.7 tp -118.64 126.5 52.07 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.046 -0.524 . . . . 1.0 109.99 179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.025 -0.988 . . . . 1.0 110.578 179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -123.7 134.88 53.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.251 -0.431 . . . . 1.0 110.164 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -133.19 135.1 7.87 Favored Glycine 0 N--CA 1.466 0.666 0 N-CA-C 110.442 -1.063 . . . . 1.0 110.442 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.11 128.31 13.78 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.969 0.414 . . . . 1.0 111.465 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.1 mt -134.25 124.17 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.838 -0.619 . . . . 1.0 110.205 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 54.2 mt -118.38 133.25 56.04 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.306 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.932 -1.032 . . . . 1.0 110.468 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.389 -0.597 . . . . 1.0 109.389 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -131.52 132.17 43.99 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.188 -0.46 . . . . 1.0 110.747 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.02 136.55 8.89 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.421 -1.071 . . . . 1.0 110.421 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.07 132.32 28.21 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.826 0.346 . . . . 1.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 45.9 mm -125.07 127.75 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.408 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 tp -117.41 126.36 52.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.731 -0.668 . . . . 1.0 110.13 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.946 -1.026 . . . . 1.0 110.566 179.984 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.484 -0.561 . . . . 1.0 109.484 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 37.3 m-85 -124.15 136.08 53.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.229 -0.441 . . . . 1.0 110.259 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.66 135.11 7.74 Favored Glycine 0 N--CA 1.466 0.652 0 N-CA-C 110.355 -1.098 . . . . 1.0 110.355 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.49 127.77 12.13 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.025 0.44 . . . . 1.0 111.271 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.99 125.29 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.73 -0.668 . . . . 1.0 110.115 179.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 57.8 mt -117.82 132.77 56.4 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 1.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.496 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 55.6 p30 . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.447 -0.575 . . . . 1.0 109.447 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -131.25 132.09 44.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.283 -0.417 . . . . 1.0 110.694 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.4 136.42 8.79 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.506 -1.037 . . . . 1.0 110.506 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.32 134.09 32.08 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.806 0.336 . . . . 1.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . 0.423 HD13 HG21 ' H' ' 5' ' ' ILE . 96.0 mt -125.55 127.82 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.149 -0.478 . . . . 1.0 110.484 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -118.05 127.56 53.92 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.056 -0.52 . . . . 1.0 110.109 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.008 -0.996 . . . . 1.0 110.595 179.942 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.497 ' H3 ' ' C ' ' E' ' 7' ' ' SER . 49.9 p-10 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.457 -0.572 . . . . 1.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -105.49 124.67 49.93 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.141 -0.481 . . . . 1.0 110.403 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -127.51 135.26 8.65 Favored Glycine 0 N--CA 1.466 0.641 0 N-CA-C 110.503 -1.039 . . . . 1.0 110.503 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.74 136.9 33.0 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.022 0.439 . . . . 1.0 110.734 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.444 ' O ' ' O ' ' E' ' 3' ' ' GLY . 19.8 tt -137.49 122.69 24.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.604 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 48.4 mt -119.21 133.81 55.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.496 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.481 179.991 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -131.4 130.8 43.04 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.21 -0.45 . . . . 1.0 110.442 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.88 137.57 10.04 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.387 -1.085 . . . . 1.0 110.387 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.28 132.62 30.03 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.864 0.364 . . . . 1.0 111.092 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.57 125.86 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 1.0 110.199 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.7 mt -114.37 131.87 56.41 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.258 -0.428 . . . . 1.0 110.48 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 71.2 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.362 179.707 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' C' ' 1' ' ' ASN . 49.8 p-10 . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -105.42 124.37 49.44 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.11 -0.495 . . . . 1.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.67 135.26 8.62 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.573 -1.011 . . . . 1.0 110.573 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 132.74 25.53 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.813 0.34 . . . . 1.0 110.86 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.35 123.34 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.121 -0.49 . . . . 1.0 109.971 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 58.9 mt -117.92 132.23 56.43 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.861 0.363 . . . . 1.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 7' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' C' ' 7' ' ' SER . 14.6 t . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.001 -1.0 . . . . 1.0 110.439 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.352 -0.61 . . . . 1.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -131.59 130.68 42.52 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.428 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.37 9.96 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.365 -1.094 . . . . 1.0 110.365 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.17 134.55 32.94 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.919 0.39 . . . . 1.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.85 127.16 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.013 -0.539 . . . . 1.0 110.47 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 15.9 mt -115.27 131.43 56.93 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.084 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.955 -1.021 . . . . 1.0 110.546 179.896 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' E' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.482 -0.562 . . . . 1.0 109.482 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -105.84 124.76 50.09 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.126 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -127.52 137.01 9.57 Favored Glycine 0 N--CA 1.467 0.73 0 N-CA-C 110.46 -1.056 . . . . 1.0 110.46 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 132.81 24.49 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.894 0.378 . . . . 1.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . 0.432 HG23 HD11 ' E' ' 5' ' ' ILE . 96.3 mt -131.86 121.53 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.971 -0.559 . . . . 1.0 110.386 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 50.8 mt -117.84 133.31 56.06 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.107 -0.497 . . . . 1.0 110.242 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 7' ' ' SER . . . . . 0.497 ' C ' ' H3 ' ' A' ' 1' ' ' ASN . 10.3 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.099 -0.953 . . . . 1.0 110.491 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.364 -0.606 . . . . 1.0 109.364 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -131.52 130.91 42.95 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.171 -0.468 . . . . 1.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.07 137.54 9.98 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.79 133.86 30.99 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.854 0.359 . . . . 1.0 110.882 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.5 126.43 67.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 CA-C-N 116.136 -0.484 . . . . 1.0 110.512 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -113.32 129.8 56.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.46 -0.791 . . . . 1.0 110.07 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.59 179.913 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' G' ' 1' ' ' ASN . 49.5 p-10 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.46 -0.57 . . . . 1.0 109.46 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -105.83 125.34 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.156 -0.474 . . . . 1.0 110.429 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.46 136.51 9.14 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.416 -1.073 . . . . 1.0 110.416 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 131.76 24.14 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.923 0.392 . . . . 1.0 111.016 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.4 mm -128.57 121.77 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.79 -0.641 . . . . 1.0 110.495 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 55.7 mt -119.0 132.15 56.05 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.072 -0.344 . . . . 1.0 110.072 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.474 -179.879 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.411 -0.589 . . . . 1.0 109.411 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -130.85 131.03 44.34 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.935 0.398 . . . . 1.0 110.395 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 138.24 10.41 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.494 -1.042 . . . . 1.0 110.494 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.82 29.33 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.883 0.373 . . . . 1.0 111.046 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.5 mm -123.41 126.72 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 115.998 -0.546 . . . . 1.0 110.138 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 16.1 mt -115.98 133.94 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.192 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.077 -0.963 . . . . 1.0 110.337 179.851 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.411 ' H2 ' ' C ' ' E' ' 7' ' ' SER . 99.1 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.313 -0.625 . . . . 1.0 109.313 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -104.89 122.97 46.9 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.243 -0.435 . . . . 1.0 110.437 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -130.28 133.64 7.47 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.82 136.0 31.98 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-O 121.026 0.441 . . . . 1.0 110.925 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 19.9 tt -134.63 124.74 45.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.681 -0.69 . . . . 1.0 110.421 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 62.1 mt -121.62 133.44 54.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.825 -0.625 . . . . 1.0 110.53 -179.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.531 179.891 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' D' ' 6' ' ' LEU . 67.4 t80 -130.26 131.06 45.32 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.2 -0.454 . . . . 1.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 139.45 11.2 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.445 -1.062 . . . . 1.0 110.445 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.43 134.44 27.26 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.027 0.441 . . . . 1.0 111.365 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.39 128.72 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.899 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' LEU . . . . . 0.418 ' O ' ' O ' ' D' ' 2' ' ' PHE . 50.3 tp -120.99 134.12 55.29 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.903 0.382 . . . . 1.0 111.082 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' SER . . . . . 0.448 ' OG ' ' OD1' ' F' ' 1' ' ' ASN . 11.6 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.795 -1.097 . . . . 1.0 110.057 179.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.366 -0.605 . . . . 1.0 109.366 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -105.07 123.14 47.3 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.203 -0.453 . . . . 1.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.91 133.6 7.36 Favored Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.325 -1.11 . . . . 1.0 110.325 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.01 132.71 25.56 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.885 0.374 . . . . 1.0 110.884 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.67 124.95 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 116.081 -0.509 . . . . 1.0 109.994 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 68.9 mt -120.06 132.85 55.59 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.217 -0.447 . . . . 1.0 110.34 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 21.3 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.545 179.947 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 1' ' ' ASN . . . . . 0.423 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.2 p30 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.35 -0.611 . . . . 1.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 2' ' ' PHE . . . . . 0.418 ' O ' ' O ' ' B' ' 6' ' ' LEU . 68.7 t80 -130.13 130.93 45.41 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.251 -0.432 . . . . 1.0 110.686 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.94 139.11 11.0 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.366 -1.094 . . . . 1.0 110.366 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 134.21 27.24 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.987 0.423 . . . . 1.0 111.168 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.39 128.7 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.011 179.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 6' ' ' LEU . . . . . 0.407 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.6 tp -120.3 128.91 53.74 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.178 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.568 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.307 -0.627 . . . . 1.0 109.307 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.11 123.28 47.55 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.163 -0.472 . . . . 1.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.5 136.38 8.84 Favored Glycine 0 N--CA 1.466 0.644 0 N-CA-C 110.136 -1.186 . . . . 1.0 110.136 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 130.51 20.58 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.812 0.339 . . . . 1.0 111.231 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 5' ' ' ILE . . . . . 0.407 ' O ' ' O ' ' A' ' 3' ' ' GLY . 47.9 mm -126.13 123.5 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.276 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 68.2 mt -120.61 132.49 55.16 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.434 -0.348 . . . . 1.0 110.275 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 7' ' ' SER . . . . . 0.411 ' C ' ' H2 ' ' A' ' 1' ' ' ASN . 27.5 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.931 -1.033 . . . . 1.0 110.566 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 1' ' ' ASN . . . . . 0.448 ' OD1' ' OG ' ' B' ' 7' ' ' SER . 57.2 p30 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.514 -0.55 . . . . 1.0 109.514 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 2' ' ' PHE . . . . . 0.434 ' O ' ' O ' ' H' ' 6' ' ' LEU . 68.5 t80 -130.38 130.73 44.74 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.209 -0.451 . . . . 1.0 110.797 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.01 139.1 10.98 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.47 133.86 26.37 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.019 0.437 . . . . 1.0 111.2 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 46.5 mm -124.73 128.26 73.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.789 -0.642 . . . . 1.0 109.91 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 6' ' ' LEU . . . . . 0.409 ' O ' ' O ' ' H' ' 2' ' ' PHE . 50.9 tp -119.3 128.58 54.27 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.165 -0.471 . . . . 1.0 110.291 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.634 -179.951 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.09 123.84 48.51 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.236 -0.438 . . . . 1.0 110.546 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.54 135.75 8.39 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.187 -1.165 . . . . 1.0 110.187 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.76 131.66 22.89 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.979 0.419 . . . . 1.0 111.099 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.8 mm -126.48 123.61 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.447 179.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 67.2 mt -120.97 131.54 54.39 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.155 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.9 p . . . . . 0 C--O 1.221 -0.404 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.556 -179.942 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 1' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 56.7 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.441 -0.577 . . . . 1.0 109.441 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 2' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' F' ' 6' ' ' LEU . 69.5 t80 -130.03 130.86 45.48 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.216 -0.447 . . . . 1.0 110.706 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.35 139.3 11.07 Favored Glycine 0 N--CA 1.465 0.603 0 N-CA-C 110.474 -1.05 . . . . 1.0 110.474 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.03 135.19 28.99 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.972 0.415 . . . . 1.0 111.252 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.09 128.03 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.907 -0.588 . . . . 1.0 109.934 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 6' ' ' LEU . . . . . 0.434 ' O ' ' O ' ' F' ' 2' ' ' PHE . 50.5 tp -119.84 131.54 55.31 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.383 -0.371 . . . . 1.0 110.393 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 51.7 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.061 -0.971 . . . . 1.0 110.287 179.846 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.394 -0.595 . . . . 1.0 109.394 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.626 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.63 125.68 51.64 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.525 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.36 134.58 7.57 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.249 -1.14 . . . . 1.0 110.249 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.06 137.84 31.34 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.014 0.435 . . . . 1.0 110.906 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 5' ' ' ILE . 11.1 tp -135.5 125.83 43.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 115.839 -0.618 . . . . 1.0 110.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.635 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.0 mt -124.6 128.15 48.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.849 -0.614 . . . . 1.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.035 -0.984 . . . . 1.0 110.515 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.371 -0.603 . . . . 1.0 109.371 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -132.88 130.05 39.19 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.276 -0.42 . . . . 1.0 110.22 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.08 137.06 9.35 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 110.592 -1.003 . . . . 1.0 110.592 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.75 29.22 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.914 0.387 . . . . 1.0 111.284 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -123.19 125.24 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.835 179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -115.04 133.01 56.41 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.374 -0.376 . . . . 1.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.92 -1.038 . . . . 1.0 110.342 179.077 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.342 -0.614 . . . . 1.0 109.342 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.29 126.05 52.39 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.2 -0.455 . . . . 1.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.3 134.7 7.54 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 110.309 -1.116 . . . . 1.0 110.309 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.87 135.14 27.4 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.869 0.366 . . . . 1.0 110.962 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.52 125.39 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.231 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.76 130.79 53.18 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.435 -0.348 . . . . 1.0 110.364 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 33.9 p . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.986 -1.007 . . . . 1.0 110.578 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.315 -0.624 . . . . 1.0 109.315 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 35.8 t80 -132.95 129.76 38.68 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.278 -0.419 . . . . 1.0 110.367 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.73 136.71 9.2 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.31 133.97 31.92 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.027 0.442 . . . . 1.0 111.179 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.8 mm -124.0 127.06 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.7 -0.682 . . . . 1.0 110.18 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 16.2 mt -117.38 131.52 56.76 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.218 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.036 -0.983 . . . . 1.0 110.574 179.958 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.37 -0.604 . . . . 1.0 109.37 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.635 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.1 m-85 -107.49 125.59 51.46 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.268 -0.424 . . . . 1.0 110.446 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.07 135.87 8.36 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.257 -1.137 . . . . 1.0 110.257 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 135.56 26.77 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.986 0.422 . . . . 1.0 111.071 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -132.24 125.09 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.853 -0.612 . . . . 1.0 110.273 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.626 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.7 mt -124.31 130.74 53.04 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.332 -0.394 . . . . 1.0 110.519 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.566 179.952 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.372 -0.603 . . . . 1.0 109.372 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -133.14 130.09 38.75 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.092 -0.504 . . . . 1.0 110.418 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.2 137.19 9.42 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.427 -1.069 . . . . 1.0 110.427 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.48 131.93 26.9 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.826 0.346 . . . . 1.0 111.246 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.5 mm -122.86 125.75 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.968 -0.56 . . . . 1.0 109.965 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -114.5 129.07 56.63 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.124 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.018 -0.992 . . . . 1.0 110.586 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -107.26 126.03 51.9 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.473 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.65 134.74 7.63 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.252 -1.139 . . . . 1.0 110.252 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 138.94 31.7 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.98 0.419 . . . . 1.0 110.67 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.2 tp -136.09 125.9 40.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.793 -0.64 . . . . 1.0 110.253 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 85.5 mt -125.68 130.56 51.81 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 1.0 110.427 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.984 -1.007 . . . . 1.0 110.373 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.479 -0.563 . . . . 1.0 109.479 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -132.53 130.3 40.2 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.219 -0.446 . . . . 1.0 110.415 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.45 137.73 9.76 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.474 -1.051 . . . . 1.0 110.474 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.37 133.26 29.17 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.887 0.375 . . . . 1.0 111.184 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 95.7 mt -123.35 125.62 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 115.914 -0.584 . . . . 1.0 110.002 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -115.58 132.18 56.71 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.175 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.086 -0.959 . . . . 1.0 110.566 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.431 -0.581 . . . . 1.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' C' ' 6' ' ' LEU . 57.8 m-85 -130.67 149.61 52.25 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.308 -0.405 . . . . 1.0 110.357 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -146.49 148.36 19.98 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.622 -0.991 . . . . 1.0 110.622 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.75 142.05 26.25 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.984 0.421 . . . . 1.0 111.214 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.482 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.9 tp -135.0 127.61 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 115.71 -0.677 . . . . 1.0 109.876 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' C' ' 2' ' ' PHE . 42.4 mt -123.66 132.3 53.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.518 -0.31 . . . . 1.0 110.309 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.4 ' OXT' ' O ' ' E' ' 1' ' ' ASN . 66.3 m . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.768 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 1' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 28.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.415 -0.587 . . . . 1.0 109.415 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -132.76 130.57 40.11 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.35 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.55 140.62 11.97 Favored Glycine 0 N--CA 1.466 0.658 0 N-CA-C 110.452 -1.059 . . . . 1.0 110.452 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 139.08 34.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.94 0.4 . . . . 1.0 111.156 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -131.3 129.15 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.009 -0.541 . . . . 1.0 110.411 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 50.0 tp -120.75 129.65 53.71 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.113 -0.494 . . . . 1.0 110.566 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 47.5 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.953 -1.022 . . . . 1.0 110.585 179.764 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.344 -0.613 . . . . 1.0 109.344 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 2' ' ' PHE . . . . . 0.622 ' CD2' ' ND2' ' D' ' 1' ' ' ASN . 61.7 m-85 -130.67 149.53 52.28 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.289 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.54 149.27 21.39 Favored Glycine 0 N--CA 1.463 0.466 0 N-CA-C 110.491 -1.044 . . . . 1.0 110.491 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.46 140.05 22.54 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 1.0 111.098 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.28 129.07 56.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.001 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 6' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 2' ' ' PHE . 45.6 mt -123.56 132.58 53.93 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.317 -0.401 . . . . 1.0 110.471 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.545 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CD2' ' C' ' 2' ' ' PHE . 29.0 p30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -132.67 130.28 39.92 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.158 -0.474 . . . . 1.0 110.29 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.47 140.04 11.58 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.392 -1.083 . . . . 1.0 110.392 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.63 141.08 37.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.08 0.467 . . . . 1.0 110.996 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 5' ' ' ILE . . . . . 0.469 ' O ' HG23 ' D' ' 5' ' ' ILE . 11.0 tp -132.27 129.57 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.363 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 49.1 tp -122.31 127.18 49.51 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.439 -0.346 . . . . 1.0 110.183 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 13.5 m . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.981 -1.009 . . . . 1.0 110.632 179.924 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 1' ' ' ASN . . . . . 0.4 ' O ' ' OXT' ' A' ' 7' ' ' SER . 99.2 m-20 . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.618 ' CD2' ' ND2' ' F' ' 1' ' ' ASN . 57.1 m-85 -130.27 149.25 52.05 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.314 -0.403 . . . . 1.0 110.262 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 3' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -146.54 147.75 18.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.65 140.7 25.03 Favored 'General case' 0 C--O 1.231 0.095 0 CA-C-O 121.052 0.454 . . . . 1.0 111.342 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 5' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -133.98 128.22 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 115.857 -0.61 . . . . 1.0 109.935 179.377 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.439 ' O ' ' O ' ' G' ' 2' ' ' PHE . 44.7 mt -123.23 132.61 54.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.463 -0.335 . . . . 1.0 110.597 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.054 -0.974 . . . . 1.0 110.587 179.928 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 1' ' ' ASN . . . . . 0.618 ' ND2' ' CD2' ' E' ' 2' ' ' PHE . 29.1 p30 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.395 -0.594 . . . . 1.0 109.395 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -132.49 130.46 40.5 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.404 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.32 140.28 11.76 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.327 -1.109 . . . . 1.0 110.327 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.63 140.39 35.04 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.918 0.39 . . . . 1.0 110.973 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 5' ' ' ILE . . . . . 0.499 ' O ' HG23 ' F' ' 5' ' ' ILE . 11.2 tp -132.47 128.31 57.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.821 -0.627 . . . . 1.0 110.475 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 47.8 tp -120.01 126.96 52.11 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.298 -0.41 . . . . 1.0 110.334 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.897 -1.049 . . . . 1.0 110.565 179.893 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.279 -0.638 . . . . 1.0 109.279 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 2' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' E' ' 6' ' ' LEU . 59.9 m-85 -130.74 150.03 52.11 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.445 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.6 148.59 20.37 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.524 -1.03 . . . . 1.0 110.524 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.15 142.09 25.84 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.927 0.394 . . . . 1.0 110.857 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 5' ' ' ILE . . . . . 0.522 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -135.12 126.89 47.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 1.0 109.73 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' E' ' 2' ' ' PHE . 53.6 mt -122.54 132.78 54.47 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.907 0.384 . . . . 1.0 110.462 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.055 -0.974 . . . . 1.0 110.607 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 1' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 29.2 p30 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.348 -0.612 . . . . 1.0 109.348 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -132.28 130.61 41.1 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.275 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.7 140.74 12.05 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.73 138.41 32.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.865 0.364 . . . . 1.0 111.187 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.48 128.22 63.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.401 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 48.8 tp -119.04 127.96 53.91 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.356 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.433 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.295 -0.632 . . . . 1.0 109.295 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.5 m-85 -106.81 123.18 47.77 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.182 -0.463 . . . . 1.0 110.404 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.54 132.84 7.24 Favored Glycine 0 N--CA 1.465 0.571 0 N-CA-C 110.285 -1.126 . . . . 1.0 110.285 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.22 137.84 34.62 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.061 0.458 . . . . 1.0 110.997 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.505 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.8 tp -134.64 126.27 47.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.682 -0.69 . . . . 1.0 110.292 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.641 HD22 ' CD2' ' E' ' 2' ' ' PHE . 82.9 mt -123.95 130.86 53.27 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.991 -0.55 . . . . 1.0 110.503 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.448 179.883 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.246 -0.65 . . . . 1.0 109.246 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 65.6 t80 -128.74 130.36 46.97 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 121.056 0.455 . . . . 1.0 110.796 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.93 137.57 9.86 Favored Glycine 0 N--CA 1.466 0.698 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.83 133.9 29.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.849 0.357 . . . . 1.0 111.257 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 46.6 mm -125.08 129.23 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.917 -0.583 . . . . 1.0 110.355 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' D' ' 2' ' ' PHE . 45.7 tp -120.35 130.94 54.64 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.288 -0.415 . . . . 1.0 110.668 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 7' ' ' SER . . . . . 0.424 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 7.9 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.247 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.333 -0.617 . . . . 1.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -107.4 123.13 47.92 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.139 -0.482 . . . . 1.0 110.166 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.75 133.35 7.42 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.251 -1.14 . . . . 1.0 110.251 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.76 135.55 29.84 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 120.989 0.424 . . . . 1.0 111.02 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -131.97 126.43 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.913 -0.585 . . . . 1.0 110.128 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.2 mt -122.6 132.47 54.31 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.432 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.974 -1.013 . . . . 1.0 110.493 -179.988 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.304 -0.628 . . . . 1.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' B' ' 6' ' ' LEU . 67.7 t80 -128.71 130.39 47.07 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.741 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.11 137.4 9.72 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.304 -1.119 . . . . 1.0 110.304 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.6 135.33 31.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.994 0.426 . . . . 1.0 111.074 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -127.31 129.6 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.428 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 46.0 tp -120.05 128.81 53.85 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.328 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.968 -1.015 . . . . 1.0 110.549 179.965 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.3 -0.63 . . . . 1.0 109.3 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.641 ' CD2' HD22 ' A' ' 6' ' ' LEU . 6.5 m-85 -106.54 123.33 47.93 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.329 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.92 133.26 7.36 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 110.28 -1.128 . . . . 1.0 110.28 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.49 133.81 29.77 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.883 0.373 . . . . 1.0 111.252 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -128.09 124.75 63.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.777 -0.647 . . . . 1.0 110.222 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 84.8 mt -123.64 131.6 53.65 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.867 0.365 . . . . 1.0 110.355 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.988 -1.005 . . . . 1.0 110.599 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 2' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' H' ' 6' ' ' LEU . 66.2 t80 -128.35 130.45 47.78 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.734 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.48 9.75 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.254 -1.138 . . . . 1.0 110.254 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -141.21 134.68 29.84 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.976 0.417 . . . . 1.0 111.102 -179.619 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -128.01 129.07 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.896 -0.593 . . . . 1.0 110.541 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 6' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' H' ' 2' ' ' PHE . 46.5 tp -118.85 128.28 54.3 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.72 -0.673 . . . . 1.0 110.266 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.049 -0.977 . . . . 1.0 110.545 179.987 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.448 -0.575 . . . . 1.0 109.448 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -106.37 124.19 49.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.167 -0.47 . . . . 1.0 110.342 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.62 132.6 6.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.93 138.67 35.78 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.025 0.44 . . . . 1.0 110.747 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 5' ' ' ILE . . . . . 0.541 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -134.88 125.28 45.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.846 -0.615 . . . . 1.0 110.079 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 83.6 mt -124.14 133.39 53.59 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.133 -0.485 . . . . 1.0 110.336 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.485 179.924 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.265 -0.642 . . . . 1.0 109.265 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 2' ' ' PHE . . . . . 0.426 ' O ' ' O ' ' F' ' 6' ' ' LEU . 67.2 t80 -128.45 130.47 47.62 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.201 -0.454 . . . . 1.0 110.681 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.92 10.03 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -141.33 134.52 29.39 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.892 0.377 . . . . 1.0 111.096 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.77 128.45 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.988 -0.551 . . . . 1.0 110.392 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' F' ' 2' ' ' PHE . 45.9 tp -118.35 127.3 53.56 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.103 -0.499 . . . . 1.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.076 -0.964 . . . . 1.0 110.372 179.893 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.443 -0.577 . . . . 1.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.637 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.78 124.37 49.95 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.105 -0.498 . . . . 1.0 110.307 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.13 133.65 7.49 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.272 -1.131 . . . . 1.0 110.272 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 136.74 32.13 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.031 0.443 . . . . 1.0 110.922 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.527 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.5 tp -133.67 126.07 50.73 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 115.753 -0.658 . . . . 1.0 110.258 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.661 HD22 ' CD2' ' E' ' 2' ' ' PHE . 84.8 mt -124.07 129.93 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.566 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.7 p . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.924 -1.036 . . . . 1.0 110.491 179.875 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.332 -0.618 . . . . 1.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 2' ' ' PHE . . . . . 0.404 ' O ' ' O ' ' D' ' 6' ' ' LEU . 71.5 t80 -129.03 130.32 46.45 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.691 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.52 137.58 9.93 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 110.404 -1.078 . . . . 1.0 110.404 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.54 134.02 29.99 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.965 0.412 . . . . 1.0 111.239 -179.49 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -124.46 128.22 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 CA-C-N 115.81 -0.632 . . . . 1.0 109.962 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 6' ' ' LEU . . . . . 0.401 ' O ' ' O ' ' D' ' 2' ' ' PHE . 47.2 tp -118.66 131.18 56.16 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.965 0.412 . . . . 1.0 110.655 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 7' ' ' SER . . . . . 0.484 ' OG ' ' CE2' ' E' ' 2' ' ' PHE . 1.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.02 -0.99 . . . . 1.0 110.309 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.38 -0.6 . . . . 1.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.21 124.35 50.14 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.18 -0.463 . . . . 1.0 110.165 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.47 133.96 7.59 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.369 -1.092 . . . . 1.0 110.369 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.65 134.48 26.93 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.984 0.421 . . . . 1.0 110.925 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.01 126.37 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 115.973 -0.558 . . . . 1.0 110.081 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.9 mt -122.99 132.04 53.97 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.319 -0.4 . . . . 1.0 110.374 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.587 179.983 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.275 -0.639 . . . . 1.0 109.275 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 2' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' B' ' 6' ' ' LEU . 73.0 t80 -129.05 130.35 46.45 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.712 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.36 9.8 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.253 -1.139 . . . . 1.0 110.253 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.32 133.87 30.13 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.941 0.4 . . . . 1.0 111.251 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.7 mm -124.22 128.79 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.744 -0.662 . . . . 1.0 110.241 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 6' ' ' LEU . . . . . 0.404 ' O ' ' O ' ' B' ' 2' ' ' PHE . 48.4 tp -119.14 127.72 53.6 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.397 . . . . 1.0 110.235 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.978 -1.01 . . . . 1.0 110.535 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.399 -0.593 . . . . 1.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.661 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -107.85 124.34 49.94 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.254 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 3' ' ' GLY . . . . . 0.453 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -130.28 134.42 7.82 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.71 133.15 26.72 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.895 0.378 . . . . 1.0 111.251 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.2 mm -127.93 125.08 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.787 -0.642 . . . . 1.0 110.235 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.637 HD22 ' CD2' ' A' ' 2' ' ' PHE . 86.6 mt -123.78 130.46 52.66 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.882 0.373 . . . . 1.0 110.478 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.577 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 2' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' H' ' 6' ' ' LEU . 71.8 t80 -128.79 130.19 46.67 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.91 0.386 . . . . 1.0 110.764 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.67 10.0 Favored Glycine 0 N--CA 1.467 0.727 0 N-CA-C 110.245 -1.142 . . . . 1.0 110.245 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.0 133.41 28.35 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.956 0.408 . . . . 1.0 111.236 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.42 128.59 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.128 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 6' ' ' LEU . . . . . 0.422 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.2 tp -118.75 128.12 54.18 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.172 -0.467 . . . . 1.0 110.256 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.908 -1.044 . . . . 1.0 110.468 179.899 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.3 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.57 124.93 50.66 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.211 -0.45 . . . . 1.0 110.284 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.82 133.48 7.32 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.217 -1.153 . . . . 1.0 110.217 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.9 137.75 33.39 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.956 0.408 . . . . 1.0 110.745 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 9.7 tp -134.09 125.77 48.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.894 -0.594 . . . . 1.0 110.178 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.9 mt -124.24 131.01 53.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.336 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.1 p . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.501 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.255 -0.646 . . . . 1.0 109.255 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 2' ' ' PHE . . . . . 0.422 ' O ' ' O ' ' F' ' 6' ' ' LEU . 72.9 t80 -128.49 130.26 47.25 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.285 -0.416 . . . . 1.0 110.74 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.54 138.03 10.22 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.276 -1.129 . . . . 1.0 110.276 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.56 134.38 30.48 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.992 0.425 . . . . 1.0 111.107 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.74 127.81 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.967 -0.56 . . . . 1.0 110.146 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 6' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' F' ' 2' ' ' PHE . 48.8 tp -118.67 128.94 55.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.418 -0.356 . . . . 1.0 110.293 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.999 -1.001 . . . . 1.0 110.419 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.48 -0.563 . . . . 1.0 109.48 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.61 ' CD2' HD22 ' E' ' 6' ' ' LEU . 9.9 m-85 -106.13 122.61 46.54 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.221 -0.445 . . . . 1.0 110.46 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.16 134.36 7.58 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.202 -1.159 . . . . 1.0 110.202 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 139.13 32.91 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.1 0.476 . . . . 1.0 111.186 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.524 ' O ' HG23 ' A' ' 5' ' ' ILE . 11.1 tp -134.04 124.96 47.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 115.599 -0.728 . . . . 1.0 110.124 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.62 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.6 mt -126.52 131.89 51.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.079 -0.51 . . . . 1.0 110.54 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.071 -0.966 . . . . 1.0 110.485 179.903 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.489 1.482 0 N-CA-C 109.396 -0.594 . . . . 1.0 109.396 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 36.2 t80 -131.98 130.74 41.85 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.291 -0.413 . . . . 1.0 110.413 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.89 138.0 10.31 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.52 132.18 27.24 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.843 0.354 . . . . 1.0 111.283 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.35 125.57 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.016 -0.538 . . . . 1.0 110.077 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -114.57 129.49 56.67 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.506 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' SER . . . . . 0.403 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 21.0 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.322 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 1.0 109.337 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -106.39 122.75 46.89 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.224 -0.443 . . . . 1.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.86 134.8 7.74 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.144 -1.183 . . . . 1.0 110.144 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.68 136.94 29.52 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.921 0.391 . . . . 1.0 111.177 -179.597 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.72 124.34 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.09 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 86.5 mt -125.37 132.13 52.85 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.456 -0.338 . . . . 1.0 110.472 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 90.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 1.0 110.559 179.88 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 109.214 -0.661 . . . . 1.0 109.214 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -132.09 130.54 41.37 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.457 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.53 10.07 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.3 -1.12 . . . . 1.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.28 134.71 31.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.01 0.433 . . . . 1.0 111.036 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -126.99 127.38 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.382 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 15.9 mt -116.11 131.57 56.9 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.351 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 118.006 -0.997 . . . . 1.0 110.517 179.864 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.442 -0.577 . . . . 1.0 109.442 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.62 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.0 m-85 -106.19 122.65 46.65 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.336 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 3' ' ' GLY . . . . . 0.417 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.31 134.89 7.83 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.208 -1.157 . . . . 1.0 110.208 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 137.01 30.37 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.951 0.405 . . . . 1.0 111.426 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.18 124.32 55.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.836 -0.62 . . . . 1.0 110.12 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.61 HD22 ' CD2' ' A' ' 2' ' ' PHE . 87.2 mt -125.87 131.37 52.39 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.186 -0.461 . . . . 1.0 110.442 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 83.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.063 -0.97 . . . . 1.0 110.579 179.821 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 2' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' H' ' 6' ' ' LEU . 36.3 t80 -132.05 130.95 41.97 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.347 -0.388 . . . . 1.0 110.519 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.08 138.39 10.51 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 131.67 25.37 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.921 0.391 . . . . 1.0 111.309 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.8 mm -122.88 126.33 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.017 -0.538 . . . . 1.0 110.127 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 6' ' ' LEU . . . . . 0.412 ' O ' ' O ' ' H' ' 2' ' ' PHE . 15.5 mt -114.99 127.59 55.76 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.137 -0.483 . . . . 1.0 109.974 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.614 179.863 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -106.38 123.25 47.77 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.304 -0.407 . . . . 1.0 110.36 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.92 134.36 7.5 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.113 -1.195 . . . . 1.0 110.113 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.8 140.04 32.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.048 0.452 . . . . 1.0 110.926 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 5' ' ' ILE . . . . . 0.528 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -134.52 124.85 45.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.698 -0.683 . . . . 1.0 110.007 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -126.87 133.34 50.73 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.456 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.98 -1.009 . . . . 1.0 110.403 -179.992 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 2' ' ' PHE . . . . . 0.412 ' O ' ' O ' ' F' ' 6' ' ' LEU . 38.3 t80 -132.01 131.13 42.23 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.375 -0.375 . . . . 1.0 110.48 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.27 138.79 10.74 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.391 -1.084 . . . . 1.0 110.391 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.79 132.48 27.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.91 0.386 . . . . 1.0 111.267 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.7 mm -122.89 126.39 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.083 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 6' ' ' LEU . . . . . 0.414 ' O ' ' O ' ' F' ' 2' ' ' PHE . 15.9 mt -116.4 129.24 56.13 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.387 -0.369 . . . . 1.0 110.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 35.1 p . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.024 -0.988 . . . . 1.0 110.38 179.827 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.628 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -106.01 122.12 45.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.435 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.62 134.22 7.46 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 110.337 -1.105 . . . . 1.0 110.337 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 138.06 30.31 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.114 0.483 . . . . 1.0 110.967 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.544 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.7 tp -135.09 125.23 44.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 115.721 -0.672 . . . . 1.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.646 HD22 ' CD2' ' E' ' 2' ' ' PHE . 87.5 mt -125.1 129.62 50.57 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.996 -0.547 . . . . 1.0 110.513 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.2 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.469 179.874 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CZ ' ' A' ' 2' ' ' PHE . 59.4 t-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 2' ' ' PHE . . . . . 0.517 ' N ' ' OD1' ' B' ' 1' ' ' ASN . 72.6 t80 -129.46 129.85 45.15 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.675 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.79 136.01 8.81 Favored Glycine 0 N--CA 1.467 0.72 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.2 134.16 27.27 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.033 0.444 . . . . 1.0 111.497 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -124.85 128.43 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.721 -0.672 . . . . 1.0 109.995 179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 6' ' ' LEU . . . . . 0.424 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 45.7 tp -121.17 132.99 55.17 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.833 0.349 . . . . 1.0 110.903 -179.625 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 7' ' ' SER . . . . . 0.506 ' OG ' ' CZ ' ' E' ' 2' ' ' PHE . 17.5 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.01 . . . . 1.0 110.562 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.286 -0.635 . . . . 1.0 109.286 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -106.62 122.42 46.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.235 -0.439 . . . . 1.0 110.241 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.41 134.87 7.72 Favored Glycine 0 N--CA 1.465 0.605 0 N-CA-C 110.384 -1.086 . . . . 1.0 110.384 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.84 135.45 26.11 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.95 0.405 . . . . 1.0 111.098 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -131.25 124.81 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.157 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 88.0 mt -124.26 132.0 53.56 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.43 -0.35 . . . . 1.0 110.284 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 32.5 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.019 -0.991 . . . . 1.0 110.55 179.847 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 1' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' D' ' 2' ' ' PHE . 60.0 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.335 -0.617 . . . . 1.0 109.335 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 2' ' ' PHE . . . . . 0.513 ' N ' ' OD1' ' D' ' 1' ' ' ASN . 74.7 t80 -129.08 129.77 45.67 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.777 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.6 135.8 8.74 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.198 -1.161 . . . . 1.0 110.198 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 133.81 26.64 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.0 0.429 . . . . 1.0 111.335 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.53 128.41 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.757 -0.656 . . . . 1.0 110.022 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 6' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' B' ' 2' ' ' PHE . 45.6 tp -120.02 128.8 53.87 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.369 -0.378 . . . . 1.0 110.298 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 7' ' ' SER . . . . . 0.425 ' OG ' ' ND2' ' B' ' 1' ' ' ASN . 3.7 m . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.002 -0.999 . . . . 1.0 110.575 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.31 -0.626 . . . . 1.0 109.31 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.646 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -106.14 122.15 45.61 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.232 -0.44 . . . . 1.0 110.275 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 3' ' ' GLY . . . . . 0.428 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.97 134.81 7.73 Favored Glycine 0 N--CA 1.465 0.6 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.462 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.28 136.07 27.62 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.969 0.414 . . . . 1.0 111.172 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.18 124.41 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.201 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.628 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.2 mt -124.49 130.89 53.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.207 -0.451 . . . . 1.0 110.428 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.551 179.908 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 1' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' F' ' 2' ' ' PHE . 59.6 t-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.367 -0.605 . . . . 1.0 109.367 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 2' ' ' PHE . . . . . 0.524 ' N ' ' OD1' ' F' ' 1' ' ' ASN . 73.0 t80 -130.22 129.52 43.47 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.041 -0.527 . . . . 1.0 110.593 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.63 136.03 8.86 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.151 -1.179 . . . . 1.0 110.151 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.57 133.38 25.51 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 121.059 0.457 . . . . 1.0 111.417 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -124.94 128.33 73.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-N 115.699 -0.682 . . . . 1.0 110.063 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' H' ' 2' ' ' PHE . 45.8 tp -119.56 127.92 53.44 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.015 -0.538 . . . . 1.0 110.28 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 7' ' ' SER . . . . . 0.478 ' OG ' ' ND2' ' H' ' 1' ' ' ASN . 7.0 m . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.005 -0.998 . . . . 1.0 110.485 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.289 -0.634 . . . . 1.0 109.289 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 2' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' H' ' 1' ' ' ASN . 7.1 m-85 -105.89 122.98 47.23 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.289 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.55 134.02 7.26 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 110.291 -1.124 . . . . 1.0 110.291 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.49 139.14 31.41 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.041 0.448 . . . . 1.0 110.759 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.8 tp -135.76 124.91 39.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 1.0 110.22 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.26 130.74 52.66 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.37 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 37.7 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.536 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 1' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' G' ' 2' ' ' PHE . 59.5 t-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.404 -0.591 . . . . 1.0 109.404 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 2' ' ' PHE . . . . . 0.519 ' N ' ' OD1' ' H' ' 1' ' ' ASN . 74.3 t80 -129.49 129.82 45.06 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.199 -0.455 . . . . 1.0 110.694 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 136.34 8.97 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.385 -1.086 . . . . 1.0 110.385 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.29 134.61 27.76 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.038 0.447 . . . . 1.0 111.288 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -125.59 127.65 71.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.931 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 6' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' F' ' 2' ' ' PHE . 47.0 tp -119.59 129.96 54.89 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.341 -0.39 . . . . 1.0 110.409 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 59.5 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.997 -1.001 . . . . 1.0 110.501 179.878 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 10.1 m-85 -105.12 123.59 48.09 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.153 -0.476 . . . . 1.0 110.28 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -128.78 137.57 9.72 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.589 -1.004 . . . . 1.0 110.589 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -144.44 141.12 29.39 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-O 120.94 0.4 . . . . 1.0 111.046 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.501 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.9 tp -141.35 125.79 17.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.71 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.636 HD22 ' CD2' ' E' ' 2' ' ' PHE . 60.2 mt -120.74 132.67 55.18 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.968 -0.56 . . . . 1.0 110.32 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.534 179.869 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.268 -0.641 . . . . 1.0 109.268 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 2' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' D' ' 6' ' ' LEU . 56.2 t80 -128.22 130.53 48.11 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.248 -0.433 . . . . 1.0 110.725 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.86 137.48 9.65 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.332 -1.107 . . . . 1.0 110.332 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.38 135.62 32.29 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.913 0.387 . . . . 1.0 111.23 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -127.03 130.05 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.888 -0.596 . . . . 1.0 110.278 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 47.0 tp -120.42 130.78 54.49 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.016 0.436 . . . . 1.0 110.604 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 117.793 -1.099 . . . . 1.0 110.208 179.607 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.353 -0.61 . . . . 1.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -105.49 123.45 47.92 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.224 -0.444 . . . . 1.0 110.212 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 3' ' ' GLY . . . . . 0.401 ' HA2' HD12 ' A' ' 5' ' ' ILE . . . -129.03 138.2 10.1 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.699 -0.96 . . . . 1.0 110.699 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.16 140.36 26.59 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.959 0.409 . . . . 1.0 110.75 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 5' ' ' ILE . . . . . 0.472 ' O ' HG23 ' C' ' 5' ' ' ILE . 19.8 tt -140.39 126.62 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 116.059 -0.518 . . . . 1.0 110.061 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 69.4 mt -120.04 133.76 55.44 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.245 -0.434 . . . . 1.0 110.27 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 34.4 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.511 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.272 -0.64 . . . . 1.0 109.272 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -128.38 130.44 47.69 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.225 -0.443 . . . . 1.0 110.632 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.9 137.3 9.53 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.278 -1.129 . . . . 1.0 110.278 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.72 136.33 32.48 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.06 0.457 . . . . 1.0 110.947 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.75 130.58 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.907 -0.588 . . . . 1.0 110.519 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 6' ' ' LEU . . . . . 0.402 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.3 tp -120.51 129.52 53.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.232 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 95.5 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.496 -179.998 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.636 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.4 m-85 -105.25 123.77 48.41 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.195 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 3' ' ' GLY . . . . . 0.489 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -129.33 138.0 9.95 Favored Glycine 0 N--CA 1.468 0.776 0 N-CA-C 110.695 -0.962 . . . . 1.0 110.695 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.03 140.2 27.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.793 0.33 . . . . 1.0 111.079 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 5' ' ' ILE . . . . . 0.493 HG23 ' O ' ' E' ' 5' ' ' ILE . 20.2 tt -140.44 125.42 19.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.465 179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 62.2 mt -119.66 132.54 55.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.282 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.543 179.943 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -128.21 130.58 48.22 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.264 -0.426 . . . . 1.0 110.666 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 137.23 9.48 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.204 -1.159 . . . . 1.0 110.204 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -140.88 136.1 31.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.059 0.457 . . . . 1.0 111.032 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -129.44 130.24 67.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 115.915 -0.584 . . . . 1.0 110.523 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.9 tp -119.84 129.02 54.21 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.575 -0.739 . . . . 1.0 110.207 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.945 -1.026 . . . . 1.0 110.556 179.864 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -105.16 124.32 49.33 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.218 -0.446 . . . . 1.0 110.3 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.62 137.72 9.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.651 -0.98 . . . . 1.0 110.651 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.38 141.13 28.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.904 0.383 . . . . 1.0 110.629 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 5' ' ' ILE . . . . . 0.502 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -141.59 126.34 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.989 -0.551 . . . . 1.0 110.312 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 65.2 mt -120.33 131.78 55.01 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.225 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 2.2 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.474 -179.917 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.376 -0.602 . . . . 1.0 109.376 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' F' ' 6' ' ' LEU . 58.1 t80 -127.79 130.47 48.75 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.941 0.401 . . . . 1.0 110.713 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.19 137.58 9.68 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.361 -1.096 . . . . 1.0 110.361 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -140.67 135.79 31.99 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.855 0.36 . . . . 1.0 111.166 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -127.17 129.88 71.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 116.013 -0.54 . . . . 1.0 110.367 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 49.2 tp -120.42 128.34 53.1 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.195 -0.457 . . . . 1.0 110.216 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 52.1 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.942 -1.028 . . . . 1.0 110.439 179.754 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -124.28 135.39 53.35 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.354 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -133.51 134.16 7.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.08 132.17 20.38 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.149 0.5 . . . . 1.0 110.946 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.608 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.1 tp -137.99 122.43 22.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.472 -0.786 . . . . 1.0 110.217 -179.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 mt -119.51 135.4 54.79 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.932 0.396 . . . . 1.0 110.888 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.3 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.116 -0.945 . . . . 1.0 110.384 179.646 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 1' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -131.57 132.35 44.04 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.18 -0.464 . . . . 1.0 110.665 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.12 136.76 9.01 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.431 -1.068 . . . . 1.0 110.431 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.61 133.37 30.61 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.801 0.334 . . . . 1.0 110.883 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -125.47 128.16 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.543 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -119.11 127.52 53.44 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.007 -0.542 . . . . 1.0 110.051 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.878 -1.058 . . . . 1.0 110.632 179.719 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.418 -0.586 . . . . 1.0 109.418 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 2' ' ' PHE . . . . . 0.402 ' N ' ' CD1' ' C' ' 2' ' ' PHE . 33.1 m-85 -123.99 135.42 53.62 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.222 -0.444 . . . . 1.0 110.21 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.42 134.77 7.57 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.496 -1.041 . . . . 1.0 110.496 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.13 128.67 15.04 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-O 121.023 0.439 . . . . 1.0 111.048 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.74 124.19 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.818 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 61.7 mt -118.35 132.48 56.27 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.809 0.337 . . . . 1.0 110.451 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 5.9 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.048 -0.977 . . . . 1.0 110.503 179.975 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 1' ' ' ASN . . . . . 0.431 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.4 -0.593 . . . . 1.0 109.4 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -132.07 131.83 42.77 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.695 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.74 136.21 8.72 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.402 -1.079 . . . . 1.0 110.402 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.14 133.11 31.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.916 0.389 . . . . 1.0 110.843 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.3 mm -124.66 128.28 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.377 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 50.7 tp -118.64 126.5 52.07 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.046 -0.524 . . . . 1.0 109.99 179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.025 -0.988 . . . . 1.0 110.578 179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -123.7 134.88 53.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.251 -0.431 . . . . 1.0 110.164 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 3' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -133.19 135.1 7.87 Favored Glycine 0 N--CA 1.466 0.666 0 N-CA-C 110.442 -1.063 . . . . 1.0 110.442 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.11 128.31 13.78 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.969 0.414 . . . . 1.0 111.465 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.1 mt -134.25 124.17 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.838 -0.619 . . . . 1.0 110.205 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 54.2 mt -118.38 133.25 56.04 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.306 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.932 -1.032 . . . . 1.0 110.468 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.389 -0.597 . . . . 1.0 109.389 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -131.52 132.17 43.99 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.188 -0.46 . . . . 1.0 110.747 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.02 136.55 8.89 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.421 -1.071 . . . . 1.0 110.421 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.07 132.32 28.21 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.826 0.346 . . . . 1.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 45.9 mm -125.07 127.75 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.408 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 tp -117.41 126.36 52.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.731 -0.668 . . . . 1.0 110.13 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.946 -1.026 . . . . 1.0 110.566 179.984 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.484 -0.561 . . . . 1.0 109.484 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 37.3 m-85 -124.15 136.08 53.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.229 -0.441 . . . . 1.0 110.259 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.66 135.11 7.74 Favored Glycine 0 N--CA 1.466 0.652 0 N-CA-C 110.355 -1.098 . . . . 1.0 110.355 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.49 127.77 12.13 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.025 0.44 . . . . 1.0 111.271 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.99 125.29 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.73 -0.668 . . . . 1.0 110.115 179.362 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 57.8 mt -117.82 132.77 56.4 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 1.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.496 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 1' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 55.6 p30 . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.447 -0.575 . . . . 1.0 109.447 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -131.25 132.09 44.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.283 -0.417 . . . . 1.0 110.694 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.4 136.42 8.79 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.506 -1.037 . . . . 1.0 110.506 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.32 134.09 32.08 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.806 0.336 . . . . 1.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.55 127.82 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.149 -0.478 . . . . 1.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -118.05 127.56 53.92 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.056 -0.52 . . . . 1.0 110.109 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.008 -0.996 . . . . 1.0 110.595 179.942 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' A' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.457 -0.572 . . . . 1.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.586 ' CD2' HD22 ' E' ' 6' ' ' LEU . 11.9 m-85 -105.49 124.67 49.93 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.141 -0.481 . . . . 1.0 110.403 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -127.51 135.26 8.65 Favored Glycine 0 N--CA 1.466 0.641 0 N-CA-C 110.503 -1.039 . . . . 1.0 110.503 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.74 136.9 33.0 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.022 0.439 . . . . 1.0 110.734 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.564 ' O ' HG23 ' A' ' 5' ' ' ILE . 19.8 tt -137.49 122.69 24.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.604 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.615 HD22 ' CD2' ' E' ' 2' ' ' PHE . 48.4 mt -119.21 133.81 55.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.496 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.481 179.991 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -131.4 130.8 43.04 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.21 -0.45 . . . . 1.0 110.442 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.88 137.57 10.04 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.387 -1.085 . . . . 1.0 110.387 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.28 132.62 30.03 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.864 0.364 . . . . 1.0 111.092 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.57 125.86 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 1.0 110.199 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.7 mt -114.37 131.87 56.41 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.258 -0.428 . . . . 1.0 110.48 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 71.2 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.362 179.707 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 1' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' C' ' 1' ' ' ASN . 49.8 p-10 . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -105.42 124.37 49.44 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.11 -0.495 . . . . 1.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.67 135.26 8.62 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.573 -1.011 . . . . 1.0 110.573 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 132.74 25.53 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.813 0.34 . . . . 1.0 110.86 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.35 123.34 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.121 -0.49 . . . . 1.0 109.971 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 58.9 mt -117.92 132.23 56.43 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.861 0.363 . . . . 1.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 14.6 t . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.001 -1.0 . . . . 1.0 110.439 -179.78 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.352 -0.61 . . . . 1.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -131.59 130.68 42.52 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.428 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.37 9.96 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.365 -1.094 . . . . 1.0 110.365 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.17 134.55 32.94 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.919 0.39 . . . . 1.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.85 127.16 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.013 -0.539 . . . . 1.0 110.47 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 15.9 mt -115.27 131.43 56.93 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.084 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.955 -1.021 . . . . 1.0 110.546 179.896 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 1' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' E' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.482 -0.562 . . . . 1.0 109.482 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.615 ' CD2' HD22 ' A' ' 6' ' ' LEU . 12.7 m-85 -105.84 124.76 50.09 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.126 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 3' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -127.52 137.01 9.57 Favored Glycine 0 N--CA 1.467 0.73 0 N-CA-C 110.46 -1.056 . . . . 1.0 110.46 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 132.81 24.49 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.894 0.378 . . . . 1.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 5' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -131.86 121.53 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.971 -0.559 . . . . 1.0 110.386 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.586 HD22 ' CD2' ' A' ' 2' ' ' PHE . 50.8 mt -117.84 133.31 56.06 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.107 -0.497 . . . . 1.0 110.242 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 7' ' ' SER . . . . . 0.41 ' O ' ' OG ' ' E' ' 7' ' ' SER . 10.3 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.099 -0.953 . . . . 1.0 110.491 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.364 -0.606 . . . . 1.0 109.364 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -131.52 130.91 42.95 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.171 -0.468 . . . . 1.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.07 137.54 9.98 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.79 133.86 30.99 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.854 0.359 . . . . 1.0 110.882 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.5 126.43 67.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 CA-C-N 116.136 -0.484 . . . . 1.0 110.512 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -113.32 129.8 56.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.46 -0.791 . . . . 1.0 110.07 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.59 179.913 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 1' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' G' ' 1' ' ' ASN . 49.5 p-10 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.46 -0.57 . . . . 1.0 109.46 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -105.83 125.34 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.156 -0.474 . . . . 1.0 110.429 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.46 136.51 9.14 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.416 -1.073 . . . . 1.0 110.416 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 131.76 24.14 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.923 0.392 . . . . 1.0 111.016 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.4 mm -128.57 121.77 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.79 -0.641 . . . . 1.0 110.495 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 55.7 mt -119.0 132.15 56.05 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.072 -0.344 . . . . 1.0 110.072 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.474 -179.879 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.411 -0.589 . . . . 1.0 109.411 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -130.85 131.03 44.34 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.935 0.398 . . . . 1.0 110.395 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 138.24 10.41 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.494 -1.042 . . . . 1.0 110.494 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.82 29.33 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.883 0.373 . . . . 1.0 111.046 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.5 mm -123.41 126.72 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 115.998 -0.546 . . . . 1.0 110.138 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 16.1 mt -115.98 133.94 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.192 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.077 -0.963 . . . . 1.0 110.337 179.851 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.313 -0.625 . . . . 1.0 109.313 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PHE . . . . . 0.607 ' CD2' HD22 ' E' ' 6' ' ' LEU . 8.2 m-85 -104.89 122.97 46.9 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.243 -0.435 . . . . 1.0 110.437 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -130.28 133.64 7.47 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.82 136.0 31.98 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-O 121.026 0.441 . . . . 1.0 110.925 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ILE . . . . . 0.545 ' O ' HG23 ' A' ' 5' ' ' ILE . 19.9 tt -134.63 124.74 45.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.681 -0.69 . . . . 1.0 110.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LEU . . . . . 0.642 HD22 ' CD2' ' E' ' 2' ' ' PHE . 62.1 mt -121.62 133.44 54.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.825 -0.625 . . . . 1.0 110.53 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.531 179.891 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 1' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 2' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' D' ' 6' ' ' LEU . 67.4 t80 -130.26 131.06 45.32 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.2 -0.454 . . . . 1.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 139.45 11.2 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.445 -1.062 . . . . 1.0 110.445 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.43 134.44 27.26 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.027 0.441 . . . . 1.0 111.365 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.39 128.72 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.899 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 6' ' ' LEU . . . . . 0.418 ' O ' ' O ' ' D' ' 2' ' ' PHE . 50.3 tp -120.99 134.12 55.29 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.903 0.382 . . . . 1.0 111.082 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 7' ' ' SER . . . . . 0.422 ' O ' ' OG ' ' B' ' 7' ' ' SER . 11.6 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.795 -1.097 . . . . 1.0 110.057 179.164 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.366 -0.605 . . . . 1.0 109.366 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -105.07 123.14 47.3 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.203 -0.453 . . . . 1.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.91 133.6 7.36 Favored Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.325 -1.11 . . . . 1.0 110.325 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.01 132.71 25.56 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.885 0.374 . . . . 1.0 110.884 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.67 124.95 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 116.081 -0.509 . . . . 1.0 109.994 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 68.9 mt -120.06 132.85 55.59 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.217 -0.447 . . . . 1.0 110.34 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 21.3 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.545 179.947 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 1' ' ' ASN . . . . . 0.423 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.2 p30 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.35 -0.611 . . . . 1.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 2' ' ' PHE . . . . . 0.418 ' O ' ' O ' ' B' ' 6' ' ' LEU . 68.7 t80 -130.13 130.93 45.41 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.251 -0.432 . . . . 1.0 110.686 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.94 139.11 11.0 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.366 -1.094 . . . . 1.0 110.366 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 134.21 27.24 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.987 0.423 . . . . 1.0 111.168 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.39 128.7 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.011 179.373 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 6' ' ' LEU . . . . . 0.407 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.6 tp -120.3 128.91 53.74 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.178 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.568 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.307 -0.627 . . . . 1.0 109.307 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 2' ' ' PHE . . . . . 0.642 ' CD2' HD22 ' A' ' 6' ' ' LEU . 8.5 m-85 -105.11 123.28 47.55 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.163 -0.472 . . . . 1.0 110.356 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.5 136.38 8.84 Favored Glycine 0 N--CA 1.466 0.644 0 N-CA-C 110.136 -1.186 . . . . 1.0 110.136 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 130.51 20.58 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.812 0.339 . . . . 1.0 111.231 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 5' ' ' ILE . . . . . 0.407 ' O ' ' O ' ' A' ' 3' ' ' GLY . 47.9 mm -126.13 123.5 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.276 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 6' ' ' LEU . . . . . 0.607 HD22 ' CD2' ' A' ' 2' ' ' PHE . 68.2 mt -120.61 132.49 55.16 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.434 -0.348 . . . . 1.0 110.275 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.931 -1.033 . . . . 1.0 110.566 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 1' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 57.2 p30 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.514 -0.55 . . . . 1.0 109.514 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 2' ' ' PHE . . . . . 0.434 ' O ' ' O ' ' H' ' 6' ' ' LEU . 68.5 t80 -130.38 130.73 44.74 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.209 -0.451 . . . . 1.0 110.797 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.01 139.1 10.98 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.47 133.86 26.37 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.019 0.437 . . . . 1.0 111.2 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 46.5 mm -124.73 128.26 73.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.789 -0.642 . . . . 1.0 109.91 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 6' ' ' LEU . . . . . 0.409 ' O ' ' O ' ' H' ' 2' ' ' PHE . 50.9 tp -119.3 128.58 54.27 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.165 -0.471 . . . . 1.0 110.291 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.634 -179.951 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.09 123.84 48.51 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.236 -0.438 . . . . 1.0 110.546 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.54 135.75 8.39 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.187 -1.165 . . . . 1.0 110.187 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.76 131.66 22.89 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.979 0.419 . . . . 1.0 111.099 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.8 mm -126.48 123.61 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.447 179.415 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 67.2 mt -120.97 131.54 54.39 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.155 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.9 p . . . . . 0 C--O 1.221 -0.404 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.556 -179.942 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 1' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 56.7 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.441 -0.577 . . . . 1.0 109.441 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 2' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' F' ' 6' ' ' LEU . 69.5 t80 -130.03 130.86 45.48 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.216 -0.447 . . . . 1.0 110.706 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.35 139.3 11.07 Favored Glycine 0 N--CA 1.465 0.603 0 N-CA-C 110.474 -1.05 . . . . 1.0 110.474 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.03 135.19 28.99 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.972 0.415 . . . . 1.0 111.252 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.09 128.03 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.907 -0.588 . . . . 1.0 109.934 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 6' ' ' LEU . . . . . 0.434 ' O ' ' O ' ' F' ' 2' ' ' PHE . 50.5 tp -119.84 131.54 55.31 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.383 -0.371 . . . . 1.0 110.393 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 51.7 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.061 -0.971 . . . . 1.0 110.287 179.846 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.394 -0.595 . . . . 1.0 109.394 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.626 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.63 125.68 51.64 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.525 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.36 134.58 7.57 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.249 -1.14 . . . . 1.0 110.249 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.06 137.84 31.34 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.014 0.435 . . . . 1.0 110.906 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 5' ' ' ILE . 11.1 tp -135.5 125.83 43.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 115.839 -0.618 . . . . 1.0 110.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.635 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.0 mt -124.6 128.15 48.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.849 -0.614 . . . . 1.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.035 -0.984 . . . . 1.0 110.515 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.371 -0.603 . . . . 1.0 109.371 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -132.88 130.05 39.19 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.276 -0.42 . . . . 1.0 110.22 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.08 137.06 9.35 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 110.592 -1.003 . . . . 1.0 110.592 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.75 29.22 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.914 0.387 . . . . 1.0 111.284 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -123.19 125.24 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.835 179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -115.04 133.01 56.41 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.374 -0.376 . . . . 1.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.92 -1.038 . . . . 1.0 110.342 179.077 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.342 -0.614 . . . . 1.0 109.342 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.29 126.05 52.39 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.2 -0.455 . . . . 1.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.3 134.7 7.54 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 110.309 -1.116 . . . . 1.0 110.309 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.87 135.14 27.4 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.869 0.366 . . . . 1.0 110.962 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.52 125.39 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.231 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.76 130.79 53.18 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.435 -0.348 . . . . 1.0 110.364 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 33.9 p . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.986 -1.007 . . . . 1.0 110.578 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.315 -0.624 . . . . 1.0 109.315 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 35.8 t80 -132.95 129.76 38.68 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.278 -0.419 . . . . 1.0 110.367 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.73 136.71 9.2 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.31 133.97 31.92 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.027 0.442 . . . . 1.0 111.179 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.8 mm -124.0 127.06 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.7 -0.682 . . . . 1.0 110.18 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 16.2 mt -117.38 131.52 56.76 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.218 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.036 -0.983 . . . . 1.0 110.574 179.958 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.37 -0.604 . . . . 1.0 109.37 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.635 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.1 m-85 -107.49 125.59 51.46 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.268 -0.424 . . . . 1.0 110.446 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.07 135.87 8.36 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.257 -1.137 . . . . 1.0 110.257 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 135.56 26.77 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.986 0.422 . . . . 1.0 111.071 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -132.24 125.09 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.853 -0.612 . . . . 1.0 110.273 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.626 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.7 mt -124.31 130.74 53.04 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.332 -0.394 . . . . 1.0 110.519 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.566 179.952 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.372 -0.603 . . . . 1.0 109.372 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -133.14 130.09 38.75 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.092 -0.504 . . . . 1.0 110.418 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.2 137.19 9.42 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.427 -1.069 . . . . 1.0 110.427 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.48 131.93 26.9 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.826 0.346 . . . . 1.0 111.246 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.5 mm -122.86 125.75 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.968 -0.56 . . . . 1.0 109.965 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -114.5 129.07 56.63 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.124 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.018 -0.992 . . . . 1.0 110.586 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -107.26 126.03 51.9 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.473 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.65 134.74 7.63 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.252 -1.139 . . . . 1.0 110.252 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 138.94 31.7 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.98 0.419 . . . . 1.0 110.67 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.2 tp -136.09 125.9 40.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.793 -0.64 . . . . 1.0 110.253 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 85.5 mt -125.68 130.56 51.81 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 1.0 110.427 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.984 -1.007 . . . . 1.0 110.373 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.479 -0.563 . . . . 1.0 109.479 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -132.53 130.3 40.2 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.219 -0.446 . . . . 1.0 110.415 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.45 137.73 9.76 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.474 -1.051 . . . . 1.0 110.474 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.37 133.26 29.17 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.887 0.375 . . . . 1.0 111.184 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 95.7 mt -123.35 125.62 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 115.914 -0.584 . . . . 1.0 110.002 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -115.58 132.18 56.71 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.175 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.086 -0.959 . . . . 1.0 110.566 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.431 -0.581 . . . . 1.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' C' ' 6' ' ' LEU . 57.8 m-85 -130.67 149.61 52.25 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.308 -0.405 . . . . 1.0 110.357 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -146.49 148.36 19.98 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.622 -0.991 . . . . 1.0 110.622 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.75 142.05 26.25 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.984 0.421 . . . . 1.0 111.214 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.482 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.9 tp -135.0 127.61 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 115.71 -0.677 . . . . 1.0 109.876 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' C' ' 2' ' ' PHE . 42.4 mt -123.66 132.3 53.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.518 -0.31 . . . . 1.0 110.309 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.4 ' OXT' ' O ' ' E' ' 1' ' ' ASN . 66.3 m . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.768 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 1' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 28.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.415 -0.587 . . . . 1.0 109.415 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -132.76 130.57 40.11 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.35 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.55 140.62 11.97 Favored Glycine 0 N--CA 1.466 0.658 0 N-CA-C 110.452 -1.059 . . . . 1.0 110.452 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 139.08 34.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.94 0.4 . . . . 1.0 111.156 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -131.3 129.15 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.009 -0.541 . . . . 1.0 110.411 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 50.0 tp -120.75 129.65 53.71 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.113 -0.494 . . . . 1.0 110.566 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 47.5 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.953 -1.022 . . . . 1.0 110.585 179.764 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.344 -0.613 . . . . 1.0 109.344 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 2' ' ' PHE . . . . . 0.622 ' CD2' ' ND2' ' D' ' 1' ' ' ASN . 61.7 m-85 -130.67 149.53 52.28 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.289 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.54 149.27 21.39 Favored Glycine 0 N--CA 1.463 0.466 0 N-CA-C 110.491 -1.044 . . . . 1.0 110.491 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.46 140.05 22.54 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 1.0 111.098 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.28 129.07 56.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.001 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 6' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 2' ' ' PHE . 45.6 mt -123.56 132.58 53.93 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.317 -0.401 . . . . 1.0 110.471 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.545 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CD2' ' C' ' 2' ' ' PHE . 29.0 p30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -132.67 130.28 39.92 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.158 -0.474 . . . . 1.0 110.29 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.47 140.04 11.58 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.392 -1.083 . . . . 1.0 110.392 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.63 141.08 37.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.08 0.467 . . . . 1.0 110.996 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 5' ' ' ILE . . . . . 0.469 ' O ' HG23 ' D' ' 5' ' ' ILE . 11.0 tp -132.27 129.57 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.363 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 49.1 tp -122.31 127.18 49.51 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.439 -0.346 . . . . 1.0 110.183 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 13.5 m . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.981 -1.009 . . . . 1.0 110.632 179.924 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' E' E ' 1' ' ' ASN . . . . . 0.4 ' O ' ' OXT' ' A' ' 7' ' ' SER . 99.2 m-20 . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.618 ' CD2' ' ND2' ' F' ' 1' ' ' ASN . 57.1 m-85 -130.27 149.25 52.05 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.314 -0.403 . . . . 1.0 110.262 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 3' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -146.54 147.75 18.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.65 140.7 25.03 Favored 'General case' 0 C--O 1.231 0.095 0 CA-C-O 121.052 0.454 . . . . 1.0 111.342 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 5' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -133.98 128.22 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 115.857 -0.61 . . . . 1.0 109.935 179.377 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.439 ' O ' ' O ' ' G' ' 2' ' ' PHE . 44.7 mt -123.23 132.61 54.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.463 -0.335 . . . . 1.0 110.597 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.054 -0.974 . . . . 1.0 110.587 179.928 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 1' ' ' ASN . . . . . 0.618 ' ND2' ' CD2' ' E' ' 2' ' ' PHE . 29.1 p30 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.395 -0.594 . . . . 1.0 109.395 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -132.49 130.46 40.5 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.404 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.32 140.28 11.76 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.327 -1.109 . . . . 1.0 110.327 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.63 140.39 35.04 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.918 0.39 . . . . 1.0 110.973 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 5' ' ' ILE . . . . . 0.499 ' O ' HG23 ' F' ' 5' ' ' ILE . 11.2 tp -132.47 128.31 57.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.821 -0.627 . . . . 1.0 110.475 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 47.8 tp -120.01 126.96 52.11 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.298 -0.41 . . . . 1.0 110.334 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.897 -1.049 . . . . 1.0 110.565 179.893 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.279 -0.638 . . . . 1.0 109.279 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 2' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' E' ' 6' ' ' LEU . 59.9 m-85 -130.74 150.03 52.11 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.445 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.6 148.59 20.37 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.524 -1.03 . . . . 1.0 110.524 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.15 142.09 25.84 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.927 0.394 . . . . 1.0 110.857 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 5' ' ' ILE . . . . . 0.522 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -135.12 126.89 47.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 1.0 109.73 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' E' ' 2' ' ' PHE . 53.6 mt -122.54 132.78 54.47 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.907 0.384 . . . . 1.0 110.462 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.055 -0.974 . . . . 1.0 110.607 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 1' ' ' ASN . . . . . 0.425 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 29.2 p30 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.348 -0.612 . . . . 1.0 109.348 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -132.28 130.61 41.1 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.275 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.7 140.74 12.05 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.73 138.41 32.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.865 0.364 . . . . 1.0 111.187 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.48 128.22 63.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.401 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 48.8 tp -119.04 127.96 53.91 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.356 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.433 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.295 -0.632 . . . . 1.0 109.295 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.5 m-85 -106.81 123.18 47.77 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.182 -0.463 . . . . 1.0 110.404 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.54 132.84 7.24 Favored Glycine 0 N--CA 1.465 0.571 0 N-CA-C 110.285 -1.126 . . . . 1.0 110.285 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.22 137.84 34.62 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.061 0.458 . . . . 1.0 110.997 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.505 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.8 tp -134.64 126.27 47.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.682 -0.69 . . . . 1.0 110.292 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.641 HD22 ' CD2' ' E' ' 2' ' ' PHE . 82.9 mt -123.95 130.86 53.27 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.991 -0.55 . . . . 1.0 110.503 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.448 179.883 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.246 -0.65 . . . . 1.0 109.246 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 65.6 t80 -128.74 130.36 46.97 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 121.056 0.455 . . . . 1.0 110.796 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.93 137.57 9.86 Favored Glycine 0 N--CA 1.466 0.698 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.83 133.9 29.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.849 0.357 . . . . 1.0 111.257 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 46.6 mm -125.08 129.23 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.917 -0.583 . . . . 1.0 110.355 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' D' ' 2' ' ' PHE . 45.7 tp -120.35 130.94 54.64 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.288 -0.415 . . . . 1.0 110.668 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 7' ' ' SER . . . . . 0.424 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 7.9 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.247 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.333 -0.617 . . . . 1.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -107.4 123.13 47.92 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.139 -0.482 . . . . 1.0 110.166 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.75 133.35 7.42 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.251 -1.14 . . . . 1.0 110.251 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.76 135.55 29.84 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 120.989 0.424 . . . . 1.0 111.02 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -131.97 126.43 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.913 -0.585 . . . . 1.0 110.128 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.2 mt -122.6 132.47 54.31 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.432 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.974 -1.013 . . . . 1.0 110.493 -179.988 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.304 -0.628 . . . . 1.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' B' ' 6' ' ' LEU . 67.7 t80 -128.71 130.39 47.07 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.741 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.11 137.4 9.72 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.304 -1.119 . . . . 1.0 110.304 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.6 135.33 31.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.994 0.426 . . . . 1.0 111.074 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -127.31 129.6 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.428 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 46.0 tp -120.05 128.81 53.85 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.328 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.968 -1.015 . . . . 1.0 110.549 179.965 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.3 -0.63 . . . . 1.0 109.3 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.641 ' CD2' HD22 ' A' ' 6' ' ' LEU . 6.5 m-85 -106.54 123.33 47.93 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.329 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.92 133.26 7.36 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 110.28 -1.128 . . . . 1.0 110.28 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.49 133.81 29.77 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.883 0.373 . . . . 1.0 111.252 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -128.09 124.75 63.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.777 -0.647 . . . . 1.0 110.222 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 84.8 mt -123.64 131.6 53.65 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.867 0.365 . . . . 1.0 110.355 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.988 -1.005 . . . . 1.0 110.599 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 2' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' H' ' 6' ' ' LEU . 66.2 t80 -128.35 130.45 47.78 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.734 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.48 9.75 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.254 -1.138 . . . . 1.0 110.254 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -141.21 134.68 29.84 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.976 0.417 . . . . 1.0 111.102 -179.619 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -128.01 129.07 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.896 -0.593 . . . . 1.0 110.541 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 6' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' H' ' 2' ' ' PHE . 46.5 tp -118.85 128.28 54.3 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.72 -0.673 . . . . 1.0 110.266 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.049 -0.977 . . . . 1.0 110.545 179.987 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.448 -0.575 . . . . 1.0 109.448 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -106.37 124.19 49.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.167 -0.47 . . . . 1.0 110.342 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.62 132.6 6.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.93 138.67 35.78 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.025 0.44 . . . . 1.0 110.747 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 5' ' ' ILE . . . . . 0.541 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -134.88 125.28 45.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.846 -0.615 . . . . 1.0 110.079 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 83.6 mt -124.14 133.39 53.59 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.133 -0.485 . . . . 1.0 110.336 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.485 179.924 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.265 -0.642 . . . . 1.0 109.265 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 2' ' ' PHE . . . . . 0.426 ' O ' ' O ' ' F' ' 6' ' ' LEU . 67.2 t80 -128.45 130.47 47.62 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.201 -0.454 . . . . 1.0 110.681 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.92 10.03 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -141.33 134.52 29.39 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.892 0.377 . . . . 1.0 111.096 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.77 128.45 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.988 -0.551 . . . . 1.0 110.392 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' F' ' 2' ' ' PHE . 45.9 tp -118.35 127.3 53.56 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.103 -0.499 . . . . 1.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.076 -0.964 . . . . 1.0 110.372 179.893 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.443 -0.577 . . . . 1.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.637 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.78 124.37 49.95 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.105 -0.498 . . . . 1.0 110.307 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.13 133.65 7.49 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.272 -1.131 . . . . 1.0 110.272 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 136.74 32.13 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.031 0.443 . . . . 1.0 110.922 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.527 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.5 tp -133.67 126.07 50.73 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 115.753 -0.658 . . . . 1.0 110.258 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.661 HD22 ' CD2' ' E' ' 2' ' ' PHE . 84.8 mt -124.07 129.93 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.566 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.7 p . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.924 -1.036 . . . . 1.0 110.491 179.875 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.332 -0.618 . . . . 1.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.404 ' O ' ' O ' ' D' ' 6' ' ' LEU . 71.5 t80 -129.03 130.32 46.45 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.691 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.52 137.58 9.93 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 110.404 -1.078 . . . . 1.0 110.404 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.54 134.02 29.99 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.965 0.412 . . . . 1.0 111.239 -179.49 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -124.46 128.22 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 CA-C-N 115.81 -0.632 . . . . 1.0 109.962 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 6' ' ' LEU . . . . . 0.401 ' O ' ' O ' ' D' ' 2' ' ' PHE . 47.2 tp -118.66 131.18 56.16 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.965 0.412 . . . . 1.0 110.655 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 7' ' ' SER . . . . . 0.484 ' OG ' ' CE2' ' E' ' 2' ' ' PHE . 1.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.02 -0.99 . . . . 1.0 110.309 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.38 -0.6 . . . . 1.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.21 124.35 50.14 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.18 -0.463 . . . . 1.0 110.165 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.47 133.96 7.59 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.369 -1.092 . . . . 1.0 110.369 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.65 134.48 26.93 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.984 0.421 . . . . 1.0 110.925 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.01 126.37 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 115.973 -0.558 . . . . 1.0 110.081 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.9 mt -122.99 132.04 53.97 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.319 -0.4 . . . . 1.0 110.374 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.587 179.983 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.275 -0.639 . . . . 1.0 109.275 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 2' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' B' ' 6' ' ' LEU . 73.0 t80 -129.05 130.35 46.45 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.712 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.36 9.8 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.253 -1.139 . . . . 1.0 110.253 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.32 133.87 30.13 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.941 0.4 . . . . 1.0 111.251 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.7 mm -124.22 128.79 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.744 -0.662 . . . . 1.0 110.241 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 6' ' ' LEU . . . . . 0.404 ' O ' ' O ' ' B' ' 2' ' ' PHE . 48.4 tp -119.14 127.72 53.6 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.397 . . . . 1.0 110.235 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.978 -1.01 . . . . 1.0 110.535 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.399 -0.593 . . . . 1.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.661 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -107.85 124.34 49.94 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.254 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 3' ' ' GLY . . . . . 0.453 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -130.28 134.42 7.82 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.71 133.15 26.72 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.895 0.378 . . . . 1.0 111.251 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.2 mm -127.93 125.08 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.787 -0.642 . . . . 1.0 110.235 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.637 HD22 ' CD2' ' A' ' 2' ' ' PHE . 86.6 mt -123.78 130.46 52.66 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.882 0.373 . . . . 1.0 110.478 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.577 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 2' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' H' ' 6' ' ' LEU . 71.8 t80 -128.79 130.19 46.67 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.91 0.386 . . . . 1.0 110.764 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.67 10.0 Favored Glycine 0 N--CA 1.467 0.727 0 N-CA-C 110.245 -1.142 . . . . 1.0 110.245 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.0 133.41 28.35 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.956 0.408 . . . . 1.0 111.236 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.42 128.59 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.128 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 6' ' ' LEU . . . . . 0.422 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.2 tp -118.75 128.12 54.18 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.172 -0.467 . . . . 1.0 110.256 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.908 -1.044 . . . . 1.0 110.468 179.899 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.3 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.57 124.93 50.66 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.211 -0.45 . . . . 1.0 110.284 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.82 133.48 7.32 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.217 -1.153 . . . . 1.0 110.217 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.9 137.75 33.39 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.956 0.408 . . . . 1.0 110.745 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 9.7 tp -134.09 125.77 48.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.894 -0.594 . . . . 1.0 110.178 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.9 mt -124.24 131.01 53.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.336 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.1 p . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.501 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.255 -0.646 . . . . 1.0 109.255 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 2' ' ' PHE . . . . . 0.422 ' O ' ' O ' ' F' ' 6' ' ' LEU . 72.9 t80 -128.49 130.26 47.25 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.285 -0.416 . . . . 1.0 110.74 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.54 138.03 10.22 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.276 -1.129 . . . . 1.0 110.276 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.56 134.38 30.48 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.992 0.425 . . . . 1.0 111.107 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.74 127.81 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.967 -0.56 . . . . 1.0 110.146 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 6' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' F' ' 2' ' ' PHE . 48.8 tp -118.67 128.94 55.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.418 -0.356 . . . . 1.0 110.293 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.999 -1.001 . . . . 1.0 110.419 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.48 -0.563 . . . . 1.0 109.48 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.61 ' CD2' HD22 ' E' ' 6' ' ' LEU . 9.9 m-85 -106.13 122.61 46.54 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.221 -0.445 . . . . 1.0 110.46 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.16 134.36 7.58 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.202 -1.159 . . . . 1.0 110.202 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 139.13 32.91 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.1 0.476 . . . . 1.0 111.186 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.524 ' O ' HG23 ' A' ' 5' ' ' ILE . 11.1 tp -134.04 124.96 47.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 115.599 -0.728 . . . . 1.0 110.124 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.62 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.6 mt -126.52 131.89 51.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.079 -0.51 . . . . 1.0 110.54 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.071 -0.966 . . . . 1.0 110.485 179.903 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.489 1.482 0 N-CA-C 109.396 -0.594 . . . . 1.0 109.396 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 36.2 t80 -131.98 130.74 41.85 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.291 -0.413 . . . . 1.0 110.413 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.89 138.0 10.31 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.52 132.18 27.24 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.843 0.354 . . . . 1.0 111.283 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.35 125.57 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.016 -0.538 . . . . 1.0 110.077 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -114.57 129.49 56.67 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.506 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' SER . . . . . 0.403 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 21.0 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.322 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 1.0 109.337 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -106.39 122.75 46.89 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.224 -0.443 . . . . 1.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.86 134.8 7.74 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.144 -1.183 . . . . 1.0 110.144 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.68 136.94 29.52 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.921 0.391 . . . . 1.0 111.177 -179.597 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.72 124.34 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.09 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 86.5 mt -125.37 132.13 52.85 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.456 -0.338 . . . . 1.0 110.472 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 90.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 1.0 110.559 179.88 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 109.214 -0.661 . . . . 1.0 109.214 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -132.09 130.54 41.37 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.457 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.53 10.07 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.3 -1.12 . . . . 1.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.28 134.71 31.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.01 0.433 . . . . 1.0 111.036 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -126.99 127.38 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.382 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 15.9 mt -116.11 131.57 56.9 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.351 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 118.006 -0.997 . . . . 1.0 110.517 179.864 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.442 -0.577 . . . . 1.0 109.442 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.62 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.0 m-85 -106.19 122.65 46.65 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.336 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 3' ' ' GLY . . . . . 0.417 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.31 134.89 7.83 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.208 -1.157 . . . . 1.0 110.208 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 137.01 30.37 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.951 0.405 . . . . 1.0 111.426 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.18 124.32 55.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.836 -0.62 . . . . 1.0 110.12 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.61 HD22 ' CD2' ' A' ' 2' ' ' PHE . 87.2 mt -125.87 131.37 52.39 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.186 -0.461 . . . . 1.0 110.442 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 83.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.063 -0.97 . . . . 1.0 110.579 179.821 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 2' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' H' ' 6' ' ' LEU . 36.3 t80 -132.05 130.95 41.97 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.347 -0.388 . . . . 1.0 110.519 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.08 138.39 10.51 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 131.67 25.37 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.921 0.391 . . . . 1.0 111.309 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.8 mm -122.88 126.33 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.017 -0.538 . . . . 1.0 110.127 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 6' ' ' LEU . . . . . 0.412 ' O ' ' O ' ' H' ' 2' ' ' PHE . 15.5 mt -114.99 127.59 55.76 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.137 -0.483 . . . . 1.0 109.974 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.614 179.863 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -106.38 123.25 47.77 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.304 -0.407 . . . . 1.0 110.36 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.92 134.36 7.5 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.113 -1.195 . . . . 1.0 110.113 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.8 140.04 32.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.048 0.452 . . . . 1.0 110.926 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 5' ' ' ILE . . . . . 0.528 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -134.52 124.85 45.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.698 -0.683 . . . . 1.0 110.007 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -126.87 133.34 50.73 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.456 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.98 -1.009 . . . . 1.0 110.403 -179.992 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 2' ' ' PHE . . . . . 0.412 ' O ' ' O ' ' F' ' 6' ' ' LEU . 38.3 t80 -132.01 131.13 42.23 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.375 -0.375 . . . . 1.0 110.48 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.27 138.79 10.74 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.391 -1.084 . . . . 1.0 110.391 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.79 132.48 27.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.91 0.386 . . . . 1.0 111.267 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.7 mm -122.89 126.39 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.083 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 6' ' ' LEU . . . . . 0.414 ' O ' ' O ' ' F' ' 2' ' ' PHE . 15.9 mt -116.4 129.24 56.13 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.387 -0.369 . . . . 1.0 110.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 35.1 p . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.024 -0.988 . . . . 1.0 110.38 179.827 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.628 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -106.01 122.12 45.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.435 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.62 134.22 7.46 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 110.337 -1.105 . . . . 1.0 110.337 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 138.06 30.31 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.114 0.483 . . . . 1.0 110.967 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.544 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.7 tp -135.09 125.23 44.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 115.721 -0.672 . . . . 1.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.646 HD22 ' CD2' ' E' ' 2' ' ' PHE . 87.5 mt -125.1 129.62 50.57 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.996 -0.547 . . . . 1.0 110.513 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.2 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.469 179.874 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CZ ' ' A' ' 2' ' ' PHE . 59.4 t-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.517 ' N ' ' OD1' ' B' ' 1' ' ' ASN . 72.6 t80 -129.46 129.85 45.15 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.675 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.79 136.01 8.81 Favored Glycine 0 N--CA 1.467 0.72 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.2 134.16 27.27 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.033 0.444 . . . . 1.0 111.497 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -124.85 128.43 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.721 -0.672 . . . . 1.0 109.995 179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 6' ' ' LEU . . . . . 0.424 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 45.7 tp -121.17 132.99 55.17 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.833 0.349 . . . . 1.0 110.903 -179.625 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 7' ' ' SER . . . . . 0.506 ' OG ' ' CZ ' ' E' ' 2' ' ' PHE . 17.5 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.01 . . . . 1.0 110.562 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.286 -0.635 . . . . 1.0 109.286 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -106.62 122.42 46.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.235 -0.439 . . . . 1.0 110.241 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.41 134.87 7.72 Favored Glycine 0 N--CA 1.465 0.605 0 N-CA-C 110.384 -1.086 . . . . 1.0 110.384 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.84 135.45 26.11 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.95 0.405 . . . . 1.0 111.098 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -131.25 124.81 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.157 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 88.0 mt -124.26 132.0 53.56 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.43 -0.35 . . . . 1.0 110.284 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 32.5 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.019 -0.991 . . . . 1.0 110.55 179.847 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 1' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' D' ' 2' ' ' PHE . 60.0 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.335 -0.617 . . . . 1.0 109.335 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 2' ' ' PHE . . . . . 0.513 ' N ' ' OD1' ' D' ' 1' ' ' ASN . 74.7 t80 -129.08 129.77 45.67 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.777 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.6 135.8 8.74 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.198 -1.161 . . . . 1.0 110.198 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 133.81 26.64 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.0 0.429 . . . . 1.0 111.335 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.53 128.41 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.757 -0.656 . . . . 1.0 110.022 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 6' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' B' ' 2' ' ' PHE . 45.6 tp -120.02 128.8 53.87 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.369 -0.378 . . . . 1.0 110.298 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 7' ' ' SER . . . . . 0.425 ' OG ' ' ND2' ' B' ' 1' ' ' ASN . 3.7 m . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.002 -0.999 . . . . 1.0 110.575 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.31 -0.626 . . . . 1.0 109.31 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.646 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -106.14 122.15 45.61 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.232 -0.44 . . . . 1.0 110.275 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 3' ' ' GLY . . . . . 0.428 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.97 134.81 7.73 Favored Glycine 0 N--CA 1.465 0.6 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.462 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.28 136.07 27.62 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.969 0.414 . . . . 1.0 111.172 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.18 124.41 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.201 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.628 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.2 mt -124.49 130.89 53.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.207 -0.451 . . . . 1.0 110.428 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.551 179.908 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 1' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' F' ' 2' ' ' PHE . 59.6 t-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.367 -0.605 . . . . 1.0 109.367 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 2' ' ' PHE . . . . . 0.524 ' N ' ' OD1' ' F' ' 1' ' ' ASN . 73.0 t80 -130.22 129.52 43.47 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.041 -0.527 . . . . 1.0 110.593 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.63 136.03 8.86 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.151 -1.179 . . . . 1.0 110.151 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.57 133.38 25.51 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 121.059 0.457 . . . . 1.0 111.417 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -124.94 128.33 73.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-N 115.699 -0.682 . . . . 1.0 110.063 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' H' ' 2' ' ' PHE . 45.8 tp -119.56 127.92 53.44 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.015 -0.538 . . . . 1.0 110.28 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 7' ' ' SER . . . . . 0.478 ' OG ' ' ND2' ' H' ' 1' ' ' ASN . 7.0 m . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.005 -0.998 . . . . 1.0 110.485 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.289 -0.634 . . . . 1.0 109.289 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 2' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' H' ' 1' ' ' ASN . 7.1 m-85 -105.89 122.98 47.23 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.289 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.55 134.02 7.26 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 110.291 -1.124 . . . . 1.0 110.291 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.49 139.14 31.41 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.041 0.448 . . . . 1.0 110.759 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.8 tp -135.76 124.91 39.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 1.0 110.22 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.26 130.74 52.66 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.37 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 37.7 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.536 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 1' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' G' ' 2' ' ' PHE . 59.5 t-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.404 -0.591 . . . . 1.0 109.404 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 2' ' ' PHE . . . . . 0.519 ' N ' ' OD1' ' H' ' 1' ' ' ASN . 74.3 t80 -129.49 129.82 45.06 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.199 -0.455 . . . . 1.0 110.694 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 136.34 8.97 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.385 -1.086 . . . . 1.0 110.385 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.29 134.61 27.76 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.038 0.447 . . . . 1.0 111.288 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -125.59 127.65 71.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.931 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 6' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' F' ' 2' ' ' PHE . 47.0 tp -119.59 129.96 54.89 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.341 -0.39 . . . . 1.0 110.409 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 59.5 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.997 -1.001 . . . . 1.0 110.501 179.878 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 10.1 m-85 -105.12 123.59 48.09 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.153 -0.476 . . . . 1.0 110.28 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -128.78 137.57 9.72 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.589 -1.004 . . . . 1.0 110.589 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -144.44 141.12 29.39 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-O 120.94 0.4 . . . . 1.0 111.046 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.501 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.9 tp -141.35 125.79 17.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.71 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.636 HD22 ' CD2' ' E' ' 2' ' ' PHE . 60.2 mt -120.74 132.67 55.18 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.968 -0.56 . . . . 1.0 110.32 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.534 179.869 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.268 -0.641 . . . . 1.0 109.268 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' D' ' 6' ' ' LEU . 56.2 t80 -128.22 130.53 48.11 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.248 -0.433 . . . . 1.0 110.725 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.86 137.48 9.65 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.332 -1.107 . . . . 1.0 110.332 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.38 135.62 32.29 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.913 0.387 . . . . 1.0 111.23 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -127.03 130.05 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.888 -0.596 . . . . 1.0 110.278 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 47.0 tp -120.42 130.78 54.49 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.016 0.436 . . . . 1.0 110.604 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 117.793 -1.099 . . . . 1.0 110.208 179.607 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.353 -0.61 . . . . 1.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -105.49 123.45 47.92 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.224 -0.444 . . . . 1.0 110.212 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 3' ' ' GLY . . . . . 0.401 ' HA2' HD12 ' A' ' 5' ' ' ILE . . . -129.03 138.2 10.1 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.699 -0.96 . . . . 1.0 110.699 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.16 140.36 26.59 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.959 0.409 . . . . 1.0 110.75 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 5' ' ' ILE . . . . . 0.472 ' O ' HG23 ' C' ' 5' ' ' ILE . 19.8 tt -140.39 126.62 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 116.059 -0.518 . . . . 1.0 110.061 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 69.4 mt -120.04 133.76 55.44 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.245 -0.434 . . . . 1.0 110.27 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 34.4 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.511 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.272 -0.64 . . . . 1.0 109.272 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -128.38 130.44 47.69 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.225 -0.443 . . . . 1.0 110.632 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.9 137.3 9.53 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.278 -1.129 . . . . 1.0 110.278 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.72 136.33 32.48 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.06 0.457 . . . . 1.0 110.947 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.75 130.58 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.907 -0.588 . . . . 1.0 110.519 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 6' ' ' LEU . . . . . 0.402 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.3 tp -120.51 129.52 53.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.232 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 95.5 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.496 -179.998 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.636 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.4 m-85 -105.25 123.77 48.41 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.195 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 3' ' ' GLY . . . . . 0.489 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -129.33 138.0 9.95 Favored Glycine 0 N--CA 1.468 0.776 0 N-CA-C 110.695 -0.962 . . . . 1.0 110.695 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.03 140.2 27.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.793 0.33 . . . . 1.0 111.079 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 5' ' ' ILE . . . . . 0.493 HG23 ' O ' ' E' ' 5' ' ' ILE . 20.2 tt -140.44 125.42 19.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.465 179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 62.2 mt -119.66 132.54 55.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.282 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.543 179.943 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -128.21 130.58 48.22 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.264 -0.426 . . . . 1.0 110.666 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 137.23 9.48 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.204 -1.159 . . . . 1.0 110.204 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -140.88 136.1 31.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.059 0.457 . . . . 1.0 111.032 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -129.44 130.24 67.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 115.915 -0.584 . . . . 1.0 110.523 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.9 tp -119.84 129.02 54.21 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.575 -0.739 . . . . 1.0 110.207 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.945 -1.026 . . . . 1.0 110.556 179.864 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -105.16 124.32 49.33 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.218 -0.446 . . . . 1.0 110.3 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.62 137.72 9.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.651 -0.98 . . . . 1.0 110.651 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.38 141.13 28.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.904 0.383 . . . . 1.0 110.629 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 5' ' ' ILE . . . . . 0.502 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -141.59 126.34 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.989 -0.551 . . . . 1.0 110.312 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 65.2 mt -120.33 131.78 55.01 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.225 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 2.2 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.474 -179.917 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.376 -0.602 . . . . 1.0 109.376 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' F' ' 6' ' ' LEU . 58.1 t80 -127.79 130.47 48.75 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.941 0.401 . . . . 1.0 110.713 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.19 137.58 9.68 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.361 -1.096 . . . . 1.0 110.361 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -140.67 135.79 31.99 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.855 0.36 . . . . 1.0 111.166 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -127.17 129.88 71.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 116.013 -0.54 . . . . 1.0 110.367 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 49.2 tp -120.42 128.34 53.1 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.195 -0.457 . . . . 1.0 110.216 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 52.1 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.942 -1.028 . . . . 1.0 110.439 179.754 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -124.28 135.39 53.35 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.354 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -133.51 134.16 7.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.08 132.17 20.38 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.149 0.5 . . . . 1.0 110.946 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.608 ' O ' HG23 ' A' ' 5' ' ' ILE . 10.1 tp -137.99 122.43 22.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.472 -0.786 . . . . 1.0 110.217 -179.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 mt -119.51 135.4 54.79 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.932 0.396 . . . . 1.0 110.888 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.3 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.116 -0.945 . . . . 1.0 110.384 179.646 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' ASN . . . . . 0.43 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -131.57 132.35 44.04 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.18 -0.464 . . . . 1.0 110.665 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.12 136.76 9.01 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.431 -1.068 . . . . 1.0 110.431 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.61 133.37 30.61 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.801 0.334 . . . . 1.0 110.883 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -125.47 128.16 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.543 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -119.11 127.52 53.44 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.007 -0.542 . . . . 1.0 110.051 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.878 -1.058 . . . . 1.0 110.632 179.719 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.418 -0.586 . . . . 1.0 109.418 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 2' ' ' PHE . . . . . 0.402 ' N ' ' CD1' ' C' ' 2' ' ' PHE . 33.1 m-85 -123.99 135.42 53.62 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.222 -0.444 . . . . 1.0 110.21 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.42 134.77 7.57 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.496 -1.041 . . . . 1.0 110.496 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.13 128.67 15.04 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-O 121.023 0.439 . . . . 1.0 111.048 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.74 124.19 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.818 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 61.7 mt -118.35 132.48 56.27 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.809 0.337 . . . . 1.0 110.451 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 5.9 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.048 -0.977 . . . . 1.0 110.503 179.975 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 1' ' ' ASN . . . . . 0.431 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.4 -0.593 . . . . 1.0 109.4 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -132.07 131.83 42.77 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.695 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.74 136.21 8.72 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.402 -1.079 . . . . 1.0 110.402 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.14 133.11 31.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.916 0.389 . . . . 1.0 110.843 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.3 mm -124.66 128.28 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.377 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 50.7 tp -118.64 126.5 52.07 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.046 -0.524 . . . . 1.0 109.99 179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.025 -0.988 . . . . 1.0 110.578 179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -123.7 134.88 53.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.251 -0.431 . . . . 1.0 110.164 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 3' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -133.19 135.1 7.87 Favored Glycine 0 N--CA 1.466 0.666 0 N-CA-C 110.442 -1.063 . . . . 1.0 110.442 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.11 128.31 13.78 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.969 0.414 . . . . 1.0 111.465 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.1 mt -134.25 124.17 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.838 -0.619 . . . . 1.0 110.205 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 54.2 mt -118.38 133.25 56.04 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.306 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.932 -1.032 . . . . 1.0 110.468 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.389 -0.597 . . . . 1.0 109.389 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -131.52 132.17 43.99 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.188 -0.46 . . . . 1.0 110.747 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.02 136.55 8.89 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.421 -1.071 . . . . 1.0 110.421 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.07 132.32 28.21 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.826 0.346 . . . . 1.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 45.9 mm -125.07 127.75 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.408 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 tp -117.41 126.36 52.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.731 -0.668 . . . . 1.0 110.13 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.946 -1.026 . . . . 1.0 110.566 179.984 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.484 -0.561 . . . . 1.0 109.484 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 37.3 m-85 -124.15 136.08 53.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.229 -0.441 . . . . 1.0 110.259 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.66 135.11 7.74 Favored Glycine 0 N--CA 1.466 0.652 0 N-CA-C 110.355 -1.098 . . . . 1.0 110.355 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.49 127.77 12.13 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.025 0.44 . . . . 1.0 111.271 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.99 125.29 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.73 -0.668 . . . . 1.0 110.115 179.362 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 57.8 mt -117.82 132.77 56.4 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 1.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.496 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 1' ' ' ASN . . . . . 0.437 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 55.6 p30 . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.447 -0.575 . . . . 1.0 109.447 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -131.25 132.09 44.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.283 -0.417 . . . . 1.0 110.694 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.4 136.42 8.79 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.506 -1.037 . . . . 1.0 110.506 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.32 134.09 32.08 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.806 0.336 . . . . 1.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.55 127.82 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.149 -0.478 . . . . 1.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -118.05 127.56 53.92 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.056 -0.52 . . . . 1.0 110.109 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.008 -0.996 . . . . 1.0 110.595 179.942 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' A' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.457 -0.572 . . . . 1.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.586 ' CD2' HD22 ' E' ' 6' ' ' LEU . 11.9 m-85 -105.49 124.67 49.93 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.141 -0.481 . . . . 1.0 110.403 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -127.51 135.26 8.65 Favored Glycine 0 N--CA 1.466 0.641 0 N-CA-C 110.503 -1.039 . . . . 1.0 110.503 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.74 136.9 33.0 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.022 0.439 . . . . 1.0 110.734 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.564 ' O ' HG23 ' A' ' 5' ' ' ILE . 19.8 tt -137.49 122.69 24.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.604 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.615 HD22 ' CD2' ' E' ' 2' ' ' PHE . 48.4 mt -119.21 133.81 55.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.496 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.481 179.991 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -131.4 130.8 43.04 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.21 -0.45 . . . . 1.0 110.442 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.88 137.57 10.04 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.387 -1.085 . . . . 1.0 110.387 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.28 132.62 30.03 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.864 0.364 . . . . 1.0 111.092 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.57 125.86 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 1.0 110.199 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.7 mt -114.37 131.87 56.41 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.258 -0.428 . . . . 1.0 110.48 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 71.2 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.362 179.707 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 1' ' ' ASN . . . . . 0.435 ' OD1' ' O ' ' C' ' 1' ' ' ASN . 49.8 p-10 . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -105.42 124.37 49.44 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.11 -0.495 . . . . 1.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.67 135.26 8.62 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.573 -1.011 . . . . 1.0 110.573 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 132.74 25.53 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.813 0.34 . . . . 1.0 110.86 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.35 123.34 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.121 -0.49 . . . . 1.0 109.971 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 58.9 mt -117.92 132.23 56.43 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.861 0.363 . . . . 1.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 14.6 t . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.001 -1.0 . . . . 1.0 110.439 -179.78 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.352 -0.61 . . . . 1.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -131.59 130.68 42.52 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.428 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.37 9.96 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.365 -1.094 . . . . 1.0 110.365 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.17 134.55 32.94 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.919 0.39 . . . . 1.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.85 127.16 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.013 -0.539 . . . . 1.0 110.47 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 15.9 mt -115.27 131.43 56.93 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.084 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.955 -1.021 . . . . 1.0 110.546 179.896 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 1' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' E' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.482 -0.562 . . . . 1.0 109.482 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.615 ' CD2' HD22 ' A' ' 6' ' ' LEU . 12.7 m-85 -105.84 124.76 50.09 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.126 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 3' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -127.52 137.01 9.57 Favored Glycine 0 N--CA 1.467 0.73 0 N-CA-C 110.46 -1.056 . . . . 1.0 110.46 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 132.81 24.49 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.894 0.378 . . . . 1.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 5' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -131.86 121.53 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.971 -0.559 . . . . 1.0 110.386 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.586 HD22 ' CD2' ' A' ' 2' ' ' PHE . 50.8 mt -117.84 133.31 56.06 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.107 -0.497 . . . . 1.0 110.242 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 7' ' ' SER . . . . . 0.41 ' O ' ' OG ' ' E' ' 7' ' ' SER . 10.3 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.099 -0.953 . . . . 1.0 110.491 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.364 -0.606 . . . . 1.0 109.364 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -131.52 130.91 42.95 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.171 -0.468 . . . . 1.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.07 137.54 9.98 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.79 133.86 30.99 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.854 0.359 . . . . 1.0 110.882 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.5 126.43 67.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 CA-C-N 116.136 -0.484 . . . . 1.0 110.512 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -113.32 129.8 56.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.46 -0.791 . . . . 1.0 110.07 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.59 179.913 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 1' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' G' ' 1' ' ' ASN . 49.5 p-10 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.46 -0.57 . . . . 1.0 109.46 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -105.83 125.34 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.156 -0.474 . . . . 1.0 110.429 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.46 136.51 9.14 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.416 -1.073 . . . . 1.0 110.416 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 131.76 24.14 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.923 0.392 . . . . 1.0 111.016 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.4 mm -128.57 121.77 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.79 -0.641 . . . . 1.0 110.495 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 55.7 mt -119.0 132.15 56.05 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.072 -0.344 . . . . 1.0 110.072 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.474 -179.879 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.411 -0.589 . . . . 1.0 109.411 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -130.85 131.03 44.34 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.935 0.398 . . . . 1.0 110.395 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 138.24 10.41 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.494 -1.042 . . . . 1.0 110.494 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.82 29.33 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.883 0.373 . . . . 1.0 111.046 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.5 mm -123.41 126.72 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 115.998 -0.546 . . . . 1.0 110.138 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 16.1 mt -115.98 133.94 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.192 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.077 -0.963 . . . . 1.0 110.337 179.851 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.313 -0.625 . . . . 1.0 109.313 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.607 ' CD2' HD22 ' E' ' 6' ' ' LEU . 8.2 m-85 -104.89 122.97 46.9 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.243 -0.435 . . . . 1.0 110.437 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -130.28 133.64 7.47 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.82 136.0 31.98 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-O 121.026 0.441 . . . . 1.0 110.925 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.545 ' O ' HG23 ' A' ' 5' ' ' ILE . 19.9 tt -134.63 124.74 45.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.681 -0.69 . . . . 1.0 110.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . 0.642 HD22 ' CD2' ' E' ' 2' ' ' PHE . 62.1 mt -121.62 133.44 54.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.825 -0.625 . . . . 1.0 110.53 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.531 179.891 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' B' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' D' ' 6' ' ' LEU . 67.4 t80 -130.26 131.06 45.32 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.2 -0.454 . . . . 1.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 139.45 11.2 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.445 -1.062 . . . . 1.0 110.445 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.43 134.44 27.26 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.027 0.441 . . . . 1.0 111.365 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.39 128.72 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.899 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' LEU . . . . . 0.418 ' O ' ' O ' ' D' ' 2' ' ' PHE . 50.3 tp -120.99 134.12 55.29 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.903 0.382 . . . . 1.0 111.082 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 7' ' ' SER . . . . . 0.422 ' O ' ' OG ' ' B' ' 7' ' ' SER . 11.6 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.795 -1.097 . . . . 1.0 110.057 179.164 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.366 -0.605 . . . . 1.0 109.366 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -105.07 123.14 47.3 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.203 -0.453 . . . . 1.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.91 133.6 7.36 Favored Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.325 -1.11 . . . . 1.0 110.325 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.01 132.71 25.56 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.885 0.374 . . . . 1.0 110.884 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.67 124.95 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 116.081 -0.509 . . . . 1.0 109.994 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 68.9 mt -120.06 132.85 55.59 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.217 -0.447 . . . . 1.0 110.34 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 21.3 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.545 179.947 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 1' ' ' ASN . . . . . 0.423 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.2 p30 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.35 -0.611 . . . . 1.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 2' ' ' PHE . . . . . 0.418 ' O ' ' O ' ' B' ' 6' ' ' LEU . 68.7 t80 -130.13 130.93 45.41 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.251 -0.432 . . . . 1.0 110.686 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.94 139.11 11.0 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.366 -1.094 . . . . 1.0 110.366 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 134.21 27.24 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.987 0.423 . . . . 1.0 111.168 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.39 128.7 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.011 179.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 6' ' ' LEU . . . . . 0.407 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.6 tp -120.3 128.91 53.74 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.178 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.568 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.307 -0.627 . . . . 1.0 109.307 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 2' ' ' PHE . . . . . 0.642 ' CD2' HD22 ' A' ' 6' ' ' LEU . 8.5 m-85 -105.11 123.28 47.55 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.163 -0.472 . . . . 1.0 110.356 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.5 136.38 8.84 Favored Glycine 0 N--CA 1.466 0.644 0 N-CA-C 110.136 -1.186 . . . . 1.0 110.136 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 130.51 20.58 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.812 0.339 . . . . 1.0 111.231 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 5' ' ' ILE . . . . . 0.407 ' O ' ' O ' ' A' ' 3' ' ' GLY . 47.9 mm -126.13 123.5 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.276 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 6' ' ' LEU . . . . . 0.607 HD22 ' CD2' ' A' ' 2' ' ' PHE . 68.2 mt -120.61 132.49 55.16 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.434 -0.348 . . . . 1.0 110.275 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.931 -1.033 . . . . 1.0 110.566 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 1' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 57.2 p30 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.514 -0.55 . . . . 1.0 109.514 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 2' ' ' PHE . . . . . 0.434 ' O ' ' O ' ' H' ' 6' ' ' LEU . 68.5 t80 -130.38 130.73 44.74 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.209 -0.451 . . . . 1.0 110.797 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.01 139.1 10.98 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.47 133.86 26.37 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.019 0.437 . . . . 1.0 111.2 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 46.5 mm -124.73 128.26 73.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.789 -0.642 . . . . 1.0 109.91 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 6' ' ' LEU . . . . . 0.409 ' O ' ' O ' ' H' ' 2' ' ' PHE . 50.9 tp -119.3 128.58 54.27 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.165 -0.471 . . . . 1.0 110.291 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.634 -179.951 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.09 123.84 48.51 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.236 -0.438 . . . . 1.0 110.546 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.54 135.75 8.39 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.187 -1.165 . . . . 1.0 110.187 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.76 131.66 22.89 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.979 0.419 . . . . 1.0 111.099 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.8 mm -126.48 123.61 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.447 179.415 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 67.2 mt -120.97 131.54 54.39 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.155 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.9 p . . . . . 0 C--O 1.221 -0.404 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.556 -179.942 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 1' ' ' ASN . . . . . 0.426 ' OD1' ' O ' ' H' ' 1' ' ' ASN . 56.7 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.441 -0.577 . . . . 1.0 109.441 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 2' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' F' ' 6' ' ' LEU . 69.5 t80 -130.03 130.86 45.48 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.216 -0.447 . . . . 1.0 110.706 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.35 139.3 11.07 Favored Glycine 0 N--CA 1.465 0.603 0 N-CA-C 110.474 -1.05 . . . . 1.0 110.474 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.03 135.19 28.99 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.972 0.415 . . . . 1.0 111.252 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.09 128.03 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.907 -0.588 . . . . 1.0 109.934 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 6' ' ' LEU . . . . . 0.434 ' O ' ' O ' ' F' ' 2' ' ' PHE . 50.5 tp -119.84 131.54 55.31 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.383 -0.371 . . . . 1.0 110.393 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 51.7 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.061 -0.971 . . . . 1.0 110.287 179.846 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.394 -0.595 . . . . 1.0 109.394 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.626 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.63 125.68 51.64 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.525 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.36 134.58 7.57 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.249 -1.14 . . . . 1.0 110.249 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.06 137.84 31.34 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.014 0.435 . . . . 1.0 110.906 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.515 HG23 ' O ' ' A' ' 5' ' ' ILE . 11.1 tp -135.5 125.83 43.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 115.839 -0.618 . . . . 1.0 110.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.635 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.0 mt -124.6 128.15 48.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.849 -0.614 . . . . 1.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.035 -0.984 . . . . 1.0 110.515 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.371 -0.603 . . . . 1.0 109.371 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -132.88 130.05 39.19 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.276 -0.42 . . . . 1.0 110.22 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.08 137.06 9.35 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 110.592 -1.003 . . . . 1.0 110.592 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.75 29.22 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.914 0.387 . . . . 1.0 111.284 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -123.19 125.24 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.835 179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -115.04 133.01 56.41 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.374 -0.376 . . . . 1.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.92 -1.038 . . . . 1.0 110.342 179.077 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.342 -0.614 . . . . 1.0 109.342 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.29 126.05 52.39 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.2 -0.455 . . . . 1.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.3 134.7 7.54 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 110.309 -1.116 . . . . 1.0 110.309 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.87 135.14 27.4 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.869 0.366 . . . . 1.0 110.962 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.52 125.39 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.231 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.76 130.79 53.18 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.435 -0.348 . . . . 1.0 110.364 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 33.9 p . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.986 -1.007 . . . . 1.0 110.578 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.315 -0.624 . . . . 1.0 109.315 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 35.8 t80 -132.95 129.76 38.68 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.278 -0.419 . . . . 1.0 110.367 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.73 136.71 9.2 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.31 133.97 31.92 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.027 0.442 . . . . 1.0 111.179 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.8 mm -124.0 127.06 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.7 -0.682 . . . . 1.0 110.18 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 16.2 mt -117.38 131.52 56.76 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.218 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.036 -0.983 . . . . 1.0 110.574 179.958 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.37 -0.604 . . . . 1.0 109.37 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.635 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.1 m-85 -107.49 125.59 51.46 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.268 -0.424 . . . . 1.0 110.446 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.07 135.87 8.36 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.257 -1.137 . . . . 1.0 110.257 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 135.56 26.77 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.986 0.422 . . . . 1.0 111.071 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -132.24 125.09 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.853 -0.612 . . . . 1.0 110.273 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.626 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.7 mt -124.31 130.74 53.04 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.332 -0.394 . . . . 1.0 110.519 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.566 179.952 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.372 -0.603 . . . . 1.0 109.372 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -133.14 130.09 38.75 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.092 -0.504 . . . . 1.0 110.418 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.2 137.19 9.42 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.427 -1.069 . . . . 1.0 110.427 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.48 131.93 26.9 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.826 0.346 . . . . 1.0 111.246 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.5 mm -122.86 125.75 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.968 -0.56 . . . . 1.0 109.965 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -114.5 129.07 56.63 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.124 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.018 -0.992 . . . . 1.0 110.586 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -107.26 126.03 51.9 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.473 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.65 134.74 7.63 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.252 -1.139 . . . . 1.0 110.252 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 138.94 31.7 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.98 0.419 . . . . 1.0 110.67 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.2 tp -136.09 125.9 40.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.793 -0.64 . . . . 1.0 110.253 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 85.5 mt -125.68 130.56 51.81 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 1.0 110.427 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.984 -1.007 . . . . 1.0 110.373 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.479 -0.563 . . . . 1.0 109.479 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -132.53 130.3 40.2 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.219 -0.446 . . . . 1.0 110.415 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.45 137.73 9.76 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.474 -1.051 . . . . 1.0 110.474 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.37 133.26 29.17 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.887 0.375 . . . . 1.0 111.184 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 95.7 mt -123.35 125.62 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 115.914 -0.584 . . . . 1.0 110.002 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -115.58 132.18 56.71 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.175 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.086 -0.959 . . . . 1.0 110.566 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.431 -0.581 . . . . 1.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' C' ' 6' ' ' LEU . 57.8 m-85 -130.67 149.61 52.25 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.308 -0.405 . . . . 1.0 110.357 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -146.49 148.36 19.98 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.622 -0.991 . . . . 1.0 110.622 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.75 142.05 26.25 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.984 0.421 . . . . 1.0 111.214 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.482 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.9 tp -135.0 127.61 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 115.71 -0.677 . . . . 1.0 109.876 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' C' ' 2' ' ' PHE . 42.4 mt -123.66 132.3 53.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.518 -0.31 . . . . 1.0 110.309 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.4 ' OXT' ' O ' ' E' ' 1' ' ' ASN . 66.3 m . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.768 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . 0.436 ' O ' ' OD1' ' B' ' 1' ' ' ASN . 28.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.415 -0.587 . . . . 1.0 109.415 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -132.76 130.57 40.11 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.35 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.55 140.62 11.97 Favored Glycine 0 N--CA 1.466 0.658 0 N-CA-C 110.452 -1.059 . . . . 1.0 110.452 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 139.08 34.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.94 0.4 . . . . 1.0 111.156 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -131.3 129.15 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.009 -0.541 . . . . 1.0 110.411 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 50.0 tp -120.75 129.65 53.71 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.113 -0.494 . . . . 1.0 110.566 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 47.5 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.953 -1.022 . . . . 1.0 110.585 179.764 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.344 -0.613 . . . . 1.0 109.344 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . 0.622 ' CD2' ' ND2' ' D' ' 1' ' ' ASN . 61.7 m-85 -130.67 149.53 52.28 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.289 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.54 149.27 21.39 Favored Glycine 0 N--CA 1.463 0.466 0 N-CA-C 110.491 -1.044 . . . . 1.0 110.491 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.46 140.05 22.54 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 1.0 111.098 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.28 129.07 56.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.001 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 2' ' ' PHE . 45.6 mt -123.56 132.58 53.93 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.317 -0.401 . . . . 1.0 110.471 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.545 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CD2' ' C' ' 2' ' ' PHE . 29.0 p30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -132.67 130.28 39.92 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.158 -0.474 . . . . 1.0 110.29 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.47 140.04 11.58 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.392 -1.083 . . . . 1.0 110.392 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.63 141.08 37.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.08 0.467 . . . . 1.0 110.996 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . 0.469 HG23 ' O ' ' D' ' 5' ' ' ILE . 11.0 tp -132.27 129.57 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.363 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 49.1 tp -122.31 127.18 49.51 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.439 -0.346 . . . . 1.0 110.183 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 13.5 m . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.981 -1.009 . . . . 1.0 110.632 179.924 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . 0.4 ' O ' ' OXT' ' A' ' 7' ' ' SER . 99.2 m-20 . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.618 ' CD2' ' ND2' ' F' ' 1' ' ' ASN . 57.1 m-85 -130.27 149.25 52.05 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.314 -0.403 . . . . 1.0 110.262 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -146.54 147.75 18.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.65 140.7 25.03 Favored 'General case' 0 C--O 1.231 0.095 0 CA-C-O 121.052 0.454 . . . . 1.0 111.342 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -133.98 128.22 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 115.857 -0.61 . . . . 1.0 109.935 179.377 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.439 ' O ' ' O ' ' G' ' 2' ' ' PHE . 44.7 mt -123.23 132.61 54.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.463 -0.335 . . . . 1.0 110.597 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.054 -0.974 . . . . 1.0 110.587 179.928 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . 0.618 ' ND2' ' CD2' ' E' ' 2' ' ' PHE . 29.1 p30 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.395 -0.594 . . . . 1.0 109.395 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -132.49 130.46 40.5 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.404 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.32 140.28 11.76 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.327 -1.109 . . . . 1.0 110.327 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.63 140.39 35.04 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.918 0.39 . . . . 1.0 110.973 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . 0.499 HG23 ' O ' ' F' ' 5' ' ' ILE . 11.2 tp -132.47 128.31 57.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.821 -0.627 . . . . 1.0 110.475 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 47.8 tp -120.01 126.96 52.11 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.298 -0.41 . . . . 1.0 110.334 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.897 -1.049 . . . . 1.0 110.565 179.893 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.279 -0.638 . . . . 1.0 109.279 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' E' ' 6' ' ' LEU . 59.9 m-85 -130.74 150.03 52.11 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.445 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.6 148.59 20.37 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.524 -1.03 . . . . 1.0 110.524 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.15 142.09 25.84 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.927 0.394 . . . . 1.0 110.857 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . 0.522 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -135.12 126.89 47.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 1.0 109.73 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' E' ' 2' ' ' PHE . 53.6 mt -122.54 132.78 54.47 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.907 0.384 . . . . 1.0 110.462 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.055 -0.974 . . . . 1.0 110.607 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . 0.425 ' O ' ' OD1' ' H' ' 1' ' ' ASN . 29.2 p30 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.348 -0.612 . . . . 1.0 109.348 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -132.28 130.61 41.1 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.275 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.7 140.74 12.05 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.73 138.41 32.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.865 0.364 . . . . 1.0 111.187 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.48 128.22 63.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.401 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 48.8 tp -119.04 127.96 53.91 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.356 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.433 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.295 -0.632 . . . . 1.0 109.295 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.5 m-85 -106.81 123.18 47.77 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.182 -0.463 . . . . 1.0 110.404 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.54 132.84 7.24 Favored Glycine 0 N--CA 1.465 0.571 0 N-CA-C 110.285 -1.126 . . . . 1.0 110.285 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.22 137.84 34.62 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.061 0.458 . . . . 1.0 110.997 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.505 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.8 tp -134.64 126.27 47.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.682 -0.69 . . . . 1.0 110.292 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.641 HD22 ' CD2' ' E' ' 2' ' ' PHE . 82.9 mt -123.95 130.86 53.27 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.991 -0.55 . . . . 1.0 110.503 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.448 179.883 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.246 -0.65 . . . . 1.0 109.246 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 65.6 t80 -128.74 130.36 46.97 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 121.056 0.455 . . . . 1.0 110.796 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.93 137.57 9.86 Favored Glycine 0 N--CA 1.466 0.698 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.83 133.9 29.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.849 0.357 . . . . 1.0 111.257 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 46.6 mm -125.08 129.23 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.917 -0.583 . . . . 1.0 110.355 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' D' ' 2' ' ' PHE . 45.7 tp -120.35 130.94 54.64 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.288 -0.415 . . . . 1.0 110.668 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . 0.424 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 7.9 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.247 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.333 -0.617 . . . . 1.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -107.4 123.13 47.92 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.139 -0.482 . . . . 1.0 110.166 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.75 133.35 7.42 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.251 -1.14 . . . . 1.0 110.251 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.76 135.55 29.84 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 120.989 0.424 . . . . 1.0 111.02 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -131.97 126.43 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.913 -0.585 . . . . 1.0 110.128 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.2 mt -122.6 132.47 54.31 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.432 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.974 -1.013 . . . . 1.0 110.493 -179.988 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.304 -0.628 . . . . 1.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' B' ' 6' ' ' LEU . 67.7 t80 -128.71 130.39 47.07 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.741 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.11 137.4 9.72 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.304 -1.119 . . . . 1.0 110.304 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.6 135.33 31.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.994 0.426 . . . . 1.0 111.074 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -127.31 129.6 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.428 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 46.0 tp -120.05 128.81 53.85 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.328 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.968 -1.015 . . . . 1.0 110.549 179.965 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.3 -0.63 . . . . 1.0 109.3 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.641 ' CD2' HD22 ' A' ' 6' ' ' LEU . 6.5 m-85 -106.54 123.33 47.93 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.329 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.92 133.26 7.36 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 110.28 -1.128 . . . . 1.0 110.28 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.49 133.81 29.77 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.883 0.373 . . . . 1.0 111.252 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -128.09 124.75 63.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.777 -0.647 . . . . 1.0 110.222 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 84.8 mt -123.64 131.6 53.65 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.867 0.365 . . . . 1.0 110.355 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.988 -1.005 . . . . 1.0 110.599 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' H' ' 6' ' ' LEU . 66.2 t80 -128.35 130.45 47.78 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.734 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.48 9.75 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.254 -1.138 . . . . 1.0 110.254 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -141.21 134.68 29.84 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.976 0.417 . . . . 1.0 111.102 -179.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -128.01 129.07 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.896 -0.593 . . . . 1.0 110.541 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' H' ' 2' ' ' PHE . 46.5 tp -118.85 128.28 54.3 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.72 -0.673 . . . . 1.0 110.266 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.049 -0.977 . . . . 1.0 110.545 179.987 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.448 -0.575 . . . . 1.0 109.448 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -106.37 124.19 49.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.167 -0.47 . . . . 1.0 110.342 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.62 132.6 6.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.93 138.67 35.78 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.025 0.44 . . . . 1.0 110.747 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . 0.541 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -134.88 125.28 45.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.846 -0.615 . . . . 1.0 110.079 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 83.6 mt -124.14 133.39 53.59 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.133 -0.485 . . . . 1.0 110.336 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.485 179.924 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.265 -0.642 . . . . 1.0 109.265 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . 0.426 ' O ' ' O ' ' F' ' 6' ' ' LEU . 67.2 t80 -128.45 130.47 47.62 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.201 -0.454 . . . . 1.0 110.681 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.92 10.03 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -141.33 134.52 29.39 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.892 0.377 . . . . 1.0 111.096 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.77 128.45 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.988 -0.551 . . . . 1.0 110.392 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' F' ' 2' ' ' PHE . 45.9 tp -118.35 127.3 53.56 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.103 -0.499 . . . . 1.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.076 -0.964 . . . . 1.0 110.372 179.893 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.443 -0.577 . . . . 1.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.637 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.78 124.37 49.95 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.105 -0.498 . . . . 1.0 110.307 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.13 133.65 7.49 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.272 -1.131 . . . . 1.0 110.272 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 136.74 32.13 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.031 0.443 . . . . 1.0 110.922 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.527 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.5 tp -133.67 126.07 50.73 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 115.753 -0.658 . . . . 1.0 110.258 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.661 HD22 ' CD2' ' E' ' 2' ' ' PHE . 84.8 mt -124.07 129.93 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.566 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.7 p . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.924 -1.036 . . . . 1.0 110.491 179.875 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.332 -0.618 . . . . 1.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . 0.404 ' O ' ' O ' ' D' ' 6' ' ' LEU . 71.5 t80 -129.03 130.32 46.45 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.691 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.52 137.58 9.93 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 110.404 -1.078 . . . . 1.0 110.404 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.54 134.02 29.99 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.965 0.412 . . . . 1.0 111.239 -179.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -124.46 128.22 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 CA-C-N 115.81 -0.632 . . . . 1.0 109.962 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . 0.401 ' O ' ' O ' ' D' ' 2' ' ' PHE . 47.2 tp -118.66 131.18 56.16 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.965 0.412 . . . . 1.0 110.655 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . 0.484 ' OG ' ' CE2' ' E' ' 2' ' ' PHE . 1.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.02 -0.99 . . . . 1.0 110.309 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.38 -0.6 . . . . 1.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.21 124.35 50.14 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.18 -0.463 . . . . 1.0 110.165 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.47 133.96 7.59 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.369 -1.092 . . . . 1.0 110.369 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.65 134.48 26.93 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.984 0.421 . . . . 1.0 110.925 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.01 126.37 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 115.973 -0.558 . . . . 1.0 110.081 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.9 mt -122.99 132.04 53.97 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.319 -0.4 . . . . 1.0 110.374 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.587 179.983 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.275 -0.639 . . . . 1.0 109.275 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' B' ' 6' ' ' LEU . 73.0 t80 -129.05 130.35 46.45 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.712 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.36 9.8 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.253 -1.139 . . . . 1.0 110.253 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.32 133.87 30.13 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.941 0.4 . . . . 1.0 111.251 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.7 mm -124.22 128.79 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.744 -0.662 . . . . 1.0 110.241 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . 0.404 ' O ' ' O ' ' B' ' 2' ' ' PHE . 48.4 tp -119.14 127.72 53.6 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.397 . . . . 1.0 110.235 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.978 -1.01 . . . . 1.0 110.535 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.399 -0.593 . . . . 1.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.661 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -107.85 124.34 49.94 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.254 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . 0.453 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -130.28 134.42 7.82 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.71 133.15 26.72 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.895 0.378 . . . . 1.0 111.251 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.2 mm -127.93 125.08 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.787 -0.642 . . . . 1.0 110.235 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.637 HD22 ' CD2' ' A' ' 2' ' ' PHE . 86.6 mt -123.78 130.46 52.66 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.882 0.373 . . . . 1.0 110.478 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.577 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' H' ' 6' ' ' LEU . 71.8 t80 -128.79 130.19 46.67 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.91 0.386 . . . . 1.0 110.764 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.67 10.0 Favored Glycine 0 N--CA 1.467 0.727 0 N-CA-C 110.245 -1.142 . . . . 1.0 110.245 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.0 133.41 28.35 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.956 0.408 . . . . 1.0 111.236 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.42 128.59 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.128 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . 0.422 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.2 tp -118.75 128.12 54.18 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.172 -0.467 . . . . 1.0 110.256 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.908 -1.044 . . . . 1.0 110.468 179.899 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.3 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.57 124.93 50.66 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.211 -0.45 . . . . 1.0 110.284 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.82 133.48 7.32 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.217 -1.153 . . . . 1.0 110.217 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.9 137.75 33.39 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.956 0.408 . . . . 1.0 110.745 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 9.7 tp -134.09 125.77 48.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.894 -0.594 . . . . 1.0 110.178 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.9 mt -124.24 131.01 53.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.336 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.1 p . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.501 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.255 -0.646 . . . . 1.0 109.255 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . 0.422 ' O ' ' O ' ' F' ' 6' ' ' LEU . 72.9 t80 -128.49 130.26 47.25 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.285 -0.416 . . . . 1.0 110.74 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.54 138.03 10.22 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.276 -1.129 . . . . 1.0 110.276 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.56 134.38 30.48 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.992 0.425 . . . . 1.0 111.107 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.74 127.81 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.967 -0.56 . . . . 1.0 110.146 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' F' ' 2' ' ' PHE . 48.8 tp -118.67 128.94 55.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.418 -0.356 . . . . 1.0 110.293 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.999 -1.001 . . . . 1.0 110.419 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.48 -0.563 . . . . 1.0 109.48 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.61 ' CD2' HD22 ' E' ' 6' ' ' LEU . 9.9 m-85 -106.13 122.61 46.54 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.221 -0.445 . . . . 1.0 110.46 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.16 134.36 7.58 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.202 -1.159 . . . . 1.0 110.202 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 139.13 32.91 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.1 0.476 . . . . 1.0 111.186 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 5' ' ' ILE . 11.1 tp -134.04 124.96 47.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 115.599 -0.728 . . . . 1.0 110.124 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.62 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.6 mt -126.52 131.89 51.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.079 -0.51 . . . . 1.0 110.54 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.071 -0.966 . . . . 1.0 110.485 179.903 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.489 1.482 0 N-CA-C 109.396 -0.594 . . . . 1.0 109.396 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 36.2 t80 -131.98 130.74 41.85 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.291 -0.413 . . . . 1.0 110.413 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.89 138.0 10.31 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.52 132.18 27.24 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.843 0.354 . . . . 1.0 111.283 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.35 125.57 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.016 -0.538 . . . . 1.0 110.077 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -114.57 129.49 56.67 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.506 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . 0.403 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 21.0 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.322 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 1.0 109.337 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -106.39 122.75 46.89 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.224 -0.443 . . . . 1.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.86 134.8 7.74 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.144 -1.183 . . . . 1.0 110.144 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.68 136.94 29.52 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.921 0.391 . . . . 1.0 111.177 -179.597 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.72 124.34 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.09 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 86.5 mt -125.37 132.13 52.85 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.456 -0.338 . . . . 1.0 110.472 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 90.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 1.0 110.559 179.88 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 109.214 -0.661 . . . . 1.0 109.214 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -132.09 130.54 41.37 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.457 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.53 10.07 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.3 -1.12 . . . . 1.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.28 134.71 31.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.01 0.433 . . . . 1.0 111.036 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -126.99 127.38 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.382 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 15.9 mt -116.11 131.57 56.9 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.351 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 118.006 -0.997 . . . . 1.0 110.517 179.864 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.442 -0.577 . . . . 1.0 109.442 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.62 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.0 m-85 -106.19 122.65 46.65 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.336 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . 0.417 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.31 134.89 7.83 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.208 -1.157 . . . . 1.0 110.208 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 137.01 30.37 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.951 0.405 . . . . 1.0 111.426 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.18 124.32 55.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.836 -0.62 . . . . 1.0 110.12 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.61 HD22 ' CD2' ' A' ' 2' ' ' PHE . 87.2 mt -125.87 131.37 52.39 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.186 -0.461 . . . . 1.0 110.442 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 83.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.063 -0.97 . . . . 1.0 110.579 179.821 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' H' ' 6' ' ' LEU . 36.3 t80 -132.05 130.95 41.97 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.347 -0.388 . . . . 1.0 110.519 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.08 138.39 10.51 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 131.67 25.37 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.921 0.391 . . . . 1.0 111.309 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.8 mm -122.88 126.33 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.017 -0.538 . . . . 1.0 110.127 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . 0.412 ' O ' ' O ' ' H' ' 2' ' ' PHE . 15.5 mt -114.99 127.59 55.76 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.137 -0.483 . . . . 1.0 109.974 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.614 179.863 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -106.38 123.25 47.77 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.304 -0.407 . . . . 1.0 110.36 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.92 134.36 7.5 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.113 -1.195 . . . . 1.0 110.113 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.8 140.04 32.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.048 0.452 . . . . 1.0 110.926 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . 0.528 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -134.52 124.85 45.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.698 -0.683 . . . . 1.0 110.007 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -126.87 133.34 50.73 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.456 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.98 -1.009 . . . . 1.0 110.403 -179.992 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . 0.412 ' O ' ' O ' ' F' ' 6' ' ' LEU . 38.3 t80 -132.01 131.13 42.23 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.375 -0.375 . . . . 1.0 110.48 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.27 138.79 10.74 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.391 -1.084 . . . . 1.0 110.391 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.79 132.48 27.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.91 0.386 . . . . 1.0 111.267 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.7 mm -122.89 126.39 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.083 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . 0.414 ' O ' ' O ' ' F' ' 2' ' ' PHE . 15.9 mt -116.4 129.24 56.13 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.387 -0.369 . . . . 1.0 110.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 35.1 p . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.024 -0.988 . . . . 1.0 110.38 179.827 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.628 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -106.01 122.12 45.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.435 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.62 134.22 7.46 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 110.337 -1.105 . . . . 1.0 110.337 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 138.06 30.31 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.114 0.483 . . . . 1.0 110.967 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.544 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.7 tp -135.09 125.23 44.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 115.721 -0.672 . . . . 1.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.646 HD22 ' CD2' ' E' ' 2' ' ' PHE . 87.5 mt -125.1 129.62 50.57 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.996 -0.547 . . . . 1.0 110.513 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.2 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.469 179.874 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CZ ' ' A' ' 2' ' ' PHE . 59.4 t-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . 0.517 ' N ' ' OD1' ' B' ' 1' ' ' ASN . 72.6 t80 -129.46 129.85 45.15 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.675 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.79 136.01 8.81 Favored Glycine 0 N--CA 1.467 0.72 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.2 134.16 27.27 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.033 0.444 . . . . 1.0 111.497 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -124.85 128.43 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.721 -0.672 . . . . 1.0 109.995 179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . 0.424 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 45.7 tp -121.17 132.99 55.17 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.833 0.349 . . . . 1.0 110.903 -179.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . 0.506 ' OG ' ' CZ ' ' E' ' 2' ' ' PHE . 17.5 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.01 . . . . 1.0 110.562 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.286 -0.635 . . . . 1.0 109.286 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -106.62 122.42 46.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.235 -0.439 . . . . 1.0 110.241 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.41 134.87 7.72 Favored Glycine 0 N--CA 1.465 0.605 0 N-CA-C 110.384 -1.086 . . . . 1.0 110.384 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.84 135.45 26.11 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.95 0.405 . . . . 1.0 111.098 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -131.25 124.81 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.157 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 88.0 mt -124.26 132.0 53.56 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.43 -0.35 . . . . 1.0 110.284 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 32.5 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.019 -0.991 . . . . 1.0 110.55 179.847 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' D' ' 2' ' ' PHE . 60.0 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.335 -0.617 . . . . 1.0 109.335 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . 0.513 ' N ' ' OD1' ' D' ' 1' ' ' ASN . 74.7 t80 -129.08 129.77 45.67 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.777 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.6 135.8 8.74 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.198 -1.161 . . . . 1.0 110.198 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 133.81 26.64 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.0 0.429 . . . . 1.0 111.335 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.53 128.41 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.757 -0.656 . . . . 1.0 110.022 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' B' ' 2' ' ' PHE . 45.6 tp -120.02 128.8 53.87 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.369 -0.378 . . . . 1.0 110.298 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . 0.425 ' OG ' ' ND2' ' B' ' 1' ' ' ASN . 3.7 m . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.002 -0.999 . . . . 1.0 110.575 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.31 -0.626 . . . . 1.0 109.31 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.646 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -106.14 122.15 45.61 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.232 -0.44 . . . . 1.0 110.275 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . 0.428 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.97 134.81 7.73 Favored Glycine 0 N--CA 1.465 0.6 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.462 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.28 136.07 27.62 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.969 0.414 . . . . 1.0 111.172 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.18 124.41 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.201 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.628 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.2 mt -124.49 130.89 53.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.207 -0.451 . . . . 1.0 110.428 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.551 179.908 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' F' ' 2' ' ' PHE . 59.6 t-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.367 -0.605 . . . . 1.0 109.367 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . 0.524 ' N ' ' OD1' ' F' ' 1' ' ' ASN . 73.0 t80 -130.22 129.52 43.47 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.041 -0.527 . . . . 1.0 110.593 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.63 136.03 8.86 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.151 -1.179 . . . . 1.0 110.151 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.57 133.38 25.51 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 121.059 0.457 . . . . 1.0 111.417 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -124.94 128.33 73.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-N 115.699 -0.682 . . . . 1.0 110.063 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' H' ' 2' ' ' PHE . 45.8 tp -119.56 127.92 53.44 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.015 -0.538 . . . . 1.0 110.28 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . 0.478 ' OG ' ' ND2' ' H' ' 1' ' ' ASN . 7.0 m . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.005 -0.998 . . . . 1.0 110.485 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.289 -0.634 . . . . 1.0 109.289 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' H' ' 1' ' ' ASN . 7.1 m-85 -105.89 122.98 47.23 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.289 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.55 134.02 7.26 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 110.291 -1.124 . . . . 1.0 110.291 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.49 139.14 31.41 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.041 0.448 . . . . 1.0 110.759 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . 0.513 ' O ' HG23 ' G' ' 5' ' ' ILE . 10.8 tp -135.76 124.91 39.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 1.0 110.22 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.26 130.74 52.66 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.37 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 37.7 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.536 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' G' ' 2' ' ' PHE . 59.5 t-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.404 -0.591 . . . . 1.0 109.404 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . 0.519 ' N ' ' OD1' ' H' ' 1' ' ' ASN . 74.3 t80 -129.49 129.82 45.06 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.199 -0.455 . . . . 1.0 110.694 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 136.34 8.97 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.385 -1.086 . . . . 1.0 110.385 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.29 134.61 27.76 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.038 0.447 . . . . 1.0 111.288 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -125.59 127.65 71.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.931 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' F' ' 2' ' ' PHE . 47.0 tp -119.59 129.96 54.89 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.341 -0.39 . . . . 1.0 110.409 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 59.5 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.997 -1.001 . . . . 1.0 110.501 179.878 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 10.1 m-85 -105.12 123.59 48.09 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.153 -0.476 . . . . 1.0 110.28 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -128.78 137.57 9.72 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.589 -1.004 . . . . 1.0 110.589 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -144.44 141.12 29.39 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-O 120.94 0.4 . . . . 1.0 111.046 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.501 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.9 tp -141.35 125.79 17.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.71 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.636 HD22 ' CD2' ' E' ' 2' ' ' PHE . 60.2 mt -120.74 132.67 55.18 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.968 -0.56 . . . . 1.0 110.32 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.534 179.869 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.268 -0.641 . . . . 1.0 109.268 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' D' ' 6' ' ' LEU . 56.2 t80 -128.22 130.53 48.11 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.248 -0.433 . . . . 1.0 110.725 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.86 137.48 9.65 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.332 -1.107 . . . . 1.0 110.332 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.38 135.62 32.29 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.913 0.387 . . . . 1.0 111.23 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -127.03 130.05 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.888 -0.596 . . . . 1.0 110.278 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 47.0 tp -120.42 130.78 54.49 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.016 0.436 . . . . 1.0 110.604 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 117.793 -1.099 . . . . 1.0 110.208 179.607 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.353 -0.61 . . . . 1.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -105.49 123.45 47.92 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.224 -0.444 . . . . 1.0 110.212 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . 0.401 ' HA2' HD12 ' A' ' 5' ' ' ILE . . . -129.03 138.2 10.1 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.699 -0.96 . . . . 1.0 110.699 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.16 140.36 26.59 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.959 0.409 . . . . 1.0 110.75 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . 0.472 HG23 ' O ' ' C' ' 5' ' ' ILE . 19.8 tt -140.39 126.62 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 116.059 -0.518 . . . . 1.0 110.061 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 69.4 mt -120.04 133.76 55.44 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.245 -0.434 . . . . 1.0 110.27 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 34.4 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.511 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.272 -0.64 . . . . 1.0 109.272 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -128.38 130.44 47.69 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.225 -0.443 . . . . 1.0 110.632 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.9 137.3 9.53 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.278 -1.129 . . . . 1.0 110.278 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.72 136.33 32.48 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.06 0.457 . . . . 1.0 110.947 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.75 130.58 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.907 -0.588 . . . . 1.0 110.519 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . 0.402 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.3 tp -120.51 129.52 53.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.232 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 95.5 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.496 -179.998 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.636 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.4 m-85 -105.25 123.77 48.41 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.195 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . 0.489 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -129.33 138.0 9.95 Favored Glycine 0 N--CA 1.468 0.776 0 N-CA-C 110.695 -0.962 . . . . 1.0 110.695 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.03 140.2 27.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.793 0.33 . . . . 1.0 111.079 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . 0.493 HG23 ' O ' ' E' ' 5' ' ' ILE . 20.2 tt -140.44 125.42 19.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.465 179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 62.2 mt -119.66 132.54 55.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.282 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.543 179.943 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -128.21 130.58 48.22 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.264 -0.426 . . . . 1.0 110.666 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 137.23 9.48 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.204 -1.159 . . . . 1.0 110.204 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -140.88 136.1 31.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.059 0.457 . . . . 1.0 111.032 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -129.44 130.24 67.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 115.915 -0.584 . . . . 1.0 110.523 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.9 tp -119.84 129.02 54.21 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.575 -0.739 . . . . 1.0 110.207 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.945 -1.026 . . . . 1.0 110.556 179.864 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -105.16 124.32 49.33 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.218 -0.446 . . . . 1.0 110.3 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.62 137.72 9.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.651 -0.98 . . . . 1.0 110.651 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.38 141.13 28.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.904 0.383 . . . . 1.0 110.629 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . 0.502 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -141.59 126.34 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.989 -0.551 . . . . 1.0 110.312 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 65.2 mt -120.33 131.78 55.01 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.225 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 2.2 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.474 -179.917 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.376 -0.602 . . . . 1.0 109.376 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' F' ' 6' ' ' LEU . 58.1 t80 -127.79 130.47 48.75 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.941 0.401 . . . . 1.0 110.713 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.19 137.58 9.68 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.361 -1.096 . . . . 1.0 110.361 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -140.67 135.79 31.99 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.855 0.36 . . . . 1.0 111.166 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -127.17 129.88 71.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 116.013 -0.54 . . . . 1.0 110.367 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 49.2 tp -120.42 128.34 53.1 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.195 -0.457 . . . . 1.0 110.216 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 52.1 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.942 -1.028 . . . . 1.0 110.439 179.754 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -124.28 135.39 53.35 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.354 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -133.51 134.16 7.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.08 132.17 20.38 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.149 0.5 . . . . 1.0 110.946 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.608 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.1 tp -137.99 122.43 22.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.472 -0.786 . . . . 1.0 110.217 -179.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 mt -119.51 135.4 54.79 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.932 0.396 . . . . 1.0 110.888 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.3 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.116 -0.945 . . . . 1.0 110.384 179.646 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . 0.43 ' O ' ' OD1' ' B' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -131.57 132.35 44.04 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.18 -0.464 . . . . 1.0 110.665 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.12 136.76 9.01 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.431 -1.068 . . . . 1.0 110.431 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.61 133.37 30.61 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.801 0.334 . . . . 1.0 110.883 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -125.47 128.16 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.543 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -119.11 127.52 53.44 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.007 -0.542 . . . . 1.0 110.051 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.878 -1.058 . . . . 1.0 110.632 179.719 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.418 -0.586 . . . . 1.0 109.418 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . 0.402 ' N ' ' CD1' ' C' ' 2' ' ' PHE . 33.1 m-85 -123.99 135.42 53.62 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.222 -0.444 . . . . 1.0 110.21 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.42 134.77 7.57 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.496 -1.041 . . . . 1.0 110.496 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.13 128.67 15.04 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-O 121.023 0.439 . . . . 1.0 111.048 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.74 124.19 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.818 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 61.7 mt -118.35 132.48 56.27 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.809 0.337 . . . . 1.0 110.451 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 5.9 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.048 -0.977 . . . . 1.0 110.503 179.975 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . 0.431 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.4 -0.593 . . . . 1.0 109.4 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -132.07 131.83 42.77 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.695 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.74 136.21 8.72 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.402 -1.079 . . . . 1.0 110.402 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.14 133.11 31.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.916 0.389 . . . . 1.0 110.843 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.3 mm -124.66 128.28 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.377 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 50.7 tp -118.64 126.5 52.07 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.046 -0.524 . . . . 1.0 109.99 179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.025 -0.988 . . . . 1.0 110.578 179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -123.7 134.88 53.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.251 -0.431 . . . . 1.0 110.164 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -133.19 135.1 7.87 Favored Glycine 0 N--CA 1.466 0.666 0 N-CA-C 110.442 -1.063 . . . . 1.0 110.442 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.11 128.31 13.78 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.969 0.414 . . . . 1.0 111.465 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.1 mt -134.25 124.17 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.838 -0.619 . . . . 1.0 110.205 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 54.2 mt -118.38 133.25 56.04 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.306 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.932 -1.032 . . . . 1.0 110.468 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.389 -0.597 . . . . 1.0 109.389 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -131.52 132.17 43.99 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.188 -0.46 . . . . 1.0 110.747 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.02 136.55 8.89 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.421 -1.071 . . . . 1.0 110.421 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.07 132.32 28.21 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.826 0.346 . . . . 1.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 45.9 mm -125.07 127.75 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.408 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 tp -117.41 126.36 52.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.731 -0.668 . . . . 1.0 110.13 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.946 -1.026 . . . . 1.0 110.566 179.984 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.484 -0.561 . . . . 1.0 109.484 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 37.3 m-85 -124.15 136.08 53.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.229 -0.441 . . . . 1.0 110.259 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.66 135.11 7.74 Favored Glycine 0 N--CA 1.466 0.652 0 N-CA-C 110.355 -1.098 . . . . 1.0 110.355 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.49 127.77 12.13 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.025 0.44 . . . . 1.0 111.271 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.99 125.29 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.73 -0.668 . . . . 1.0 110.115 179.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 57.8 mt -117.82 132.77 56.4 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 1.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.496 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . 0.437 ' O ' ' OD1' ' H' ' 1' ' ' ASN . 55.6 p30 . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.447 -0.575 . . . . 1.0 109.447 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -131.25 132.09 44.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.283 -0.417 . . . . 1.0 110.694 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.4 136.42 8.79 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.506 -1.037 . . . . 1.0 110.506 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.32 134.09 32.08 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.806 0.336 . . . . 1.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.55 127.82 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.149 -0.478 . . . . 1.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -118.05 127.56 53.92 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.056 -0.52 . . . . 1.0 110.109 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.008 -0.996 . . . . 1.0 110.595 179.942 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' A' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.457 -0.572 . . . . 1.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.586 ' CD2' HD22 ' E' ' 6' ' ' LEU . 11.9 m-85 -105.49 124.67 49.93 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.141 -0.481 . . . . 1.0 110.403 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -127.51 135.26 8.65 Favored Glycine 0 N--CA 1.466 0.641 0 N-CA-C 110.503 -1.039 . . . . 1.0 110.503 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.74 136.9 33.0 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.022 0.439 . . . . 1.0 110.734 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.564 HG23 ' O ' ' A' ' 5' ' ' ILE . 19.8 tt -137.49 122.69 24.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.604 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.615 HD22 ' CD2' ' E' ' 2' ' ' PHE . 48.4 mt -119.21 133.81 55.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.496 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.481 179.991 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -131.4 130.8 43.04 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.21 -0.45 . . . . 1.0 110.442 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.88 137.57 10.04 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.387 -1.085 . . . . 1.0 110.387 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.28 132.62 30.03 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.864 0.364 . . . . 1.0 111.092 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.57 125.86 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 1.0 110.199 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.7 mt -114.37 131.87 56.41 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.258 -0.428 . . . . 1.0 110.48 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 71.2 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.362 179.707 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . 0.435 ' O ' ' OD1' ' C' ' 1' ' ' ASN . 49.8 p-10 . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -105.42 124.37 49.44 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.11 -0.495 . . . . 1.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.67 135.26 8.62 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.573 -1.011 . . . . 1.0 110.573 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 132.74 25.53 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.813 0.34 . . . . 1.0 110.86 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.35 123.34 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.121 -0.49 . . . . 1.0 109.971 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 58.9 mt -117.92 132.23 56.43 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.861 0.363 . . . . 1.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 14.6 t . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.001 -1.0 . . . . 1.0 110.439 -179.78 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.352 -0.61 . . . . 1.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -131.59 130.68 42.52 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.428 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.37 9.96 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.365 -1.094 . . . . 1.0 110.365 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.17 134.55 32.94 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.919 0.39 . . . . 1.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.85 127.16 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.013 -0.539 . . . . 1.0 110.47 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 15.9 mt -115.27 131.43 56.93 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.084 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.955 -1.021 . . . . 1.0 110.546 179.896 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' E' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.482 -0.562 . . . . 1.0 109.482 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.615 ' CD2' HD22 ' A' ' 6' ' ' LEU . 12.7 m-85 -105.84 124.76 50.09 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.126 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -127.52 137.01 9.57 Favored Glycine 0 N--CA 1.467 0.73 0 N-CA-C 110.46 -1.056 . . . . 1.0 110.46 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 132.81 24.49 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.894 0.378 . . . . 1.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -131.86 121.53 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.971 -0.559 . . . . 1.0 110.386 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.586 HD22 ' CD2' ' A' ' 2' ' ' PHE . 50.8 mt -117.84 133.31 56.06 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.107 -0.497 . . . . 1.0 110.242 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . 0.41 ' O ' ' OG ' ' E' ' 7' ' ' SER . 10.3 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.099 -0.953 . . . . 1.0 110.491 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.364 -0.606 . . . . 1.0 109.364 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -131.52 130.91 42.95 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.171 -0.468 . . . . 1.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.07 137.54 9.98 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.79 133.86 30.99 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.854 0.359 . . . . 1.0 110.882 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.5 126.43 67.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 CA-C-N 116.136 -0.484 . . . . 1.0 110.512 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -113.32 129.8 56.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.46 -0.791 . . . . 1.0 110.07 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.59 179.913 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' G' ' 1' ' ' ASN . 49.5 p-10 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.46 -0.57 . . . . 1.0 109.46 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -105.83 125.34 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.156 -0.474 . . . . 1.0 110.429 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.46 136.51 9.14 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.416 -1.073 . . . . 1.0 110.416 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 131.76 24.14 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.923 0.392 . . . . 1.0 111.016 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.4 mm -128.57 121.77 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.79 -0.641 . . . . 1.0 110.495 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 55.7 mt -119.0 132.15 56.05 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.072 -0.344 . . . . 1.0 110.072 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.474 -179.879 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.411 -0.589 . . . . 1.0 109.411 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -130.85 131.03 44.34 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.935 0.398 . . . . 1.0 110.395 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 138.24 10.41 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.494 -1.042 . . . . 1.0 110.494 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.82 29.33 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.883 0.373 . . . . 1.0 111.046 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.5 mm -123.41 126.72 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 115.998 -0.546 . . . . 1.0 110.138 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 16.1 mt -115.98 133.94 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.192 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.077 -0.963 . . . . 1.0 110.337 179.851 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.313 -0.625 . . . . 1.0 109.313 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PHE . . . . . 0.607 ' CD2' HD22 ' E' ' 6' ' ' LEU . 8.2 m-85 -104.89 122.97 46.9 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.243 -0.435 . . . . 1.0 110.437 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -130.28 133.64 7.47 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.82 136.0 31.98 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-O 121.026 0.441 . . . . 1.0 110.925 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . 0.545 HG23 ' O ' ' A' ' 5' ' ' ILE . 19.9 tt -134.63 124.74 45.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.681 -0.69 . . . . 1.0 110.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LEU . . . . . 0.642 HD22 ' CD2' ' E' ' 2' ' ' PHE . 62.1 mt -121.62 133.44 54.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.825 -0.625 . . . . 1.0 110.53 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.531 179.891 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 1' ' ' ASN . . . . . 0.419 ' O ' ' OD1' ' B' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 2' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' D' ' 6' ' ' LEU . 67.4 t80 -130.26 131.06 45.32 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.2 -0.454 . . . . 1.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 139.45 11.2 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.445 -1.062 . . . . 1.0 110.445 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.43 134.44 27.26 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.027 0.441 . . . . 1.0 111.365 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.39 128.72 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.899 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' LEU . . . . . 0.418 ' O ' ' O ' ' D' ' 2' ' ' PHE . 50.3 tp -120.99 134.12 55.29 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.903 0.382 . . . . 1.0 111.082 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' SER . . . . . 0.422 ' O ' ' OG ' ' B' ' 7' ' ' SER . 11.6 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.795 -1.097 . . . . 1.0 110.057 179.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.366 -0.605 . . . . 1.0 109.366 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -105.07 123.14 47.3 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.203 -0.453 . . . . 1.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.91 133.6 7.36 Favored Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.325 -1.11 . . . . 1.0 110.325 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.01 132.71 25.56 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.885 0.374 . . . . 1.0 110.884 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.67 124.95 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 116.081 -0.509 . . . . 1.0 109.994 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 68.9 mt -120.06 132.85 55.59 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.217 -0.447 . . . . 1.0 110.34 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 21.3 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.545 179.947 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 1' ' ' ASN . . . . . 0.423 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.2 p30 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.35 -0.611 . . . . 1.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 2' ' ' PHE . . . . . 0.418 ' O ' ' O ' ' B' ' 6' ' ' LEU . 68.7 t80 -130.13 130.93 45.41 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.251 -0.432 . . . . 1.0 110.686 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.94 139.11 11.0 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.366 -1.094 . . . . 1.0 110.366 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 134.21 27.24 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.987 0.423 . . . . 1.0 111.168 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.39 128.7 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.011 179.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 6' ' ' LEU . . . . . 0.407 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.6 tp -120.3 128.91 53.74 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.178 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.568 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.307 -0.627 . . . . 1.0 109.307 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 2' ' ' PHE . . . . . 0.642 ' CD2' HD22 ' A' ' 6' ' ' LEU . 8.5 m-85 -105.11 123.28 47.55 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.163 -0.472 . . . . 1.0 110.356 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.5 136.38 8.84 Favored Glycine 0 N--CA 1.466 0.644 0 N-CA-C 110.136 -1.186 . . . . 1.0 110.136 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 130.51 20.58 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.812 0.339 . . . . 1.0 111.231 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 5' ' ' ILE . . . . . 0.407 ' O ' ' O ' ' A' ' 3' ' ' GLY . 47.9 mm -126.13 123.5 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.276 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 6' ' ' LEU . . . . . 0.607 HD22 ' CD2' ' A' ' 2' ' ' PHE . 68.2 mt -120.61 132.49 55.16 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.434 -0.348 . . . . 1.0 110.275 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.931 -1.033 . . . . 1.0 110.566 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 1' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 57.2 p30 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.514 -0.55 . . . . 1.0 109.514 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 2' ' ' PHE . . . . . 0.434 ' O ' ' O ' ' H' ' 6' ' ' LEU . 68.5 t80 -130.38 130.73 44.74 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.209 -0.451 . . . . 1.0 110.797 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.01 139.1 10.98 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.47 133.86 26.37 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.019 0.437 . . . . 1.0 111.2 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 46.5 mm -124.73 128.26 73.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.789 -0.642 . . . . 1.0 109.91 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 6' ' ' LEU . . . . . 0.409 ' O ' ' O ' ' H' ' 2' ' ' PHE . 50.9 tp -119.3 128.58 54.27 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.165 -0.471 . . . . 1.0 110.291 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.634 -179.951 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.09 123.84 48.51 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.236 -0.438 . . . . 1.0 110.546 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.54 135.75 8.39 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.187 -1.165 . . . . 1.0 110.187 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.76 131.66 22.89 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.979 0.419 . . . . 1.0 111.099 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.8 mm -126.48 123.61 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.447 179.415 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 67.2 mt -120.97 131.54 54.39 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.155 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.9 p . . . . . 0 C--O 1.221 -0.404 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.556 -179.942 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 1' ' ' ASN . . . . . 0.426 ' O ' ' OD1' ' H' ' 1' ' ' ASN . 56.7 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.441 -0.577 . . . . 1.0 109.441 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 2' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' F' ' 6' ' ' LEU . 69.5 t80 -130.03 130.86 45.48 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.216 -0.447 . . . . 1.0 110.706 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.35 139.3 11.07 Favored Glycine 0 N--CA 1.465 0.603 0 N-CA-C 110.474 -1.05 . . . . 1.0 110.474 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.03 135.19 28.99 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.972 0.415 . . . . 1.0 111.252 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.09 128.03 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.907 -0.588 . . . . 1.0 109.934 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 6' ' ' LEU . . . . . 0.434 ' O ' ' O ' ' F' ' 2' ' ' PHE . 50.5 tp -119.84 131.54 55.31 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.383 -0.371 . . . . 1.0 110.393 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 51.7 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.061 -0.971 . . . . 1.0 110.287 179.846 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.394 -0.595 . . . . 1.0 109.394 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.626 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.63 125.68 51.64 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.525 179.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.36 134.58 7.57 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.249 -1.14 . . . . 1.0 110.249 179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.06 137.84 31.34 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.014 0.435 . . . . 1.0 110.906 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.515 HG23 ' O ' ' A' ' 5' ' ' ILE . 11.1 tp -135.5 125.83 43.29 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 115.839 -0.618 . . . . 1.0 110.483 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.635 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.0 mt -124.6 128.15 48.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.849 -0.614 . . . . 1.0 110.433 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 4.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.035 -0.984 . . . . 1.0 110.515 179.961 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.371 -0.603 . . . . 1.0 109.371 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 33.3 t80 -132.88 130.05 39.19 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.276 -0.42 . . . . 1.0 110.22 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.08 137.06 9.35 Favored Glycine 0 N--CA 1.467 0.736 0 N-CA-C 110.592 -1.003 . . . . 1.0 110.592 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.75 29.22 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.914 0.387 . . . . 1.0 111.284 -179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -123.19 125.24 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.963 -0.562 . . . . 1.0 109.835 179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -115.04 133.01 56.41 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.374 -0.376 . . . . 1.0 110.945 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.92 -1.038 . . . . 1.0 110.342 179.077 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.342 -0.614 . . . . 1.0 109.342 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.29 126.05 52.39 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.2 -0.455 . . . . 1.0 110.353 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.3 134.7 7.54 Favored Glycine 0 N--CA 1.464 0.561 0 N-CA-C 110.309 -1.116 . . . . 1.0 110.309 179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.87 135.14 27.4 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.869 0.366 . . . . 1.0 110.962 -179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.52 125.39 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.231 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.76 130.79 53.18 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.435 -0.348 . . . . 1.0 110.364 179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 33.9 p . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.986 -1.007 . . . . 1.0 110.578 179.954 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.315 -0.624 . . . . 1.0 109.315 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 35.8 t80 -132.95 129.76 38.68 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.278 -0.419 . . . . 1.0 110.367 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.73 136.71 9.2 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.31 133.97 31.92 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.027 0.442 . . . . 1.0 111.179 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.8 mm -124.0 127.06 73.36 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.7 -0.682 . . . . 1.0 110.18 179.476 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 16.2 mt -117.38 131.52 56.76 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.238 -0.437 . . . . 1.0 110.218 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.036 -0.983 . . . . 1.0 110.574 179.958 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.37 -0.604 . . . . 1.0 109.37 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.635 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.1 m-85 -107.49 125.59 51.46 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.268 -0.424 . . . . 1.0 110.446 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.07 135.87 8.36 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.257 -1.137 . . . . 1.0 110.257 179.377 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.49 135.56 26.77 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 120.986 0.422 . . . . 1.0 111.071 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -132.24 125.09 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.853 -0.612 . . . . 1.0 110.273 179.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.626 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.7 mt -124.31 130.74 53.04 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.332 -0.394 . . . . 1.0 110.519 179.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 14.9 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.566 179.952 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.372 -0.603 . . . . 1.0 109.372 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -133.14 130.09 38.75 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.092 -0.504 . . . . 1.0 110.418 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.2 137.19 9.42 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.427 -1.069 . . . . 1.0 110.427 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.48 131.93 26.9 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.826 0.346 . . . . 1.0 111.246 -179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.5 mm -122.86 125.75 72.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.968 -0.56 . . . . 1.0 109.965 179.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -114.5 129.07 56.63 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.124 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.018 -0.992 . . . . 1.0 110.586 179.978 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -107.26 126.03 51.9 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.473 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.65 134.74 7.63 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.252 -1.139 . . . . 1.0 110.252 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 138.94 31.7 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.98 0.419 . . . . 1.0 110.67 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.2 tp -136.09 125.9 40.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.793 -0.64 . . . . 1.0 110.253 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 85.5 mt -125.68 130.56 51.81 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.275 -0.42 . . . . 1.0 110.427 179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.984 -1.007 . . . . 1.0 110.373 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.479 -0.563 . . . . 1.0 109.479 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 35.9 t80 -132.53 130.3 40.2 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.219 -0.446 . . . . 1.0 110.415 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.45 137.73 9.76 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.474 -1.051 . . . . 1.0 110.474 179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.37 133.26 29.17 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.887 0.375 . . . . 1.0 111.184 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 95.7 mt -123.35 125.62 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 115.914 -0.584 . . . . 1.0 110.002 179.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -115.58 132.18 56.71 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.367 -0.379 . . . . 1.0 110.175 -179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.086 -0.959 . . . . 1.0 110.566 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.431 -0.581 . . . . 1.0 109.431 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.43 ' O ' ' O ' ' C' ' 6' ' ' LEU . 57.8 m-85 -130.67 149.61 52.25 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.308 -0.405 . . . . 1.0 110.357 179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -146.49 148.36 19.98 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.622 -0.991 . . . . 1.0 110.622 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.75 142.05 26.25 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.984 0.421 . . . . 1.0 111.214 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.482 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.9 tp -135.0 127.61 48.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 115.71 -0.677 . . . . 1.0 109.876 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' C' ' 2' ' ' PHE . 42.4 mt -123.66 132.3 53.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.518 -0.31 . . . . 1.0 110.309 -179.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.4 ' OXT' ' O ' ' E' ' 1' ' ' ASN . 66.3 m . . . . . 0 C--O 1.221 -0.444 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.768 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . 0.436 ' O ' ' OD1' ' B' ' 1' ' ' ASN . 28.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.415 -0.587 . . . . 1.0 109.415 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 60.8 t80 -132.76 130.57 40.11 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.35 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.55 140.62 11.97 Favored Glycine 0 N--CA 1.466 0.658 0 N-CA-C 110.452 -1.059 . . . . 1.0 110.452 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.07 139.08 34.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.94 0.4 . . . . 1.0 111.156 -179.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -131.3 129.15 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.009 -0.541 . . . . 1.0 110.411 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 50.0 tp -120.75 129.65 53.71 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.113 -0.494 . . . . 1.0 110.566 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 47.5 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.953 -1.022 . . . . 1.0 110.585 179.764 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.344 -0.613 . . . . 1.0 109.344 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . 0.622 ' CD2' ' ND2' ' D' ' 1' ' ' ASN . 61.7 m-85 -130.67 149.53 52.28 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.289 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.54 149.27 21.39 Favored Glycine 0 N--CA 1.463 0.466 0 N-CA-C 110.491 -1.044 . . . . 1.0 110.491 179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.46 140.05 22.54 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.928 0.394 . . . . 1.0 111.098 -179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.28 129.07 56.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.001 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . 0.43 ' O ' ' O ' ' A' ' 2' ' ' PHE . 45.6 mt -123.56 132.58 53.93 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.317 -0.401 . . . . 1.0 110.471 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 18.6 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.545 179.853 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CD2' ' C' ' 2' ' ' PHE . 29.0 p30 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -132.67 130.28 39.92 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.158 -0.474 . . . . 1.0 110.29 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.47 140.04 11.58 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.392 -1.083 . . . . 1.0 110.392 179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.63 141.08 37.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.08 0.467 . . . . 1.0 110.996 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . 0.469 HG23 ' O ' ' D' ' 5' ' ' ILE . 11.0 tp -132.27 129.57 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-N 115.652 -0.704 . . . . 1.0 110.363 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 49.1 tp -122.31 127.18 49.51 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.439 -0.346 . . . . 1.0 110.183 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 13.5 m . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.981 -1.009 . . . . 1.0 110.632 179.924 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . 0.4 ' O ' ' OXT' ' A' ' 7' ' ' SER . 99.2 m-20 . . . . . 0 N--CA 1.488 1.444 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.618 ' CD2' ' ND2' ' F' ' 1' ' ' ASN . 57.1 m-85 -130.27 149.25 52.05 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.314 -0.403 . . . . 1.0 110.262 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -146.54 147.75 18.91 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.65 140.7 25.03 Favored 'General case' 0 C--O 1.231 0.095 0 CA-C-O 121.052 0.454 . . . . 1.0 111.342 -179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . 0.433 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -133.98 128.22 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 115.857 -0.61 . . . . 1.0 109.935 179.377 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.439 ' O ' ' O ' ' G' ' 2' ' ' PHE . 44.7 mt -123.23 132.61 54.1 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.463 -0.335 . . . . 1.0 110.597 -179.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.054 -0.974 . . . . 1.0 110.587 179.928 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . 0.618 ' ND2' ' CD2' ' E' ' 2' ' ' PHE . 29.1 p30 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.395 -0.594 . . . . 1.0 109.395 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -132.49 130.46 40.5 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.404 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.32 140.28 11.76 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.327 -1.109 . . . . 1.0 110.327 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.63 140.39 35.04 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.918 0.39 . . . . 1.0 110.973 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . 0.499 HG23 ' O ' ' F' ' 5' ' ' ILE . 11.2 tp -132.47 128.31 57.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.821 -0.627 . . . . 1.0 110.475 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 47.8 tp -120.01 126.96 52.11 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.298 -0.41 . . . . 1.0 110.334 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 16.6 m . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.897 -1.049 . . . . 1.0 110.565 179.893 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.279 -0.638 . . . . 1.0 109.279 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' E' ' 6' ' ' LEU . 59.9 m-85 -130.74 150.03 52.11 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.445 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -146.6 148.59 20.37 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.524 -1.03 . . . . 1.0 110.524 179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.15 142.09 25.84 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.927 0.394 . . . . 1.0 110.857 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . 0.522 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -135.12 126.89 47.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.728 -0.669 . . . . 1.0 109.73 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' E' ' 2' ' ' PHE . 53.6 mt -122.54 132.78 54.47 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.907 0.384 . . . . 1.0 110.462 -179.592 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 48.7 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.055 -0.974 . . . . 1.0 110.607 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . 0.425 ' O ' ' OD1' ' H' ' 1' ' ' ASN . 29.2 p30 . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.348 -0.612 . . . . 1.0 109.348 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 58.6 t80 -132.28 130.61 41.1 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.275 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.7 140.74 12.05 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 110.407 -1.077 . . . . 1.0 110.407 179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.73 138.41 32.34 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.865 0.364 . . . . 1.0 111.187 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.48 128.22 63.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.401 179.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 48.8 tp -119.04 127.96 53.91 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.311 -0.404 . . . . 1.0 110.356 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 32.6 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.029 -0.986 . . . . 1.0 110.433 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.295 -0.632 . . . . 1.0 109.295 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.5 m-85 -106.81 123.18 47.77 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.182 -0.463 . . . . 1.0 110.404 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.54 132.84 7.24 Favored Glycine 0 N--CA 1.465 0.571 0 N-CA-C 110.285 -1.126 . . . . 1.0 110.285 179.319 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.22 137.84 34.62 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 121.061 0.458 . . . . 1.0 110.997 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.505 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.8 tp -134.64 126.27 47.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.682 -0.69 . . . . 1.0 110.292 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.641 HD22 ' CD2' ' E' ' 2' ' ' PHE . 82.9 mt -123.95 130.86 53.27 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.991 -0.55 . . . . 1.0 110.503 -179.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.448 179.883 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.246 -0.65 . . . . 1.0 109.246 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 65.6 t80 -128.74 130.36 46.97 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 121.056 0.455 . . . . 1.0 110.796 -179.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.93 137.57 9.86 Favored Glycine 0 N--CA 1.466 0.698 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.83 133.9 29.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.849 0.357 . . . . 1.0 111.257 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 46.6 mm -125.08 129.23 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.917 -0.583 . . . . 1.0 110.355 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' D' ' 2' ' ' PHE . 45.7 tp -120.35 130.94 54.64 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.288 -0.415 . . . . 1.0 110.668 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . 0.424 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 7.9 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 118.032 -0.985 . . . . 1.0 110.247 179.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.55 0 N-CA-C 109.333 -0.617 . . . . 1.0 109.333 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 6.7 m-85 -107.4 123.13 47.92 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.139 -0.482 . . . . 1.0 110.166 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.75 133.35 7.42 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.251 -1.14 . . . . 1.0 110.251 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.76 135.55 29.84 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 120.989 0.424 . . . . 1.0 111.02 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -131.97 126.43 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.913 -0.585 . . . . 1.0 110.128 179.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.2 mt -122.6 132.47 54.31 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.432 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 2.3 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.974 -1.013 . . . . 1.0 110.493 -179.988 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.304 -0.628 . . . . 1.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' B' ' 6' ' ' LEU . 67.7 t80 -128.71 130.39 47.07 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.228 -0.442 . . . . 1.0 110.741 -179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.11 137.4 9.72 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.304 -1.119 . . . . 1.0 110.304 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . 0.41 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.6 135.33 31.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.994 0.426 . . . . 1.0 111.074 -179.569 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -127.31 129.6 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.428 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 46.0 tp -120.05 128.81 53.85 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.328 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 117.968 -1.015 . . . . 1.0 110.549 179.965 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.3 -0.63 . . . . 1.0 109.3 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.641 ' CD2' HD22 ' A' ' 6' ' ' LEU . 6.5 m-85 -106.54 123.33 47.93 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.329 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.92 133.26 7.36 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 110.28 -1.128 . . . . 1.0 110.28 179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.49 133.81 29.77 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.883 0.373 . . . . 1.0 111.252 -179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -128.09 124.75 63.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.777 -0.647 . . . . 1.0 110.222 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 84.8 mt -123.64 131.6 53.65 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.867 0.365 . . . . 1.0 110.355 179.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 29.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.988 -1.005 . . . . 1.0 110.599 179.882 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' H' ' 6' ' ' LEU . 66.2 t80 -128.35 130.45 47.78 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.315 -0.402 . . . . 1.0 110.734 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.48 9.75 Favored Glycine 0 N--CA 1.467 0.704 0 N-CA-C 110.254 -1.138 . . . . 1.0 110.254 179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -141.21 134.68 29.84 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.976 0.417 . . . . 1.0 111.102 -179.619 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -128.01 129.07 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.896 -0.593 . . . . 1.0 110.541 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . 0.426 ' O ' ' O ' ' H' ' 2' ' ' PHE . 46.5 tp -118.85 128.28 54.3 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.72 -0.673 . . . . 1.0 110.266 -179.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.049 -0.977 . . . . 1.0 110.545 179.987 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.448 -0.575 . . . . 1.0 109.448 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -106.37 124.19 49.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-N 116.167 -0.47 . . . . 1.0 110.342 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.62 132.6 6.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.246 -1.142 . . . . 1.0 110.246 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.93 138.67 35.78 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.025 0.44 . . . . 1.0 110.747 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . 0.541 HG23 ' O ' ' G' ' 5' ' ' ILE . 10.6 tp -134.88 125.28 45.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 115.846 -0.615 . . . . 1.0 110.079 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 83.6 mt -124.14 133.39 53.59 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.133 -0.485 . . . . 1.0 110.336 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.485 179.924 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.265 -0.642 . . . . 1.0 109.265 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . 0.426 ' O ' ' O ' ' F' ' 6' ' ' LEU . 67.2 t80 -128.45 130.47 47.62 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.201 -0.454 . . . . 1.0 110.681 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.27 137.92 10.03 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.373 -1.091 . . . . 1.0 110.373 179.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . 0.432 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -141.33 134.52 29.39 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.892 0.377 . . . . 1.0 111.096 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.77 128.45 70.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.988 -0.551 . . . . 1.0 110.392 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' F' ' 2' ' ' PHE . 45.9 tp -118.35 127.3 53.56 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.103 -0.499 . . . . 1.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 1.8 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.076 -0.964 . . . . 1.0 110.372 179.893 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.443 -0.577 . . . . 1.0 109.443 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.637 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -107.78 124.37 49.95 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.105 -0.498 . . . . 1.0 110.307 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.13 133.65 7.49 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.272 -1.131 . . . . 1.0 110.272 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 136.74 32.13 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.031 0.443 . . . . 1.0 110.922 -179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.527 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.5 tp -133.67 126.07 50.73 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 CA-C-N 115.753 -0.658 . . . . 1.0 110.258 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.661 HD22 ' CD2' ' E' ' 2' ' ' PHE . 84.8 mt -124.07 129.93 51.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.02 -0.536 . . . . 1.0 110.566 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 27.7 p . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 117.924 -1.036 . . . . 1.0 110.491 179.875 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.332 -0.618 . . . . 1.0 109.332 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.404 ' O ' ' O ' ' D' ' 6' ' ' LEU . 71.5 t80 -129.03 130.32 46.45 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.691 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.52 137.58 9.93 Favored Glycine 0 N--CA 1.465 0.619 0 N-CA-C 110.404 -1.078 . . . . 1.0 110.404 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.54 134.02 29.99 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.965 0.412 . . . . 1.0 111.239 -179.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -124.46 128.22 73.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 CA-C-N 115.81 -0.632 . . . . 1.0 109.962 179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . 0.401 ' O ' ' O ' ' D' ' 2' ' ' PHE . 47.2 tp -118.66 131.18 56.16 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 120.965 0.412 . . . . 1.0 110.655 -179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . 0.484 ' OG ' ' CE2' ' E' ' 2' ' ' PHE . 1.2 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.02 -0.99 . . . . 1.0 110.309 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.38 -0.6 . . . . 1.0 109.38 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -108.21 124.35 50.14 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.18 -0.463 . . . . 1.0 110.165 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.47 133.96 7.59 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.369 -1.092 . . . . 1.0 110.369 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.65 134.48 26.93 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-O 120.984 0.421 . . . . 1.0 110.925 -179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -131.01 126.37 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-N 115.973 -0.558 . . . . 1.0 110.081 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 85.9 mt -122.99 132.04 53.97 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.319 -0.4 . . . . 1.0 110.374 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 6.0 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.027 -0.987 . . . . 1.0 110.587 179.983 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.275 -0.639 . . . . 1.0 109.275 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . 0.401 ' O ' ' O ' ' B' ' 6' ' ' LEU . 73.0 t80 -129.05 130.35 46.45 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.712 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.36 9.8 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.253 -1.139 . . . . 1.0 110.253 179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.32 133.87 30.13 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.941 0.4 . . . . 1.0 111.251 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.7 mm -124.22 128.79 74.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.744 -0.662 . . . . 1.0 110.241 179.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . 0.404 ' O ' ' O ' ' B' ' 2' ' ' PHE . 48.4 tp -119.14 127.72 53.6 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.328 -0.397 . . . . 1.0 110.235 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 5.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.978 -1.01 . . . . 1.0 110.535 -179.978 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 61.5 t-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.399 -0.593 . . . . 1.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.661 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -107.85 124.34 49.94 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 116.156 -0.475 . . . . 1.0 110.254 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . 0.453 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -130.28 134.42 7.82 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.305 -1.118 . . . . 1.0 110.305 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.71 133.15 26.72 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.895 0.378 . . . . 1.0 111.251 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 47.2 mm -127.93 125.08 64.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.787 -0.642 . . . . 1.0 110.235 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.637 HD22 ' CD2' ' A' ' 2' ' ' PHE . 86.6 mt -123.78 130.46 52.66 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.882 0.373 . . . . 1.0 110.478 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 4.3 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.577 179.868 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.458 -0.571 . . . . 1.0 109.458 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' H' ' 6' ' ' LEU . 71.8 t80 -128.79 130.19 46.67 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.91 0.386 . . . . 1.0 110.764 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.48 137.67 10.0 Favored Glycine 0 N--CA 1.467 0.727 0 N-CA-C 110.245 -1.142 . . . . 1.0 110.245 179.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.0 133.41 28.35 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.956 0.408 . . . . 1.0 111.236 -179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.42 128.59 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.128 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . 0.422 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.2 tp -118.75 128.12 54.18 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.172 -0.467 . . . . 1.0 110.256 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.908 -1.044 . . . . 1.0 110.468 179.899 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.3 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -107.57 124.93 50.66 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.211 -0.45 . . . . 1.0 110.284 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.82 133.48 7.32 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.217 -1.153 . . . . 1.0 110.217 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.9 137.75 33.39 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.956 0.408 . . . . 1.0 110.745 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . 0.513 HG23 ' O ' ' G' ' 5' ' ' ILE . 9.7 tp -134.09 125.77 48.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 CA-C-N 115.894 -0.594 . . . . 1.0 110.178 179.838 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.9 mt -124.24 131.01 53.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.342 -0.39 . . . . 1.0 110.336 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.1 p . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 117.97 -1.014 . . . . 1.0 110.501 179.974 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.255 -0.646 . . . . 1.0 109.255 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . 0.422 ' O ' ' O ' ' F' ' 6' ' ' LEU . 72.9 t80 -128.49 130.26 47.25 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.285 -0.416 . . . . 1.0 110.74 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.54 138.03 10.22 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.276 -1.129 . . . . 1.0 110.276 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.56 134.38 30.48 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.992 0.425 . . . . 1.0 111.107 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.74 127.81 72.94 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.967 -0.56 . . . . 1.0 110.146 179.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . 0.421 ' O ' ' O ' ' F' ' 2' ' ' PHE . 48.8 tp -118.67 128.94 55.0 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.418 -0.356 . . . . 1.0 110.293 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 66.5 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.999 -1.001 . . . . 1.0 110.419 179.896 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.48 -0.563 . . . . 1.0 109.48 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.61 ' CD2' HD22 ' E' ' 6' ' ' LEU . 9.9 m-85 -106.13 122.61 46.54 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.221 -0.445 . . . . 1.0 110.46 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.16 134.36 7.58 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.202 -1.159 . . . . 1.0 110.202 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.67 139.13 32.91 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.1 0.476 . . . . 1.0 111.186 -179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.524 HG23 ' O ' ' A' ' 5' ' ' ILE . 11.1 tp -134.04 124.96 47.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.231 0 CA-C-N 115.599 -0.728 . . . . 1.0 110.124 179.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.62 HD22 ' CD2' ' E' ' 2' ' ' PHE . 86.6 mt -126.52 131.89 51.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.079 -0.51 . . . . 1.0 110.54 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 44.3 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.071 -0.966 . . . . 1.0 110.485 179.903 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.489 1.482 0 N-CA-C 109.396 -0.594 . . . . 1.0 109.396 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' D' ' 6' ' ' LEU . 36.2 t80 -131.98 130.74 41.85 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.291 -0.413 . . . . 1.0 110.413 -179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.89 138.0 10.31 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.341 -1.104 . . . . 1.0 110.341 179.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.52 132.18 27.24 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.843 0.354 . . . . 1.0 111.283 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.35 125.57 71.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.016 -0.538 . . . . 1.0 110.077 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.8 mt -114.57 129.49 56.67 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.204 -0.453 . . . . 1.0 110.506 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . 0.403 ' OXT' ' OG ' ' B' ' 7' ' ' SER . 21.0 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.322 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.337 -0.616 . . . . 1.0 109.337 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -106.39 122.75 46.89 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.224 -0.443 . . . . 1.0 110.381 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.86 134.8 7.74 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 110.144 -1.183 . . . . 1.0 110.144 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.68 136.94 29.52 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.921 0.391 . . . . 1.0 111.177 -179.597 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.72 124.34 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.09 179.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 86.5 mt -125.37 132.13 52.85 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.456 -0.338 . . . . 1.0 110.472 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 90.7 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.031 -0.985 . . . . 1.0 110.559 179.88 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.492 1.662 0 N-CA-C 109.214 -0.661 . . . . 1.0 109.214 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 38.5 t80 -132.09 130.54 41.37 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.457 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.53 10.07 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.3 -1.12 . . . . 1.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.28 134.71 31.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.01 0.433 . . . . 1.0 111.036 -179.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -126.99 127.38 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 115.885 -0.598 . . . . 1.0 110.382 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' B' ' 2' ' ' PHE . 15.9 mt -116.11 131.57 56.9 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.351 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 4.4 m . . . . . 0 C--O 1.221 -0.408 0 CA-C-O 118.006 -0.997 . . . . 1.0 110.517 179.864 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 62.0 t-20 . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 109.442 -0.577 . . . . 1.0 109.442 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.62 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.0 m-85 -106.19 122.65 46.65 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.213 -0.449 . . . . 1.0 110.336 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . 0.417 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.31 134.89 7.83 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.208 -1.157 . . . . 1.0 110.208 179.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 137.01 30.37 Favored 'General case' 0 N--CA 1.462 0.151 0 CA-C-O 120.951 0.405 . . . . 1.0 111.426 -179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -131.18 124.32 55.25 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 CA-C-N 115.836 -0.62 . . . . 1.0 110.12 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.61 HD22 ' CD2' ' A' ' 2' ' ' PHE . 87.2 mt -125.87 131.37 52.39 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.186 -0.461 . . . . 1.0 110.442 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 83.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.063 -0.97 . . . . 1.0 110.579 179.821 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' H' ' 6' ' ' LEU . 36.3 t80 -132.05 130.95 41.97 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.347 -0.388 . . . . 1.0 110.519 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.08 138.39 10.51 Favored Glycine 0 N--CA 1.466 0.683 0 N-CA-C 110.336 -1.106 . . . . 1.0 110.336 179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.16 131.67 25.37 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.921 0.391 . . . . 1.0 111.309 -179.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 49.8 mm -122.88 126.33 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.017 -0.538 . . . . 1.0 110.127 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . 0.412 ' O ' ' O ' ' H' ' 2' ' ' PHE . 15.5 mt -114.99 127.59 55.76 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.137 -0.483 . . . . 1.0 109.974 179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 5.1 m . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.614 179.863 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 61.9 t-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.466 -0.568 . . . . 1.0 109.466 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -106.38 123.25 47.77 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.304 -0.407 . . . . 1.0 110.36 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.92 134.36 7.5 Favored Glycine 0 N--CA 1.466 0.635 0 N-CA-C 110.113 -1.195 . . . . 1.0 110.113 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -141.8 140.04 32.9 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.048 0.452 . . . . 1.0 110.926 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . 0.528 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -134.52 124.85 45.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.698 -0.683 . . . . 1.0 110.007 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 84.4 mt -126.87 133.34 50.73 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.456 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.98 -1.009 . . . . 1.0 110.403 -179.992 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . 0.412 ' O ' ' O ' ' F' ' 6' ' ' LEU . 38.3 t80 -132.01 131.13 42.23 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 116.375 -0.375 . . . . 1.0 110.48 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.27 138.79 10.74 Favored Glycine 0 N--CA 1.466 0.694 0 N-CA-C 110.391 -1.084 . . . . 1.0 110.391 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.79 132.48 27.27 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.91 0.386 . . . . 1.0 111.267 -179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.7 mm -122.89 126.39 73.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.083 179.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . 0.414 ' O ' ' O ' ' F' ' 2' ' ' PHE . 15.9 mt -116.4 129.24 56.13 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.387 -0.369 . . . . 1.0 110.198 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 35.1 p . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.024 -0.988 . . . . 1.0 110.38 179.827 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.407 -0.59 . . . . 1.0 109.407 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.628 ' CD2' HD22 ' E' ' 6' ' ' LEU . 6.9 m-85 -106.01 122.12 45.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.254 -0.43 . . . . 1.0 110.435 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -132.62 134.22 7.46 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 110.337 -1.105 . . . . 1.0 110.337 179.472 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 138.06 30.31 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-O 121.114 0.483 . . . . 1.0 110.967 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.544 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.7 tp -135.09 125.23 44.42 Favored 'Isoleucine or valine' 0 C--O 1.234 0.246 0 CA-C-N 115.721 -0.672 . . . . 1.0 110.239 179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.646 HD22 ' CD2' ' E' ' 2' ' ' PHE . 87.5 mt -125.1 129.62 50.57 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.996 -0.547 . . . . 1.0 110.513 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.2 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.469 179.874 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . 0.622 ' ND2' ' CZ ' ' A' ' 2' ' ' PHE . 59.4 t-20 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.381 -0.6 . . . . 1.0 109.381 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.517 ' N ' ' OD1' ' B' ' 1' ' ' ASN . 72.6 t80 -129.46 129.85 45.15 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.124 -0.489 . . . . 1.0 110.675 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.79 136.01 8.81 Favored Glycine 0 N--CA 1.467 0.72 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.2 134.16 27.27 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.033 0.444 . . . . 1.0 111.497 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -124.85 128.43 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.721 -0.672 . . . . 1.0 109.995 179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . 0.424 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 45.7 tp -121.17 132.99 55.17 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 120.833 0.349 . . . . 1.0 110.903 -179.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . 0.506 ' OG ' ' CZ ' ' E' ' 2' ' ' PHE . 17.5 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.01 . . . . 1.0 110.562 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.491 1.594 0 N-CA-C 109.286 -0.635 . . . . 1.0 109.286 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -106.62 122.42 46.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.235 -0.439 . . . . 1.0 110.241 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.41 134.87 7.72 Favored Glycine 0 N--CA 1.465 0.605 0 N-CA-C 110.384 -1.086 . . . . 1.0 110.384 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.84 135.45 26.11 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.95 0.405 . . . . 1.0 111.098 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -131.25 124.81 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.157 179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 88.0 mt -124.26 132.0 53.56 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.43 -0.35 . . . . 1.0 110.284 179.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 32.5 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.019 -0.991 . . . . 1.0 110.55 179.847 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . 0.513 ' OD1' ' N ' ' D' ' 2' ' ' PHE . 60.0 t-20 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.335 -0.617 . . . . 1.0 109.335 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . 0.513 ' N ' ' OD1' ' D' ' 1' ' ' ASN . 74.7 t80 -129.08 129.77 45.67 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.24 -0.436 . . . . 1.0 110.777 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.6 135.8 8.74 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.198 -1.161 . . . . 1.0 110.198 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.28 133.81 26.64 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.0 0.429 . . . . 1.0 111.335 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.53 128.41 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.757 -0.656 . . . . 1.0 110.022 179.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . 0.435 ' O ' ' O ' ' B' ' 2' ' ' PHE . 45.6 tp -120.02 128.8 53.87 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.369 -0.378 . . . . 1.0 110.298 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . 0.425 ' OG ' ' ND2' ' B' ' 1' ' ' ASN . 3.7 m . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 118.002 -0.999 . . . . 1.0 110.575 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 12.6 m120 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.31 -0.626 . . . . 1.0 109.31 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.646 ' CD2' HD22 ' A' ' 6' ' ' LEU . 7.0 m-85 -106.14 122.15 45.61 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.232 -0.44 . . . . 1.0 110.275 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . 0.428 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -132.97 134.81 7.73 Favored Glycine 0 N--CA 1.465 0.6 0 N-CA-C 110.35 -1.1 . . . . 1.0 110.35 179.462 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.28 136.07 27.62 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.969 0.414 . . . . 1.0 111.172 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.18 124.41 52.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.201 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.628 HD22 ' CD2' ' A' ' 2' ' ' PHE . 88.2 mt -124.49 130.89 53.29 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.207 -0.451 . . . . 1.0 110.428 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 13.7 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.551 179.908 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . 0.524 ' OD1' ' N ' ' F' ' 2' ' ' PHE . 59.6 t-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.367 -0.605 . . . . 1.0 109.367 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . 0.524 ' N ' ' OD1' ' F' ' 1' ' ' ASN . 73.0 t80 -130.22 129.52 43.47 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.041 -0.527 . . . . 1.0 110.593 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.63 136.03 8.86 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.151 -1.179 . . . . 1.0 110.151 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.57 133.38 25.51 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 121.059 0.457 . . . . 1.0 111.417 -179.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 47.0 mm -124.94 128.33 73.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 CA-C-N 115.699 -0.682 . . . . 1.0 110.063 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . 0.428 ' O ' ' O ' ' H' ' 2' ' ' PHE . 45.8 tp -119.56 127.92 53.44 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.015 -0.538 . . . . 1.0 110.28 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . 0.478 ' OG ' ' ND2' ' H' ' 1' ' ' ASN . 7.0 m . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 118.005 -0.998 . . . . 1.0 110.485 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 12.5 m120 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.289 -0.634 . . . . 1.0 109.289 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . 0.531 ' CE1' ' ND2' ' H' ' 1' ' ' ASN . 7.1 m-85 -105.89 122.98 47.23 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.289 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -133.55 134.02 7.26 Favored Glycine 0 N--CA 1.465 0.579 0 N-CA-C 110.291 -1.124 . . . . 1.0 110.291 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.49 139.14 31.41 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 121.041 0.448 . . . . 1.0 110.759 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . 0.513 ' O ' HG23 ' G' ' 5' ' ' ILE . 10.8 tp -135.76 124.91 39.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 1.0 110.22 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.26 130.74 52.66 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.259 -0.428 . . . . 1.0 110.37 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 37.7 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 118.003 -0.999 . . . . 1.0 110.536 179.96 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . 0.531 ' ND2' ' CE1' ' G' ' 2' ' ' PHE . 59.5 t-20 . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.404 -0.591 . . . . 1.0 109.404 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . 0.519 ' N ' ' OD1' ' H' ' 1' ' ' ASN . 74.3 t80 -129.49 129.82 45.06 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.199 -0.455 . . . . 1.0 110.694 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 136.34 8.97 Favored Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.385 -1.086 . . . . 1.0 110.385 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.29 134.61 27.76 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.038 0.447 . . . . 1.0 111.288 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -125.59 127.65 71.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.931 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . 0.429 ' O ' ' O ' ' F' ' 2' ' ' PHE . 47.0 tp -119.59 129.96 54.89 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.341 -0.39 . . . . 1.0 110.409 -179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 59.5 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.997 -1.001 . . . . 1.0 110.501 179.878 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.623 ' CD2' HD22 ' E' ' 6' ' ' LEU . 10.1 m-85 -105.12 123.59 48.09 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.153 -0.476 . . . . 1.0 110.28 179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.425 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -128.78 137.57 9.72 Favored Glycine 0 CA--C 1.525 0.659 0 N-CA-C 110.589 -1.004 . . . . 1.0 110.589 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -144.44 141.12 29.39 Favored 'General case' 0 C--O 1.232 0.17 0 CA-C-O 120.94 0.4 . . . . 1.0 111.046 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.501 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.9 tp -141.35 125.79 17.24 Favored 'Isoleucine or valine' 0 C--O 1.233 0.222 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.71 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.636 HD22 ' CD2' ' E' ' 2' ' ' PHE . 60.2 mt -120.74 132.67 55.18 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.968 -0.56 . . . . 1.0 110.32 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 6.8 p . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.534 179.869 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.595 0 N-CA-C 109.268 -0.641 . . . . 1.0 109.268 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.402 ' O ' ' O ' ' D' ' 6' ' ' LEU . 56.2 t80 -128.22 130.53 48.11 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.248 -0.433 . . . . 1.0 110.725 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.86 137.48 9.65 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.332 -1.107 . . . . 1.0 110.332 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' D' ' 4' ' ' ALA . . . -140.38 135.62 32.29 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.913 0.387 . . . . 1.0 111.23 -179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -127.03 130.05 71.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.888 -0.596 . . . . 1.0 110.278 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 47.0 tp -120.42 130.78 54.49 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.016 0.436 . . . . 1.0 110.604 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 52.0 p . . . . . 0 C--O 1.222 -0.346 0 CA-C-O 117.793 -1.099 . . . . 1.0 110.208 179.607 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.353 -0.61 . . . . 1.0 109.353 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 10.9 m-85 -105.49 123.45 47.92 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.224 -0.444 . . . . 1.0 110.212 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . 0.401 ' HA2' HD12 ' A' ' 5' ' ' ILE . . . -129.03 138.2 10.1 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.699 -0.96 . . . . 1.0 110.699 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -146.16 140.36 26.59 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.959 0.409 . . . . 1.0 110.75 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . 0.472 HG23 ' O ' ' C' ' 5' ' ' ILE . 19.8 tt -140.39 126.62 21.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-N 116.059 -0.518 . . . . 1.0 110.061 179.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 69.4 mt -120.04 133.76 55.44 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.245 -0.434 . . . . 1.0 110.27 -179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 34.4 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.993 -1.003 . . . . 1.0 110.511 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.272 -0.64 . . . . 1.0 109.272 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 58.0 t80 -128.38 130.44 47.69 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 116.225 -0.443 . . . . 1.0 110.632 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.9 137.3 9.53 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.278 -1.129 . . . . 1.0 110.278 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . 0.401 ' O ' ' O ' ' B' ' 4' ' ' ALA . . . -140.72 136.33 32.48 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.06 0.457 . . . . 1.0 110.947 -179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -128.75 130.58 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.907 -0.588 . . . . 1.0 110.519 179.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . 0.402 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.3 tp -120.51 129.52 53.86 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.889 -0.596 . . . . 1.0 110.232 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 95.5 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.496 -179.998 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.636 ' CD2' HD22 ' A' ' 6' ' ' LEU . 10.4 m-85 -105.25 123.77 48.41 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.162 -0.472 . . . . 1.0 110.195 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . 0.489 ' HA2' HD12 ' G' ' 5' ' ' ILE . . . -129.33 138.0 9.95 Favored Glycine 0 N--CA 1.468 0.776 0 N-CA-C 110.695 -0.962 . . . . 1.0 110.695 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.03 140.2 27.96 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.793 0.33 . . . . 1.0 111.079 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . 0.493 HG23 ' O ' ' E' ' 5' ' ' ILE . 20.2 tt -140.44 125.42 19.38 Favored 'Isoleucine or valine' 0 C--O 1.233 0.223 0 CA-C-N 116.076 -0.511 . . . . 1.0 110.465 179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.623 HD22 ' CD2' ' A' ' 2' ' ' PHE . 62.2 mt -119.66 132.54 55.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.282 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.994 -1.003 . . . . 1.0 110.543 179.943 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.502 -0.555 . . . . 1.0 109.502 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 56.2 t80 -128.21 130.58 48.22 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 116.264 -0.426 . . . . 1.0 110.666 -179.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.93 137.23 9.48 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.204 -1.159 . . . . 1.0 110.204 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' H' ' 4' ' ' ALA . . . -140.88 136.1 31.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.059 0.457 . . . . 1.0 111.032 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.9 mt -129.44 130.24 67.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 115.915 -0.584 . . . . 1.0 110.523 179.501 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . 0.427 ' O ' ' O ' ' H' ' 2' ' ' PHE . 49.9 tp -119.84 129.02 54.21 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.575 -0.739 . . . . 1.0 110.207 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 91.7 p . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.945 -1.026 . . . . 1.0 110.556 179.864 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.374 -0.602 . . . . 1.0 109.374 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -105.16 124.32 49.33 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.218 -0.446 . . . . 1.0 110.3 179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.62 137.72 9.75 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.651 -0.98 . . . . 1.0 110.651 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.38 141.13 28.18 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.904 0.383 . . . . 1.0 110.629 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . 0.502 HG23 ' O ' ' G' ' 5' ' ' ILE . 11.1 tp -141.59 126.34 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.989 -0.551 . . . . 1.0 110.312 179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 65.2 mt -120.33 131.78 55.01 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.296 -0.411 . . . . 1.0 110.225 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 2.2 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.999 -1.0 . . . . 1.0 110.474 -179.917 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.376 -0.602 . . . . 1.0 109.376 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . 0.427 ' O ' ' O ' ' F' ' 6' ' ' LEU . 58.1 t80 -127.79 130.47 48.75 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.941 0.401 . . . . 1.0 110.713 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -129.19 137.58 9.68 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.361 -1.096 . . . . 1.0 110.361 179.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . 0.405 ' O ' ' O ' ' F' ' 4' ' ' ALA . . . -140.67 135.79 31.99 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.855 0.36 . . . . 1.0 111.166 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -127.17 129.88 71.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 116.013 -0.54 . . . . 1.0 110.367 179.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 49.2 tp -120.42 128.34 53.1 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.195 -0.457 . . . . 1.0 110.216 179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 52.1 p . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 117.942 -1.028 . . . . 1.0 110.439 179.754 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.339 -0.615 . . . . 1.0 109.339 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -124.28 135.39 53.35 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.27 -0.423 . . . . 1.0 110.354 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -133.51 134.16 7.33 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.57 -1.012 . . . . 1.0 110.57 179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -145.08 132.17 20.38 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.149 0.5 . . . . 1.0 110.946 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.608 HG23 ' O ' ' A' ' 5' ' ' ILE . 10.1 tp -137.99 122.43 22.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.472 -0.786 . . . . 1.0 110.217 -179.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 mt -119.51 135.4 54.79 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.932 0.396 . . . . 1.0 110.888 -179.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.3 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.116 -0.945 . . . . 1.0 110.384 179.646 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . 0.43 ' O ' ' OD1' ' B' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.423 -0.584 . . . . 1.0 109.423 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -131.57 132.35 44.04 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 116.18 -0.464 . . . . 1.0 110.665 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.12 136.76 9.01 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.431 -1.068 . . . . 1.0 110.431 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.61 133.37 30.61 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.801 0.334 . . . . 1.0 110.883 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.1 mt -125.47 128.16 72.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.07 -0.514 . . . . 1.0 110.543 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -119.11 127.52 53.44 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.007 -0.542 . . . . 1.0 110.051 179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.878 -1.058 . . . . 1.0 110.632 179.719 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.418 -0.586 . . . . 1.0 109.418 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . 0.402 ' N ' ' CD1' ' C' ' 2' ' ' PHE . 33.1 m-85 -123.99 135.42 53.62 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 116.222 -0.444 . . . . 1.0 110.21 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.42 134.77 7.57 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.496 -1.041 . . . . 1.0 110.496 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -147.13 128.67 15.04 Favored 'General case' 0 N--CA 1.462 0.13 0 CA-C-O 121.023 0.439 . . . . 1.0 111.048 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.2 mt -133.74 124.19 46.97 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.818 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 61.7 mt -118.35 132.48 56.27 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.809 0.337 . . . . 1.0 110.451 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 5.9 t . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.048 -0.977 . . . . 1.0 110.503 179.975 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . 0.431 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.4 -0.593 . . . . 1.0 109.4 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -132.07 131.83 42.77 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.206 -0.452 . . . . 1.0 110.695 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.74 136.21 8.72 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 110.402 -1.079 . . . . 1.0 110.402 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.14 133.11 31.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.916 0.389 . . . . 1.0 110.843 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.3 mm -124.66 128.28 73.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.377 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 50.7 tp -118.64 126.5 52.07 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.046 -0.524 . . . . 1.0 109.99 179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 11.4 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.025 -0.988 . . . . 1.0 110.578 179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.382 -0.599 . . . . 1.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -123.7 134.88 53.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.251 -0.431 . . . . 1.0 110.164 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -133.19 135.1 7.87 Favored Glycine 0 N--CA 1.466 0.666 0 N-CA-C 110.442 -1.063 . . . . 1.0 110.442 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -148.11 128.31 13.78 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.969 0.414 . . . . 1.0 111.465 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . 0.428 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.1 mt -134.25 124.17 45.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.838 -0.619 . . . . 1.0 110.205 179.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . . . . . . . . . 54.2 mt -118.38 133.25 56.04 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.306 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.932 -1.032 . . . . 1.0 110.468 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 55.5 p30 . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.389 -0.597 . . . . 1.0 109.389 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 57.9 t80 -131.52 132.17 43.99 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.188 -0.46 . . . . 1.0 110.747 -179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.02 136.55 8.89 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.421 -1.071 . . . . 1.0 110.421 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.07 132.32 28.21 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.826 0.346 . . . . 1.0 110.877 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 45.9 mm -125.07 127.75 72.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.408 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 52.4 tp -117.41 126.36 52.53 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.731 -0.668 . . . . 1.0 110.13 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.946 -1.026 . . . . 1.0 110.566 179.984 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.484 -0.561 . . . . 1.0 109.484 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 37.3 m-85 -124.15 136.08 53.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.229 -0.441 . . . . 1.0 110.259 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -134.66 135.11 7.74 Favored Glycine 0 N--CA 1.466 0.652 0 N-CA-C 110.355 -1.098 . . . . 1.0 110.355 179.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -149.49 127.77 12.13 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 121.025 0.44 . . . . 1.0 111.271 -179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.99 125.29 48.36 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.73 -0.668 . . . . 1.0 110.115 179.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 57.8 mt -117.82 132.77 56.4 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 1.0 110.251 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 1.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 118.038 -0.982 . . . . 1.0 110.496 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . 0.437 ' O ' ' OD1' ' H' ' 1' ' ' ASN . 55.6 p30 . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.447 -0.575 . . . . 1.0 109.447 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -131.25 132.09 44.37 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.283 -0.417 . . . . 1.0 110.694 -179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.4 136.42 8.79 Favored Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.506 -1.037 . . . . 1.0 110.506 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.32 134.09 32.08 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.806 0.336 . . . . 1.0 110.84 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.55 127.82 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.149 -0.478 . . . . 1.0 110.484 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 51.1 tp -118.05 127.56 53.92 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.056 -0.52 . . . . 1.0 110.109 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.008 -0.996 . . . . 1.0 110.595 179.942 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' A' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.457 -0.572 . . . . 1.0 109.457 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.586 ' CD2' HD22 ' E' ' 6' ' ' LEU . 11.9 m-85 -105.49 124.67 49.93 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.141 -0.481 . . . . 1.0 110.403 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.429 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -127.51 135.26 8.65 Favored Glycine 0 N--CA 1.466 0.641 0 N-CA-C 110.503 -1.039 . . . . 1.0 110.503 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.74 136.9 33.0 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.022 0.439 . . . . 1.0 110.734 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.564 HG23 ' O ' ' A' ' 5' ' ' ILE . 19.8 tt -137.49 122.69 24.97 Favored 'Isoleucine or valine' 0 C--O 1.235 0.301 0 CA-C-N 115.752 -0.658 . . . . 1.0 110.604 -179.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.615 HD22 ' CD2' ' E' ' 2' ' ' PHE . 48.4 mt -119.21 133.81 55.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.85 -0.614 . . . . 1.0 110.496 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.014 -0.993 . . . . 1.0 110.481 179.991 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.397 -0.594 . . . . 1.0 109.397 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -131.4 130.8 43.04 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.21 -0.45 . . . . 1.0 110.442 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.88 137.57 10.04 Favored Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.387 -1.085 . . . . 1.0 110.387 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.28 132.62 30.03 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.864 0.364 . . . . 1.0 111.092 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 48.3 mm -123.57 125.86 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-N 115.976 -0.556 . . . . 1.0 110.199 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . . . . . . . . . 15.7 mt -114.37 131.87 56.41 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.258 -0.428 . . . . 1.0 110.48 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . . . . . . . . . 71.2 p . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 118.058 -0.972 . . . . 1.0 110.362 179.707 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . 0.435 ' O ' ' OD1' ' C' ' 1' ' ' ASN . 49.8 p-10 . . . . . 0 N--CA 1.492 1.627 0 N-CA-C 109.432 -0.581 . . . . 1.0 109.432 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -105.42 124.37 49.44 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.11 -0.495 . . . . 1.0 110.177 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.67 135.26 8.62 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.573 -1.011 . . . . 1.0 110.573 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 132.74 25.53 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.813 0.34 . . . . 1.0 110.86 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.35 123.34 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.121 -0.49 . . . . 1.0 109.971 179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 58.9 mt -117.92 132.23 56.43 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.861 0.363 . . . . 1.0 110.284 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 14.6 t . . . . . 0 C--O 1.222 -0.38 0 CA-C-O 118.001 -1.0 . . . . 1.0 110.439 -179.78 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 N--CA 1.49 1.542 0 N-CA-C 109.352 -0.61 . . . . 1.0 109.352 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . . . . . . . . . 32.0 t80 -131.59 130.68 42.52 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.329 -0.396 . . . . 1.0 110.428 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.69 137.37 9.96 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 110.365 -1.094 . . . . 1.0 110.365 179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.17 134.55 32.94 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.919 0.39 . . . . 1.0 110.99 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 96.7 mt -126.85 127.16 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.013 -0.539 . . . . 1.0 110.47 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . . . . . . . . . 15.9 mt -115.27 131.43 56.93 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 115.935 -0.575 . . . . 1.0 110.084 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.955 -1.021 . . . . 1.0 110.546 179.896 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . 0.424 ' OD1' ' O ' ' E' ' 1' ' ' ASN . 49.9 p-10 . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.482 -0.562 . . . . 1.0 109.482 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.615 ' CD2' HD22 ' A' ' 6' ' ' LEU . 12.7 m-85 -105.84 124.76 50.09 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.126 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 5' ' ' ILE . . . -127.52 137.01 9.57 Favored Glycine 0 N--CA 1.467 0.73 0 N-CA-C 110.46 -1.056 . . . . 1.0 110.46 179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.7 132.81 24.49 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.894 0.378 . . . . 1.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . 0.429 ' O ' ' O ' ' A' ' 3' ' ' GLY . 96.3 mt -131.86 121.53 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.971 -0.559 . . . . 1.0 110.386 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.586 HD22 ' CD2' ' A' ' 2' ' ' PHE . 50.8 mt -117.84 133.31 56.06 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.107 -0.497 . . . . 1.0 110.242 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . 0.41 ' O ' ' OG ' ' E' ' 7' ' ' SER . 10.3 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.099 -0.953 . . . . 1.0 110.491 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 . . . . . 0 N--CA 1.491 1.622 0 N-CA-C 109.364 -0.606 . . . . 1.0 109.364 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -131.52 130.91 42.95 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.171 -0.468 . . . . 1.0 110.413 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.07 137.54 9.98 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 110.263 -1.135 . . . . 1.0 110.263 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.79 133.86 30.99 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.854 0.359 . . . . 1.0 110.882 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 96.8 mt -127.5 126.43 67.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.32 0 CA-C-N 116.136 -0.484 . . . . 1.0 110.512 179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . . . . . . . . . 15.6 mt -113.32 129.8 56.44 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.46 -0.791 . . . . 1.0 110.07 -179.549 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.95 -1.024 . . . . 1.0 110.59 179.913 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . 0.431 ' OD1' ' O ' ' G' ' 1' ' ' ASN . 49.5 p-10 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.46 -0.57 . . . . 1.0 109.46 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -105.83 125.34 50.87 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.156 -0.474 . . . . 1.0 110.429 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -128.46 136.51 9.14 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.416 -1.073 . . . . 1.0 110.416 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.04 131.76 24.14 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.923 0.392 . . . . 1.0 111.016 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.4 mm -128.57 121.77 55.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-N 115.79 -0.641 . . . . 1.0 110.495 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 55.7 mt -119.0 132.15 56.05 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.072 -0.344 . . . . 1.0 110.072 179.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.474 -179.879 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.411 -0.589 . . . . 1.0 109.411 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . . . . . . . . . 31.8 t80 -130.85 131.03 44.34 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.935 0.398 . . . . 1.0 110.395 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 138.24 10.41 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.494 -1.042 . . . . 1.0 110.494 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -139.88 132.82 29.33 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.883 0.373 . . . . 1.0 111.046 -179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 48.5 mm -123.41 126.72 73.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 115.998 -0.546 . . . . 1.0 110.138 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . . . . . . . . . 16.1 mt -115.98 133.94 55.5 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.29 -0.414 . . . . 1.0 110.192 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 78.7 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.077 -0.963 . . . . 1.0 110.337 179.851 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.313 -0.625 . . . . 1.0 109.313 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.607 ' CD2' HD22 ' E' ' 6' ' ' LEU . 8.2 m-85 -104.89 122.97 46.9 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.243 -0.435 . . . . 1.0 110.437 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' E' ' 5' ' ' ILE . . . -130.28 133.64 7.47 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.292 -1.123 . . . . 1.0 110.292 179.471 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -140.82 136.0 31.98 Favored 'General case' 0 CA--C 1.519 -0.238 0 CA-C-O 121.026 0.441 . . . . 1.0 110.925 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.545 HG23 ' O ' ' A' ' 5' ' ' ILE . 19.9 tt -134.63 124.74 45.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.681 -0.69 . . . . 1.0 110.421 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . 0.642 HD22 ' CD2' ' E' ' 2' ' ' PHE . 62.1 mt -121.62 133.44 54.98 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.825 -0.625 . . . . 1.0 110.53 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 51.4 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.934 -1.031 . . . . 1.0 110.531 179.891 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' ASN . . . . . 0.419 ' O ' ' OD1' ' B' ' 1' ' ' ASN . 56.0 p30 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.402 -0.592 . . . . 1.0 109.402 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.407 ' O ' ' O ' ' D' ' 6' ' ' LEU . 67.4 t80 -130.26 131.06 45.32 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.2 -0.454 . . . . 1.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.16 139.45 11.2 Favored Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.445 -1.062 . . . . 1.0 110.445 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.43 134.44 27.26 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 121.027 0.441 . . . . 1.0 111.365 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . . . . . . . . . 96.3 mt -124.39 128.72 73.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 115.845 -0.616 . . . . 1.0 109.899 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' LEU . . . . . 0.418 ' O ' ' O ' ' D' ' 2' ' ' PHE . 50.3 tp -120.99 134.12 55.29 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.903 0.382 . . . . 1.0 111.082 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' SER . . . . . 0.422 ' O ' ' OG ' ' B' ' 7' ' ' SER . 11.6 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 117.795 -1.097 . . . . 1.0 110.057 179.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 109.366 -0.605 . . . . 1.0 109.366 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 2' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -105.07 123.14 47.3 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.203 -0.453 . . . . 1.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.91 133.6 7.36 Favored Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.325 -1.11 . . . . 1.0 110.325 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.01 132.71 25.56 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.885 0.374 . . . . 1.0 110.884 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 5' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.67 124.95 57.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 116.081 -0.509 . . . . 1.0 109.994 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 6' ' ' LEU . . . . . . . . . . . . . 68.9 mt -120.06 132.85 55.59 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.217 -0.447 . . . . 1.0 110.34 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 7' ' ' SER . . . . . . . . . . . . . 21.3 t . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.987 -1.006 . . . . 1.0 110.545 179.947 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 1' ' ' ASN . . . . . 0.423 ' O ' ' OD1' ' D' ' 1' ' ' ASN . 56.2 p30 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.35 -0.611 . . . . 1.0 109.35 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 2' ' ' PHE . . . . . 0.418 ' O ' ' O ' ' B' ' 6' ' ' LEU . 68.7 t80 -130.13 130.93 45.41 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.251 -0.432 . . . . 1.0 110.686 -179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 3' ' ' GLY . . . . . . . . . . . . . . . -126.94 139.11 11.0 Favored Glycine 0 N--CA 1.467 0.733 0 N-CA-C 110.366 -1.094 . . . . 1.0 110.366 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.26 134.21 27.24 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.987 0.423 . . . . 1.0 111.168 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 5' ' ' ILE . . . . . . . . . . . . . 47.4 mm -124.39 128.7 73.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.011 179.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 6' ' ' LEU . . . . . 0.407 ' O ' ' O ' ' B' ' 2' ' ' PHE . 49.6 tp -120.3 128.91 53.74 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.178 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 7' ' ' SER . . . . . . . . . . . . . 40.1 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.568 179.972 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.491 1.621 0 N-CA-C 109.307 -0.627 . . . . 1.0 109.307 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 2' ' ' PHE . . . . . 0.642 ' CD2' HD22 ' A' ' 6' ' ' LEU . 8.5 m-85 -105.11 123.28 47.55 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 116.163 -0.472 . . . . 1.0 110.356 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 3' ' ' GLY . . . . . . . . . . . . . . . -130.5 136.38 8.84 Favored Glycine 0 N--CA 1.466 0.644 0 N-CA-C 110.136 -1.186 . . . . 1.0 110.136 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 4' ' ' ALA . . . . . . . . . . . . . . . -143.51 130.51 20.58 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.812 0.339 . . . . 1.0 111.231 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 5' ' ' ILE . . . . . 0.407 ' O ' ' O ' ' A' ' 3' ' ' GLY . 47.9 mm -126.13 123.5 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.877 -0.601 . . . . 1.0 110.276 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 6' ' ' LEU . . . . . 0.607 HD22 ' CD2' ' A' ' 2' ' ' PHE . 68.2 mt -120.61 132.49 55.16 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.434 -0.348 . . . . 1.0 110.275 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 7' ' ' SER . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.931 -1.033 . . . . 1.0 110.566 179.975 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 1' ' ' ASN . . . . . 0.429 ' OD1' ' O ' ' F' ' 1' ' ' ASN . 57.2 p30 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.514 -0.55 . . . . 1.0 109.514 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 2' ' ' PHE . . . . . 0.434 ' O ' ' O ' ' H' ' 6' ' ' LEU . 68.5 t80 -130.38 130.73 44.74 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.209 -0.451 . . . . 1.0 110.797 -179.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.01 139.1 10.98 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.358 -1.097 . . . . 1.0 110.358 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.47 133.86 26.37 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.019 0.437 . . . . 1.0 111.2 -179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 5' ' ' ILE . . . . . . . . . . . . . 46.5 mm -124.73 128.26 73.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-N 115.789 -0.642 . . . . 1.0 109.91 179.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 6' ' ' LEU . . . . . 0.409 ' O ' ' O ' ' H' ' 2' ' ' PHE . 50.9 tp -119.3 128.58 54.27 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.165 -0.471 . . . . 1.0 110.291 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 7' ' ' SER . . . . . . . . . . . . . 26.9 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.004 -0.998 . . . . 1.0 110.634 -179.951 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 1' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 1.0 109.375 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 2' ' ' PHE . . . . . . . . . . . . . 8.5 m-85 -105.09 123.84 48.51 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.236 -0.438 . . . . 1.0 110.546 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 3' ' ' GLY . . . . . . . . . . . . . . . -131.54 135.75 8.39 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.187 -1.165 . . . . 1.0 110.187 179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.76 131.66 22.89 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.979 0.419 . . . . 1.0 111.099 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 5' ' ' ILE . . . . . . . . . . . . . 44.8 mm -126.48 123.61 63.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.826 -0.624 . . . . 1.0 110.447 179.415 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 6' ' ' LEU . . . . . . . . . . . . . 67.2 mt -120.97 131.54 54.39 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.155 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 7' ' ' SER . . . . . . . . . . . . . 27.9 p . . . . . 0 C--O 1.221 -0.404 0 CA-C-O 117.973 -1.013 . . . . 1.0 110.556 -179.942 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 1' ' ' ASN . . . . . 0.426 ' O ' ' OD1' ' H' ' 1' ' ' ASN . 56.7 p30 . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.441 -0.577 . . . . 1.0 109.441 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 2' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' F' ' 6' ' ' LEU . 69.5 t80 -130.03 130.86 45.48 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.216 -0.447 . . . . 1.0 110.706 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 3' ' ' GLY . . . . . . . . . . . . . . . -127.35 139.3 11.07 Favored Glycine 0 N--CA 1.465 0.603 0 N-CA-C 110.474 -1.05 . . . . 1.0 110.474 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 4' ' ' ALA . . . . . . . . . . . . . . . -142.03 135.19 28.99 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.972 0.415 . . . . 1.0 111.252 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 5' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.09 128.03 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.907 -0.588 . . . . 1.0 109.934 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 6' ' ' LEU . . . . . 0.434 ' O ' ' O ' ' F' ' 2' ' ' PHE . 50.5 tp -119.84 131.54 55.31 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.383 -0.371 . . . . 1.0 110.393 -179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 7' ' ' SER . . . . . . . . . . . . . 51.7 p . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.061 -0.971 . . . . 1.0 110.287 179.846 . . . . . . . . 0 0 . 1 stop_ save_